Cephem compounds

ABSTRACT

The present invention relates to a compound of the formula [I]: wherein R&lt;SUP&gt;1 &lt;/SUP&gt;is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R&lt;SUP&gt;2 &lt;/SUP&gt;is hydrogen or amino protecting group, or R&lt;SUP&gt;1 &lt;/SUP&gt;and R&lt;SUP&gt;2 &lt;/SUP&gt;are bonded together and form lower alkylene or lower alkenylene; R&lt;SUP&gt;3 &lt;/SUP&gt;is hydrogen or lower alkyl; R&lt;SUP&gt;4 &lt;/SUP&gt;is R&lt;SUP&gt;5 &lt;/SUP&gt;is carboxy or protected carboxy; and R&lt;SUP&gt;6 &lt;/SUP&gt;is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

TECHNICAL FIELD

The present invention relates to new cephem compounds andpharmaceutically acceptable salts thereof. More particularly, thepresent invention relates to new cephem compounds and pharmaceuticallyacceptable salts thereof, which have antimicrobial activities, toprocesses for preparation thereof, to pharmaceutical compositioncomprising the same, and to a method for treating infectious diseases inhuman being and animals.

DISCLOSURE OF INVENTION

One object of the present invention is to provide novel cephem compoundsand pharmaceutically acceptable salts thereof, which are highly activeagainst a number of pathogenic microorganisms.

Another object of the present invention is to provide processes for thepreparation of said cephem compounds and salts thereof.

A further object of the present invention is to provide a pharmaceuticalcomposition comprising, as an active ingredient, said cephem compoundsor their pharmaceutically acceptable salts.

Still further object of the present invention is to provide a method fortreating infectious diseases caused by pathogenic microorganisms, whichcomprises administering said cephem compounds to infected human being oranimals.

The object cephem compounds of the present invention are novel and canbe represented by the following general formula [I]:

wherein

-   R¹ is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and-   R² is hydrogen or amino protecting group, or-   R¹ and R² are bonded together and form lower alkylene or lower    alkenylene;-   R³ is hydrogen or lower alkyl;-   R⁴ is    -   wherein    -   A is        -   wherein X is O or NH,    -   R⁷ is hydrogen, lower alkyl or amino protecting group,    -   R⁸ is hydrogen or hydroxy,    -   R⁹ is amino, mono or di(lower)alkylamino, protected amino,        guanidino, protected guanidino or saturated 3- to 8-membered        heterocyclic group containing 1 to 4 nitrogen atoms optionally        substituted by amino or protected amino,    -   k, m, n and q are independently 0 or 1, and    -   p is 0, 1, 2 or 3;-   R⁵ is carboxy or protected carboxy; and-   R⁶ is amino or protected amino.

As to the object compound [I], the following points are to be noted.

That is, the object compound [I] includes syn isomer (Z form), antiisomer (E form) and a mixture thereof. Syn isomer (Z form) means onegeometrical isomer having the partial structure represented by thefollowing formula:

wherein R⁵ and R⁶ are each as defined above, and anti isomer (E form)means the other geometrical isomer having the partial structurerepresented by the following formula:

wherein R⁵ and R⁶ are each as defined above, and all of such geometricalisomers and mixture thereof are included within the scope of thisinvention.

In the present specification and claims, the partial structure of thesegeometrical isomers and mixture thereof are represented for conveniencesake by the following formula:

wherein R⁵ and R⁶ are each as defined above.

Another point to be noted is that the pyrazolio moiety of the compound[I] can also exist in the tautomeric form, and such tautomericequilibrium can be represented by the following formula.

wherein R¹, R², R³ and R⁴ are each as defined above.

Both of the above tautomeric isomers are included within the scope ofthe present invention, and-in the present specification and claims,however, the object compound [I] is represented for convenience sake byone expression of the pyrazolio group of the formula (A).

The cephem compound [I] of the present invention can be prepared by thefollowing processes as illustrated in the following.

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, A, k, m, n, p and

-   q are each as defined above,-   R¹⁰ is protected carboxy,-   Y is a leaving group,-   Z^({circle around (−)}) is an anion,-   R¹a is protected hydroxy(lower)alkyl,-   R¹b is hydroxy(lower)alkyl,-   R⁹a is protected amino, protected guanidino or saturated 3- to    8-membered heterocyclic group containing 1 to 4 nitrogen atoms    substituted by protected amino, and-   R⁹b is amino, guanidino or saturated 3- to 8-membered heterocyclic    group containing 1 to 4 nitrogen atoms substituted by amino.

The starting compounds [II] and [VI] can be prepared by the followingprocesses.

wherein R¹, R², R³, R⁴, R⁵, ⁶, R¹⁰, Y and Z^({circle around (−)}) areeach as defined above,

-   R¹¹ is protected amino,-   R¹² is protected carboxy, and-   R¹³ is amino protecting group or lower alkyl.

The starting compounds [VII] and [XI] or salts thereof can be preparedby the methods disclosed in the Preparations 3-6, 8-47 and 49-102described later or similar manners thereto.

In the above and subsequent descriptions of this specification, suitableexamples of the various definitions are explained in detail as follows.

The term “lower” is used to mean a group having 1 to 6, preferably 1 to4, carbon atoms, unless otherwise indicated.

Suitable “lower alkyl”, and “lower alkyl” moiety in“hydroxy(lower)alkyl”, “protected hydroxy(lower)alkyl”,“aryl(lower)alkyl”, “halo(lower)alkyl” and “mono ordi(lower)alkylamino”, include straight or branched alkyl having 1 to 6carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, tert-pentyl and hexyl, in which morepreferred one is C₁-C₄ alkyl.

Suitable “hydroxy(lower)alkyl” includes hydroxy(C₃-C₆)alkyl such ashydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl,2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl and6-hydroxyhexyl, in which more preferred one is hydroxy(C₁-C₄)alkyl.

Suitable “halo(lower)alkyl” includes straight or branched alkyl having 1to 6 carbon atoms substituted by 1 to 5 halogen atoms such as chlorine,bromine, iodine and fluorine. Preferred examples of “halo(lower)alkyl”include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,bromomethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl,2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 3-fluoropropyland 2,2,3,3,3-pentafluoropropyl, in which more preferred one ishalo(C₁-C₄)alkyl.

Suitable “mono or di(lower)alkylamino” includes mono ordi(C₁-C₆)alkylamino such as methylamino, dimethylamino, ethylamino,diethylamino, N-ethyl-N-methylamino, propylamino, butylamino andN-ethyl-N-propylamino, in which more preferred one is mono or di (C₁-C₄)alkylamino.

Suitable “lower alkylene” formed by R¹ and R² includes straight alkylenehaving 1 to 6, preferably 2 to 4 carbon atoms, such as methylene,ethylene, trimethylene and tetramethylene, in which more preferred oneis straight alkylene having 2 or 3 carbon atoms.

Suitable “lower alkenylene” formed by R¹ and R² includes straightalkenylene having 2 to 6, preferably 2 to 4 carbon atoms, such asvinylene and propenylene, in which more preferred one is straightalkenylene having 2 or 3 carbon atoms.

Suitable “saturated 3- to 8-membered heterocyclic group containing 1 to4 nitrogen atoms” includes azetidinyl (e.g., 1-azetidinyl and3-azetidinyl), pyrrolidinyl (e.g., 1-pyrrolidinyl and 3-pyrrolidinyl),imidazolidinyl (e.g., 1-imidazolidinyl and 4-imidazolidinyl),piperidinyl (e.g., 1-piperidinyl and 4-piperidinyl) and piperazinyl(e.g., 1-piperazinyl), in which more preferred one is saturated 4- to6-membered heterocyclic group containing 1 to 4 nitrogen atoms.

The saturated 3- to 8-membered heterocyclic group containing 1 to 4nitrogen atoms is optionally substituted by amino or protected amino.Suitable examples of “saturated 3- to 8-membered heterocyclic groupcontaining 1 to 4 nitrogen atoms optionally substituted by amino orprotected amino” include 1-azetidinyl, 3-amino-1-azetidinyl,3-tert-butoxycarbonylamino-1-azetidinyl, 3-azetidinyl, 1-pyrrolidinyl,3-amino-1-pyrrolidinyl, 3-tert-butoxycarbonylamino-1-pyrrolidinyl,3-pyrrolidinyl, 1-piperidinyl, 4-piperidinyl and 1-piperazinyl.

Suitable “aryl” moiety in “aryl(lower)alkyl” includes C₆-C₁₂ aryl suchas phenyl and naphthyl, in which more preferred one is phenyl.

Suitable “aryl(lower)alkyl” includes mono-, di- or triphenyl(lower)alkylsuch as benzyl, phenethyl, benzhydryl and trityl.

Suitable “lower alkanoyl” and “lower alkanoyl” moiety in “loweralkanoylamino” include straight or branched alkanoyl having 1 to 6carbon atoms, such as formyl, acetyl, propionyl, butyryl, isobutyryl,valeryl, isovaleryl, pivaloyl and hexanoyl, in which more preferred oneis C₁-C₄ alkanoyl.

Suitable “lower alkoxy” moiety in “lower alkoxycarbonyl” and “loweralkoxycarbonylamino” includes straight or branched alkoxy having 1 to 6carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy,isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, tert-pentyloxy andhexyloxy, in which more preferred one is C₁-C₄ alkoxy.

Suitable “amino protecting group” in “protected amino” includes an acylgroup as mentioned below, substituted or unsubstitutedaryl(lower)alkylidene [e.g., benzylidene, hydroxybenzylidene, etc.],aryl(lower)alkyl such as mono-, di- or triphenyl(lower)alkyl [e.g.,benzyl, phenethyl, benzhydryl, trityl, etc.], and the like.

Suitable “acyl” includes lower alkanoyl [e.g., formyl, acetyl,propionyl, hexanoyl, pivaloyl, etc.], mono(or di ortri)halo(lower)alkanoyl [e.g., chloroacetyl, trifluoroacetyl, etc.],lower alkoxycarbonyl [e.g., methoxycarbonyl, ethoxycarbonyl,tert-butoxycarbonyl, tert-pentyloxycarbonyl, hexyloxycarbonyl, etc.],carbamoyl, aroyl [e.g., benzoyl, toluoyl, naphthoyl, etc.],aryl(lower)alkanoyl [e.g., phenylacetyl, phenylpropionyl, etc.],aryloxycarbonyl [e.g., phenoxycarbonyl, naphthyloxycarbonyl, etc.],aryloxy(lower)alkanoyl [e.g., phenoxyacetyl, phenoxypropionyl, etc.],arylglyoxyloyl [e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc.],aryl(lower)alkoxycarbonyl which optionally substituted by suitablesubstituent(s) [e.g., benzyloxycarbonyl, phenethyloxycarbonyl,p-nitrobenzyloxycarbonyl, etc.], and the like.

Preferable examples of “amino protecting group” include aryl(lower)alkyland acyl, in which more preferred ones are aryl(lower)alkyl, loweralkanoyl and lower alkoxycarbonyl, and particularly preferred ones aremono-, di- or triphenyl(C₁-C₆)alkyl, C₁-C₆ alkanoyl and(C₁-C₆)alkoxycarbonyl.

Preferable examples of “protected amino” include aryl(lower)alkylaminoand acylamino, in which more preferred ones are aryl(lower)alkylamino,lower alkanoylamino and lower alkoxycarbonylamino, and particularlypreferred ones are mono-, di- or triphenyl(C₁-C₆)alkylamino, C₁-C₆alkanoylamino and (C₁-C₆) alkoxycarbonylamino.

Preferable examples of “protected guanidino” include acylguanidino(monoacylguanidino and diacylguanidino) such as2,3-bis[(lower)alkoxycarbonyl]guanidino [e.g.,2,3-bis(tert-butoxycarbonyl)guanidino], in which more preferred one is2,3-bis [(C₁-C₆)alkoxycarbonyl]guanidino.

Suitable “protected hydroxy” in the “protected hydroxy(lower)alkyl”includes acyloxy group, aryl(lower)alkyloxy group, and the like.Suitable “acyl” moiety in the “acyloxy” includes lower alkanoyl [e.g.,formyl, acetyl, propionyl, hexanoyl, pivaloyl, etc.], mono(or di ortri)halo(lower)alkanoyl, [e.g., chloroacetyl, trifluoroacetyl, etc.],lower alkoxycarbonyl, [e.g., methoxycarbonyl, ethoxycarbonyl,tert-butoxycarbonyl, tert-pentyloxycarbonyl, hexyloxycarbonyl, etc.],carbamoyl, and the like. Suitable “aryl(lower)alkyl” moiety in the“aryl(lower)alkyloxy” includes mono-, di- or triphenyl(lower)alkyl[e.g., benzyl, phenethyl, benzhydryl, trityl, etc.], and the like.

Suitable “protected carboxy” includes esterified carboxy and the like,and concrete examples of esterified carboxy include lower alkoxycarbonyl[e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl,tert-butoxycarbonyl, pentyloxycarbonyl-, hexyloxycarbonyl,l-cyclopropylethoxycarbonyl, etc.] which may have suitablesubstituent(s), for example, lower alkanoyloxy(lower)alkoxycarbonyl[e.g., acetoxymethoxycarbonyl, propionyloxymethoxycarbonyl,butyryloxymethoxycarbonyl, valeryloxymethoxycarbonyl,pivaloyloxymethoxycarbonyl, 1-acetoxyethoxycarbonyl,1-propionyloxyethoxycarbonyl, 2-propionyloxyethoxycarbonyl,hexanoyloxymethoxycarbonyl, etc.], loweralkanesulfonyl(lower)alkoxycarbonyl, [e.g., 2-mesylethoxycarbonyl, etc.]or mono(or di or tri)halo(lower)alkoxycarbonyl [e.g.,2-iodoethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, etc.]; loweralkenyloxycarbonyl [e.g., vinyloxycarbonyl, allyloxycarbonyl, etc.];lower alkynyloxycarbonyl [e.g., ethynyloxycarbonyl, propynyloxycarbonyl,etc.]; aryl(lower)alkoxycarbonyl which may have suitable substituent(s)[e.g., benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl,4-nitrobezyloxycarbonyl, phenethyloxycarbonyl, trityloxycarbonyl,benzhydryloxycarbonyl, bis(methoxyphenyl)methoxycarbonyl,3,4-dimethoxybenzyloxycarbonyl,4-hydroxy-3,5-di-tert-butylbenzyloxycarbonyl, etc.]; aryloxycarbonylwhich may have suitable substituent(s) [e.g., phenoxycarbonyl,4-chlorophenoxycarbonyl, tolyloxycarbonyl, 4-tert-butylphenoxycarbonyl,xylyloxycarbonyl, mesityloxycarbonyl, cumenyloxycarbonyl, etc.]; and thelike.

Preferable examples of “protected carboxy” include lower alkoxycarbonyland aryl(lower)alkoxycarbonyl which may have suitable substituent(s), inwhich more preferred one is (C₁-C₆)alkoxycarbonyl.

Suitable “leaving group” includes halogen [e.g., chlorine, bromine,iodine, etc.] or acyloxy such as arylsulfonyloxy [e.g.,benzenesulfonyloxy, tosyloxy, etc.], lower alkylsulfonyloxy [e.g.,mesyloxy, etc.], lower alkanoyloxy [e.g., acetyloxy, propionyloxy,etc.], and the like.

Suitable “anion” includes formate, acetate, trifluoroacetate, maleate,tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate,chloride, bromide, iodide, sulfate, hydrogen sulfate, phosphate, and thelike.

Suitable pharmaceutically acceptable salts of the object compound [I]are conventional non-toxic salts and include, for example, a salt with abase or an acid addition salt such as a salt with an inorganic base, forexample, an alkali metal salt [e.g., sodium salt, potassium salt, etc.],an alkaline earth metal salt [e.g., calcium salt, magnesium salt, etc.],an ammonium salt; a salt with an organic base, for example, an organicamine salt [e.g., trimethylamine salt, triethylamine salt, pyridinesalt, picoline salt, ethanolamine salt, triethanolamine salt,dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt, etc.]; aninorganic acid addition salt [e.g., hydrochloride, hydrobromide,sulfate, hydrogen sulfate, phosphate, etc.]; an organic carboxylic orsulfonic acid addition salt [e.g., formate, acetate, trifluoroacetate,maleate, tartrate, citrate, fumarate, methanesulfonate,benzenesulfonate, toluenesulfonate, etc.]; and a salt with a basic oracidic amino acid [e.g., arginine, aspartic acid, glutamic acid, etc.].

The preferred embodiments of the cephem compound of the presentinvention represented by the general formula [I] are as follows.

(1) The compound of the formula [I] wherein

-   R¹ is lower alkyl or hydroxy(lower)alkyl, and-   R² is hydrogen or amino protecting group, or-   R¹ and R² are bonded together and form lower alkylene;-   R³ is hydrogen;-   A is

wherein X is O or NH;

-   R⁷ is hydrogen or amino protecting group;-   R⁹ is amino or protected amino; and-   p is 0, 1 or 2,-   or a pharmaceutically acceptable salt thereof.

(2) The compound of (1) above wherein R⁸ is hydrogen, or apharmaceutically acceptable salt thereof.

(3) The compound of the formula [I] wherein

-   R¹ is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and-   R² is hydrogen, aryl(lower)alkyl or acyl, or-   R¹ and R² are bonded together and form lower alkylene or lower    alkenylene;-   R⁵ is carboxy or esterified carboxy;-   R⁶ is amino or acylamino;-   R⁷ is hydrogen, lower alkyl or acyl; and-   R⁹ is amino, mono or di(lower)alkylamino, acylamino, guanidino,    acylguanidino or saturated 3- to 8-membered heterocyclic group    containing 1 to 4 nitrogen atoms optionally substituted by amino or    acylamino,-   or a pharmaceutically acceptable salt thereof.

(4) The compound of (3) above wherein

-   R¹ is lower alkyl or hydroxy(lower)alkyl, and-   R² is hydrogen, aryl(lower)alkyl or acyl, or-   R¹ and R² are bonded together and form lower alkylene;-   R⁵ is carboxy or esterified carboxy;-   R⁶ is amino or acylamino;-   R⁷ is hydrogen or acyl; and-   R⁹ is amino or acylamino,-   or a pharmaceutically acceptable salt thereof.

(5) The compound of (4) above wherein

-   R¹ is lower alkyl or hydroxy(lower)alkyl, and-   R² is hydrogen, aryl(lower)alkyl, lower alkanoyl or lower    alkoxycarbonyl, or-   R¹ and R² are bonded together and form lower alkylene;-   R⁵ is carboxy or lower alkoxycarbonyl;-   R⁶ is amino, lower alkanoylamino or lower alkoxycarbonylamino;-   R⁷ is hydrogen, lower alkanoyl or lower alkoxycarbonyl; and-   R⁹ is amino, lower alkanoylamino or lower alkoxycarbonylamino,-   or a pharmaceutically acceptable salt thereof.

(6) The compound of (5) above wherein

-   R¹ is C₁-C₆ alkyl or hydroxy(C₁-C₆)alkyl, and-   R² is hydrogen, mono-, di- or triphenyl(C₁-C₆)alkyl, C₁-C₆ alkanoyl    or (C₁-C₆)alkoxycarbonyl, or-   R¹ and R² are bonded together and form C₁-C₆ alkylene;-   R⁵ is carboxy or (C₁-C₆) alkoxycarbonyl;-   R⁶ is amino, C₁-C₆ alkanoylamino or (C₁-C₆) alkoxycarbonylamino;-   R⁷ is hydrogen, C₁-C₆ alkanoyl or (C₁-C₆) alkoxycarbonyl; and-   R⁹ is amino, C₁-C₆ alkanoylamino or (C₁-C₆) alkoxycarbonylamino,-   or a pharmaceutically acceptable salt thereof.

(7) The compound of (5) above wherein

-   R¹ is lower alkyl or hydroxy(lower)alkyl, and-   R² is hydrogen, or-   R¹ and R² are bonded together and form lower alkylene;-   R⁵ is carboxy;-   R⁶ is amino;-   R⁷ is hydrogen or lower alkanoyl; and-   R⁹ is amino,-   or a pharmaceutically acceptable salt thereof.

(8) The compound of (7) above wherein

-   R¹ is C₁-C₆ alkyl or hydroxy(C₁-C₆)alkyl, and-   R² is hydrogen, or-   R¹ and R² are bonded together and form C₁-C₆ alkylene;-   R⁵ is carboxy;-   R⁶ is amino;-   R⁷ is hydrogen or C₁-C₆ alkanoyl; and-   R⁹ is amino,-   or a pharmaceutically acceptable salt thereof.

(9) The compound of the formula [I] wherein

-   R⁴ is selected from the group consisting of    wherein R⁷, A, m, p and q are each as defined above in the formula    [I],-   R¹⁴ is amino, mono or di(lower)alkylamino or protected amino,-   R¹⁵ is guanidino or protected guanidino, and-   R¹⁶ is saturated 3- to 8-membered heterocyclic group containing 1 to    4 nitrogen atoms optionally substituted by amino or protected amino,-   or a pharmaceutically acceptable salt thereof.

(10) The compound of the formula [I] wherein

-   R⁴ is selected from the group consisting of    wherein-   p is 0, 1 or 2,-   q is 0 or 1,-   R⁷ is hydrogen or amino protecting group, and-   R⁹ is amino or protected amino,-   or a pharmaceutically acceptable salt thereof.

(11) The compound of (10) above wherein

-   R⁷ is hydrogen, lower alkanoyl or lower alkoxycarbonyl; and-   R⁹ is amino, lower alkanoylamino or lower alkoxycarbonylamino,-   or a pharmaceutically acceptable salt thereof.

(12) The compound of (11) above wherein

-   R⁷ is hydrogen, C₁-C₆ alkanoyl or (C₁-C₆)alkoxycarbonyl; and-   R⁹ is amino, C₁-C₆ alkanoylamino or (C₁-C₆) alkoxycarbonylamino,-   or a pharmaceutically acceptable salt thereof.

(13) The compound of (11) above wherein

-   R⁷ is hydrogen or lower alkanoyl; and-   R⁹ is amino,-   or a pharmaceutically acceptable salt thereof.

(14) The compound of (13) above wherein

-   R⁷ is hydrogen or C₁-C₆ alkanoyl; and-   R⁹ is amino,-   or a pharmaceutically acceptable salt thereof.

The processes for preparing the object compound of the present inventionare explained in detail in the following.

Process 1

The compound [I] or a salt thereof can be prepared by reacting thecompound [II] or its reactive derivative at the amino group, or a saltthereof with the compound [III] or its reactive derivative at thecarboxy group, or a salt thereof.

Suitable reactive derivative at the amino group of the compound [II]includes Schiff's base type imino or its tautomeric enamine type isomerformed by the reaction of the compound [II] with a carbonyl compoundsuch as aldehyde, ketone and the like; a silyl derivative formed by thereaction of the compound [II] with a silyl compound such asbis(trimethylsilyl)acetamide, mono(trimethylsilyl)acetamide [e.g.,N-(trimethylsilyl)acetamide], bis(trimethylsilyl)urea and the like; aderivative formed by the reaction of the compound [II] with phosphorustrichloride or phosgene.

Suitable salts of the compound [II] and its reactive derivative can bereferred to the ones as exemplified for the compound [I].

Suitable reactive derivative at the carboxy group of the compound [III]includes an acid halide, an acid anhydride, an activated amide, and anactivated ester. A suitable example of the reactive derivatives may bean acid chloride; an acid azide; a mixed acid anhydride with an acidsuch as substituted phosphoric acid [e.g., dialkylphosphoric acid,phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid,halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurousacid, thiosulfuric acid, sulfuric acid, alkanesulfonic acid [e.g.,methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g., aceticacid, propionic acid, butyric acid, isobutyric acid, pivalic acid,pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroaceticacid, etc.] and aromatic carboxylic acid [e.g., benzoic acid, etc.]; asymmetrical acid anhydride; an activated amide with imidazole,4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; anactivated ester [e.g., cyanomethyl ester, methoxymethyl ester,dimethyliminomethyl [(CH₃)₂N⁺═CH—] ester, vinyl ester, propargyl ester,p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester,pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester,phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester,carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester,8-quinolyl thioester, etc.]; or an ester with an N-hydroxy compound[e.g., N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone,N-hydroxysuccinimide, N-hydroxyphthalimide, N-hydroxy-1H-benzotriazole,etc.]. These reactive derivatives can optionally be selected from themaccording to the kind of the compound [III] to be used.

Suitable salts of the compound [III] and its reactive derivative can bereferred to the ones as exemplified for the compound [I].

The reaction is usually carried out in a conventional solvent such aswater, alcohol [e.g., methanol, ethanol, etc.], acetone, dioxane,acetonitrile, chloroform, methylene chloride, ethylene chloride,tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or anyother organic solvent which does not adversely affect the reaction.These conventional solvents may also be used in a mixture with water.

In this reaction, when the compound [III] is used in free acid form orits salt form, the reaction is preferably carried out in the presence ofa conventional condensing agent such as N,N′-dicyclohexylcarbodiimide;N-cyclohexyl-N′-morpholinoethylcarbodiimide;N-cyclohexyl-N′-(4-diethylaminocyclohexyl)carbodiimide;N,N′-diethylcarbodiimide; N,N′-diisopropylcarbodiimide;N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide;N,N′-carbonyl-bis-(2-methylimidazole);pentamethyleneketene-N-cyclohexylimine;diphenylketene-N-cyclohexylimine; ethoxyacetylene;1-alkoxy-1-chloroethylene; trialkyl phosphite; ethyl polyphosphate;isopropyl polyphosphate; phosphorus oxychloride(phosphoryl chloride);phosphorus trichloride; thionyl chloride; oxalyl chloride; lower alkylhaloformate [e.g., ethyl chloroformate, isopropyl chloroformate, etc.],triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt;2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intramolecular salt;1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-calledVilsmeier reagent prepared by the reaction of N,N-dimethylformamide withthionyl chloride, phosgene, trichloromethyl chloroformate, phosphorusoxychloride, etc.; and the like.

The reaction may also be carried out in the presence of an inorganic ororganic base such as an alkali metal bicarbonate, tri(lower)alkylamine,pyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, andthe like.

The reaction temperature is not critical, and the reaction is usuallycarried out under cooling to warming.

Process 2

The compound [Ib] or a salt thereof can be prepared by subjecting thecompound [Ia] or a salt thereof to elimination reaction of the aminoprotecting group.

Elimination reaction is carried out in accordance with a conventionalmethod such as hydrolysis and the like.

The hydrolysis is preferably carried out in the presence of a base or anacid including Lewis acid.

Suitable base includes an inorganic base and an organic base such as analkali metal [e.g., sodium, potassium, etc.], an alkaline earth metal[e.g., magnesium, calcium, etc.], the hydroxide or carbonate orhydrogencarbonate thereof, trialkylamine [e.g., trimethylamine,triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene,1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, andthe like.

Suitable acid includes an organic acid [e.g., formic acid, acetic acid,propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], andan inorganic acid [e.g., hydrochloric acid, hydrobromic acid, sulfuricacid, hydrogen chloride, hydrogen bromide, etc.].

The elimination using Lewis acid such as trihaloacetic acid [e.g.,trichloroacetic acid, trifluoroacetic acid, etc.], and the like ispreferably carried out in the presence of cation trapping agents [e.g.,anisole, phenol, etc.].

The reaction is usually carried out in a solvent such as water, alcohol[e.g., methanol, ethanol, etc.], methylene chloride, tetrahydrofuran, amixture thereof or any other solvent which does not adversely influencethe reaction. A liquid base or acid can be also used as a solvent.

The reaction temperature is not critical and the reaction is usuallycarried out under cooling to warming.

Process 3-(i)

The compound [VIII] or a salt thereof can be prepared by reacting thecompound [VI] or a salt thereof with the compound [VII] or a saltthereof.

Suitable salt of the compounds [VI], [VII] and [VIII] can be referred tothe ones as exemplified for the compound [I].

The present reaction may be carried out in a solvent such as water,phosphate buffer, acetone, chloroform, acetonitrile nitrobenzene,methylene chloride, ethylene chloride, formamide, N,N-dimethylformamide,methanol, ethanol, diethyl ether, tetrahydrofuran, dimethyl sulfoxide,or any other organic solvent which does not adversely affect thereaction, preferably in ones having strong polarities. Among thesolvents, hydrophilic solvents may be used in a mixture with water. Whenthe compound [VII] is liquid, it can also be used as a solvent.

The reaction is preferably conducted in the presence of a base, forexample, an inorganic base such as alkali metal hydroxide, alkali metalcarbonate, alkali metal hydrogencarbonate, an organic base such astrialkylamine, and the like.

The reaction temperature is not critical, and the reaction is usuallycarried out at ambient temperature, under warming or under heating. Thepresent reaction is preferably carried out in the presence of alkalimetal halide [e.g., sodium iodide, potassium iodide, etc.], alkali metalthiocyanate [e.g., sodium thiocyanate, potassium thiocyanate, etc.], andthe like.

Anion Z^({circle around (−)}) may be one derived from a leaving group Y,and it may be converted to other anion by a conventional method.

Process 3-(ii)

The compound [I] or a salt thereof can be prepared by subjecting thecompound [VIII] or a salt thereof to elimination reaction of the carboxyprotecting group.

Elimination reaction is carried out in similar manner to the reaction inthe aforementioned Process 2, and therefore the reagents to be used andreaction conditions (e.g., solvent, reaction temperature, etc.) can bereferred to those of Process 2.

Process 4

The compound [Id] or a salt thereof can be prepared by subjecting thecompound [Ic] or a salt thereof to elimination reaction of the hydroxyprotecting group.

Suitable method of this elimination reaction includes conventional onesuch as hydrolysis, reduction and the like.

(i) For hydrolysis:

The hydrolysis is preferably carried out in the presence of a base or anacid including Lewis acid.

Suitable base includes an inorganic base and an organic base such as analkali metal [e.g., sodium, potassium, etc.], an alkaline earth metal[e.g., magnesium, calcium, etc.], the hydroxide or carbonate orhydrogencarbonate thereof, trialkylamine [e.g., trimethylamine,triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene,1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, andthe like.

Suitable acid includes an organic acid [e.g., formic acid, acetic acid,propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], andan inorganic acid [e.g., hydrochloric acid, hydrobromic acid, sulfuricacid, hydrogen chloride, hydrogen bromide, etc.].

The elimination using Lewis acid such as trihaloacetic acid [e.g.,trichloroacetic acid, trifluoroacetic acid, etc.] and the like ispreferably carried out in the presence of cation trapping agents [e.g.,anisole, phenol, etc.].

The reaction is usually carried out in a solvent such as water, alcohol[e.g., methanol, ethanol, etc.], methylene chloride, tetrahydrofuran, amixture thereof or any other solvent which does not adversely influencethe reaction. A liquid base or acid can be also used as a solvent.

The reaction temperature is not critical and the reaction is usuallycarried out under cooling to warming. (ii) For reduction:

Reduction is carried out in a conventional manner, including chemicalreduction and catalytic reduction.

Suitable reducing reagents to be used in chemical reduction are acombination of a metal [e.g., tin, zinc, iron, etc.] or metalliccompound [e.g., chromium chloride, chromium acetate, etc.] and anorganic acid or inorganic acid [e.g., formic acid, acetic acid,propionic acid, trifluoroacetic acid, p-toluenesulfonic acid,hydrochloric acid, hydrobromic acid, etc.].

Suitable catalysts to be used in catalytic reduction are conventionalones such as platinum catalysts [e.g., platinum plate, spongy platinum,platinum black, colloidal platinum, platinum oxide, platinum wire,etc.], palladium catalysts [e.g., spongy palladium, palladium black,palladium oxide, palladium on carbon, colloidal palladium, palladium onbarium sulfate, palladium on barium carbonate, etc.], nickel catalysts[e.g., reduced nickel, nickel oxide, Raney nickel, etc.], cobaltcatalysts [e.g., reduced cobalt, Raney cobalt, etc.], iron catalysts[e.g., reduced iron, Raney iron, etc.], copper catalysts [e.g., reducedcopper, Raney copper, Ullman copper, etc.] and the like.

The reduction is usually carried out in a conventional solvent whichdoes not adversely influence the reaction such as water, methanol,ethanol, propanol, N,N-dimethylformamide or a mixture thereof.

Additionally, in case that the above-mentioned acids to be used inchemical reduction are liquid, they can also be used as a solvent.

Further, a suitable solvent to be used in catalytic reduction may be theabove-mentioned solvent, and other conventional solvent such as diethylether, dioxane, tetrahydrofuran, etc., or a mixture thereof.

The reaction temperature of this reduction is not critical and thereaction is usually carried out under cooling to warming.

When R⁶ is protected amino, the amino protecting group in R⁶ can beeliminated by a conventional method such as hydrolysis.

Processes A and B for the preparation of the starting compounds areexplained in detail in the following.

Process A-(i)

The compound [XII] or a salt thereof can be prepared by reacting thecompound [X] or a salt thereof with the compound [XI] or a salt thereof.

This reaction can be carried out in a similar manner to the reaction inthe aforementioned Process 3-(i), and therefore the reagents to be usedand reaction conditions (e.g., solvent, reaction temperature, etc.) canbe referred to those of Process 3-(i).

Process A-(ii)

The compound [II] or a salt thereof can be prepared by subjecting thecompound [XII] or a salt thereof to elimination reaction of the aminoprotecting groups in R¹¹ and R¹³ and the carboxy protecting group inR¹².

This reaction can be carried out in a similar manner to the reaction inthe aforementioned Process 2, and therefore the reagents to be used andreaction conditions (e.g., solvent, reaction temperature, etc.) can bereferred to those of Process 2.

Process B

The compound [VI] or a salt thereof can be prepared by reacting thecompound [XIII] or its reactive derivative at the amino group, or a saltthereof with the compound [XIV] or its reactive derivative at thecarboxy group, or a salt thereof.

This reaction can be carried out in a similar manner to the reaction inthe aforementioned Process 1, and therefore the reagents to be used andreaction conditions (e.g., solvent, reaction temperature, etc.) can bereferred to those of Process 1.

The compounds obtained by the above processes can be isolated andpurified by a conventional method such as pulverization,recrystallization, column chromatography, reprecipitation, and the like.

It is to be noted that the compound [I] and other compounds may includeone or more stereoisomer(s) such as optical isomer(s) and geometricalisomer(s) due to asymmetric carbon atom(s) and double bond(s), and allof such isomers and mixtures thereof are included within the scope ofthis invention.

The object compounds [I] and pharmaceutically acceptable salts thereofinclude solvates [e.g., enclosure compounds (e.g., hydrate, etc.)].

The object compound [I] and pharmaceutically acceptable salts thereofare novel and exhibit high antimicrobial activity, inhibiting the growthof a wide variety of pathogenic microorganisms including Gram-positiveand Gram-negative microorganisms and are useful as antimicrobial agents.

Now in order to show the utility of the object compound [I], the testdata on MIC (minimal inhibitory concentration) of a representativecompound of this invention are shown in the following.

Test Method

In vitro antibacterial activity was determined by the two-foldagar-plate dilution method as described below.

One loopful of an overnight culture of each test strain inTrypticase-soy broth (10⁶ viable cells per ml) was streaked on heartinfusion agar (HI-agar) containing graded concentrations ofrepresentative test compound, and the minimal inhibitory concentration(MIC) was expressed in μg/ml after incubation at 37° C. for 20 hours.

Test Compound

-   Compound (a):    7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[7-(3-aminopropionamido)-2,3-dihydro-5-(1H-imidazo[1,2-b]pyrazolio)]methyl-3-cephem-4-carboxylate    (Example 3)-   Compound (b):    7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-(3-aminopropionamido)-2-methyl-1-pyrazolio]methyl-3-cephem-4-carboxylate    (Example 4)-   Compound (c):    7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-(aminoacetyl)amino-2-methyl-1-pyrazolio]methyl-3-cephem-4-carboxylic    acid hydrogen sulfate (Example 6)-   Compound (d):    7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido)-3-(3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylic    acid hydrogen sulfate (Example 7)-   Compound (e):    7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-(3-amino-4-guanidino-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylic    acid hydrogen sulfate (Example 11)

Ceftazidime TABLE 1 Test results Test strain Test compound MIC (μg/ml)Pseudomonas (a) 2 aeruginosa (b) 1 FP 1380 (c) 2 (d) 2 (e) 1 Ceftazidime128

For therapeutic administration, the object compound [I] andpharmaceutically acceptable salts thereof of the present invention areused in the form of a conventional pharmaceutical preparation whichcontains said compound as an active ingredient, in admixture withpharmaceutically acceptable carriers such as an organic or inorganicsolid or liquid excipient which is suitable for oral, parenteral orexternal administration. The pharmaceutical preparations may be in asolid form such as tablet, granule, powder, capsule, or in a liquid formsuch as solution, suspension, syrup, emulsion, lemonade and the like.

If needed, there may be included in the above -preparations auxiliarysubstances, stabilizing agents, wetting agents and other commonly usedadditives such as lactose, citric acid, tartaric acid, stearic acid,magnesium stearate, terra alba, sucrose, corn starch, talc, gelatin,agar, pectin, peanut oil, olive oil, cacao butter, ethylene glycol, andthe like.

While the dosage of the compound [I] may vary from and also depend uponthe age, conditions of the patient, a kind of diseases, a kind of thecompound [I] to be applied, etc. In general amounts between 1 mg and4,000 mg or even more per day may be administered to a patient. Anaverage single dose of about 50 mg, 100 mg, 250 mg, 500 mg, 1000 mg or2000 mg of the object compounds [I] of the present invention may be usedin treating diseases infected by pathogenic microorganisms.

The following Preparations and Examples are given for the purpose ofillustrating the present invention in more detail.

Preparation 1

To a solution of(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)[(2-tert-butoxy-1,1-dimethyl-2-oxoethoxy)imino]ethanoicacid (5 g) in a mixture of tetrahydrofuran (80 ml) andN,N-dimethylformamide (20 ml) was added a solution of sodiumbis(trimethylsilyl)amide (8.33 g) in tetrahydrofuran (12 ml), and themixture was stirred for 15 minutes. To the reaction mixture was added asolution of di-tert-butyl dicarbonate (3.3 g) in tetrahydrofuran (20 ml)under ice-cooling, and the mixture was stirred under ice-cooling for 3hours. To the reaction mixture was added ethyl acetate, and the mixturewas washed with 10% aqueous potassium hydrogen sulfate solution, andthen washed with a phosphate buffer (pH 6.86). The organic layer wasseparated, dried over anhydrous magnesium sulfate, filtered andconcentrated in vacuo. The residue was triturated with diisopropyl etherand dried in vacuo to give(Z)-2-(5-[(tert-butoxycarbonyl)amino]-1,2,4-thiadiazol-3-yl)[(2-tert-butoxy-1,1-dimethyl-2-oxoethoxy)imino]ethanoicacid (3.10 g).

IR (KBr) 3191.6, 2981.4, 1714.4, 1550.5, 1153.2, 1000.9 cm⁻¹

¹H-NMR(DMSO-d₆) δ 1.37 (9H, s), 1.45 (6H, s), 1.50 (9H, s), 12.7 (1H, s)

ESI-MS: m/z=429(M−H)

Preparation 2

A mixture of N,N-dimethylformamide (0.648 ml) and phosphoryl chloride(0.781 ml) was stirred at room temperature for 30 minutes. To themixture were added tetrahydrofuran (4 ml) and(Z)-2-{5-[(tert-butoxycarbonyl)amino]-1,2,4-thiadiazol-3-yl)[(2-tert-butoxy-1,1-dimethyl-2-oxoethoxy)imino]ethanoicacid (3 g) at 4° C., and the reaction mixture was stirred at roomtemperature for 1 hour. Meanwhile, a mixture of benzhydryl7β-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride (3 g) andN-(trimethylsilyl)acetamide (8.72 g) in tetrahydrofuran (15 ml) waswarmed to make a clear solution. The solution was then cooled to −20° C.and added to the activated acid solution obtained above. The reactionmixture was stirred at a temperature of −10° C. to 0° C. for 1 hour andpoured into a mixture of ethyl acetate and water. The aqueous layer wasseparated, and the organic layer was washed with brine, dried overanhydrous magnesium sulfate and filtered. The filtrate was concentratedin vacuo and purified by column chromatography on silica gel elutingwith hexane/ethyl acetate (3:2) to give benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(4.79 g).

IR (KBr) 2981.4, 1793.5, 1720.2, 1524.8, 1371.1, 1247.7, 1151.3 cm⁻¹

¹H-NMR(DMSO-d₆) δ 1.39 (6H, s), 1.48 (3H, s), 1.50 (6H, s), 3.58 (1H, d,J=18.3 Hz), 3.76 (1H, d, J=18.3 Hz), 4.44 (2H, s), 5.29 (1H, d, J=5.0Hz), 6.01 (1H, dd, J=8.6, 5.0 Hz), 6.97 (1H, s), 7.2-7.6 (1H, m), 9.65(1H, d, J=5.0 Hz), 12.7 (1H, s)

ESI-MS: m/z=849(M+Na)

Preparation 3

To a solution of 5-amino-1-methylpyrazole (5 g) in ethanol (50 ml) wasadded isoamyl nitrite (6.92 ml), and then 20% hydrochloric acid (drops)was added at 4° C. The reaction mixture was refluxed for 2 hours andcooled to room temperature. To the reaction mixture was addeddiisopropyl ether (50 ml), and the mixture was stirred for 0.5 hour. Theresulting precipitate was collected by filtration and dried in vacuo togive 5-amino-1-methyl-4-nitrosopyrazole (3.53 g).

¹H-NMR(DMSO-d₆) δ 3.51 (3H, s), 8.07 (2H, brs), 8.51 (1H, s)

APCI-MS: m/z=127(M+H)

Preparation 4

To a solution of 5-amino-1-methyl-4-nitrosopyrazole (1 g) in water (40ml) were added concentrated sulfuric acid (0.423 ml) and palladium oncarbon (0.3 g) under a hydrogen atmosphere. The mixture was stirredovernight. The reaction mixture was filtered, and the filtrate wasevaporated in vacuo. To the residue was added isopropyl alcohol, and theresulting precipitate was collected by filtration to give4,5-diamino-1-methylpyrazole sulfuric acid salt (1.71 g).

¹H-NMR (DMSO-d₆) δ 3.54 (3H, s), 7.19 (1H, s)

ESI-MS: m/z=113(M+H)

Preparation 5

To a suspension of 1,1′-carbonyldiimidazole (9.73 g) in dehydratedchloroform (72 ml) was added tert-butyl N-(2-aminoethyl)carbamate (9.61g) under ice-cooling, and the mixture was stirred at room temperaturefor 1 hour. To the reaction mixture were added N-ethyldiisopropylamine(14.22 g) and 4,5-diamino-1-methylpyrazole sulfuric acid salt (10.51 g),and the mixture was stirred at 50° C. for 15 hours. The insolublematerials were removed by filtration. To the filtrate were addedchloroform (200 ml) and 5% aqueous sodium hydrogen carbonate solution(10.0 ml). The organic layer was separated, and the aqueous layer wasextracted with a mixed solvent of chloroform and methanol (4:1). Theorganic layers were combined, dried over anhydrous magnesium sulfate,filtered and concentrated in vacuo. The residue was triturated withethyl acetate and dried in vacuo to give5-amino-4-(3-{2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-1-methylpyrazole(14.0 g) as a solid.

¹H-NMR (DMSO-d₆) δ 1.38 (9H, s), 2.96-2.98 (2H, m), 3.03-3.07 (2H, m),3.50 (3H, s), 4.81 (2H, br), 5.92 (1H, br), 6.80 (1H, br), 6.96 (1H, s),7.18 (1H, br)

EXAMPLE 1

To a solution of benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(500 mg) in N,N-dimethylformamide (1.0 ml) was added sodium iodide (100mg), and the mixture was stirred at room temperature for 30 minutes. Tothe reaction mixture was added a solution of5-amino-4-(3-{2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-1-methylpyrazole(216 mg) in N,N-dimethylformamide (1.0 ml). The whole mixture wasstirred at 32° C. for 4 hours. To the resulting reaction mixture wereadded ethyl acetate (50 ml) and water (50 ml). The aqueous layer wasseparated, and the organic layer was washed with 10% aqueous sodiumtrifluoroacetate solution and brine, dried over anhydrous sodium sulfateand filtered. The filtrate was concentrated to about 5 ml in vacuo. Theconcentrate was poured into diusopropyl ether (75 ml), and the resultingprecipitate was collected by filtration and dried in vacuo. To asolution of the resulting solid in methylene chloride (1.8 ml) wereadded anisole (0.6 ml) and trifluoroacetic acid (1.2 ml). The resultingsolution was stirred at room temperature for 4 hours and poured intodiisopropyl ether (80 ml). The resulting precipitate was collected byfiltration and dried in vacuo to give a crude product (380 mg), whichwas purified by preparative high-performance liquid chromatography(HPLC) utilizing ODS column. The eluate containing a desired product wasconcentrated to about 30 ml in vacuo. The concentrate was adjusted toabout pH 3 with concentrated hydrochloric acid and chromatographed onDiaion® HP-20 (Mitsubishi Chemical Corporation) eluting with 30% aqueous2-propanol. The eluate was concentrated to about 30 ml in vacuo andlyophilized to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazolio}methyl-3-cephem-4-carboxylate(21 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (3H, s), 1.53 (3H, s), 3.12 (2H, t, J=5.7 Hz), 3.22(1H, d, J=17.9 Hz), 3.49 (1H, d, J=17.9 Hz) 3.46 (2H, t, J=5.7 Hz), 3.71(3H, s), 4.95 (1H, d, J=15.6 Hz), 5.15 (1H, d, J=15.6 Hz), 5.25 (1H, d,J=4.6 Hz) 5.84 (1H, d, J=4.6 Hz), 7.89 (1H, s)

Preparation 6

To absolution of5-amino-4-(3-{2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-1-methylpyrazole(597 mg) and triethylamine (243 mg) in methylene chloride (10 ml) wasadded triphenylmethyl chloride (669 mg), and the mixture was stirred atroom temperature for 19 hours. The reaction mixture was washedsuccessively with 10% aqueous citric acid solution, brine and saturatedaqueous sodium hydrogen carbonate solution. The organic layer was driedover anhydrous magnesium sulfate, filtered and concentrated in vacuo.The residue was triturated with ethyl acetate to give4-(3-{2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-1-methyl-5-triphenylmethylaminopyrazole(640 mg) as a solid.

¹H-NMR (DMSO-d₆) δ 1.38 (9H, s), 2.70 (3H, s), 2.94-2.96 (2H, m),2.99-3.01 (2H, m), 5.68 (1H, brs), 5.96 (1H, br), 6.78 (1H, br), 6.85(1H, br), 7.00 (1H, s), 7.13-7.15 (6H, m), 7.24-7.28 (9H, m)

Preparation 7

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(60 g) in toluene (600 ml) were added a solution of sodium iodide (61.8g) in 0.05 mol phosphate buffer (pH 7, 500 ml) andtricaprylylmethylammonium chloride (6.67 g). The mixture was stirred atroom temperature for 15 hours. The reaction mixture was added to amixture of ethyl acetate and water. The organic layer was washed withwater and brine, and then dried over magnesium sulfate. The magnesiumsulfate was filtered off, and the filtrate was evaporated to 255 g underreduced pressure. The concentrate was poured into diisopropyl ether (2L). The resulting precipitate was collected by filtration and dried togive benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(59.4 g).

¹H-NMR (DMSO-d₆) δ 1.39 (9H, s), 1.46 (6H, s), 3.57 and 3.87 (2H, ABq,J=18.0 Hz), 3.76 (3H, s), 4.30 (2H, bs), 5.25 (1H, d, J=4.9 Hz), 5.94(1H, dd, J=4.9, 8.7 Hz), 6.95 (1H, bs), 7.15-7.60 (1H, m), 8.17 (2H,bs), 9.53 (1H, d, J=8.7 Hz)

EXAMPLE 2

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(810 mg) in N,N-dimethylformamide (2.4 ml) was addedN-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture was added asolution of4-(3-{2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-1-methyl-5-triphenylmethylaminopyrazole(640 mg) in methylene chloride (10 ml). The whole mixture was stirred atroom temperature for 26 hours. To the resulting reaction mixture wereadded ethyl acetate (50 ml) and water (50 ml). The aqueous layer wasseparated, and the organic layer was washed with 10% aqueous sodiumtrifluoroacetate solution and brine, dried over anhydrous sodium sulfateand filtered. The filtrate was concentrated to about 5 ml in vacuo. Theconcentrate was poured into diisopropyl ether (80 ml), and the resultingprecipitate was collected by filtration and dried in vacuo. To asolution of the resulting solid in methylene chloride (2.38 ml) wereadded anisole (0.79 ml) and trifluoroacetic acid (1.58 ml). Theresulting solution was stirred at room temperature for 4 hours andpoured into diisopropyl ether (80 ml). The resulting precipitate wascollected by filtration and dried in vacuo to give a crude product (635mg), which was purified by preparative HPLC utilizing ODS column. Theeluate containing a desired product was concentrated to about 30 ml invacuo. The concentrate was adjusted to about pH 3 with concentratedhydrochloric acid and chromatographed on Diaion® HP-20 (MitsubishiChemical Corporation) eluting with 30% aqueous 2-propanol. The eluatewas concentrated to about 30 ml in vacuo and lyophilized to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazolio}methyl-3-cephem-4-carboxylate(54 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (3H, s), 1.53 (3H, s), 3.12 (2H, t, J=5.7 Hz), 3.22(1H, d, J=17.9 Hz), 3.49 (1H, d, J=17.9 Hz) 3.46 (2H, t, J=5.7 Hz), 3.71(3H, s), 4.95 (1H, d, J=15.6 Hz), 5.15 (1H, d, J=15.6 Hz), 5.25 (1H, d,J=4.6 Hz), 5.84 (1H, d, J=4.6 Hz), 7.89 (1H, s)

Preparation 8

To a solution of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (120 g) insulfuric acid (500 ml) was added potassium nitrate (111 g) underice-cooling. The mixture was stirred at room temperature for 48 hours.The reaction mixture was added to ice (2.0 kg). The crystalline residuewas collected by filtration and dried in vacuo to give7-nitro-2,3-dihydro-1H-imidazo[1,2-b]pyrazole (132 g) as a solid.

¹H-NMR (DMSO-d₆) δ 4.05-4.09 (2H, m), 4.17-4.20 (2H, m), 7.82 (1H, s),7.97 (1H, br)

Preparation 9

A suspension of 7-nitro-2,3-dihydro-1H-imidazo[1,2-b]pyrazole (97 g) ina mixed solvent of sulfuric acid (34 ml) and water (2000 ml) was treatedwith 10% palladium on carbon (10 g) under a hydrogen atmosphere at roomtemperature for 4 days. After the catalyst was filtered off, thefiltrate was concentrated in vacuo. The residue was triturated withmethanol and dried in vacuo to give7-amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole sulfuric acid salt (90.2g) as a solid.

¹H-NMR (DMSO-d₆) 8 3.87-3.90 (2H, m), 4.07-4.10 (2H, m), 7.28 (1H, s)

Preparation 10

To a solution of 7-amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole sulfuricacid salt (2.22 g) and N-ethyldiisopropylamine (2.84 g) in methylenechloride (70 ml) was addedN-[3-(tert-butoxycarbonylamino)-propionyloxy]succinimide (3.15 g). Themixture was stirred at room temperature for 4 hours. The reactionmixture was washed with saturated aqueous sodium hydrogen carbonatesolution, and the organic layer was dried over anhydrous magnesiumsulfate, filtered and concentrated in vacuo. The oily residue waspurified by column chromatography on silica gel eluting with 5%methanol/chloroform to give7-[3-(tert-butoxycarbonylamino)propionyl]amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole(2.2 g) as a solid.

¹H-NMR (CDCl₃) δ 1.44 (9H, s), 2.52 (2H, t, J=6.0 Hz), 3.36-3.47 (2H,m), 3.96 (2H, t, J=8.2 Hz), 4.18 (2H, t, J=8.2 Hz), 5.16 (1H, br), 7.16(1H, s), 7.90 (1H, br)

EXAMPLE 37β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[7-(3-aminopropionamido)-2,3-dihydro-5-(1H-imidazo[1,2-b]pyrazolio)]methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem-4-carboxylateand7-[3-(tert-butoxycarbonylamino)propionyl]amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazolein the same manner as in Example 1 as an amorphous solid.

¹H-NMR (D₂O) δ 1.51 (3H, s), 1.52 (3H, s), 2.83 (2H, t, J=6.4 Hz), 3.26(1H, d, J=17.9 Hz), 3.53 (1H, d, J=17.9 Hz), 3.31 (2H, t, J=6.4 Hz),4.15 (2H, t, J=8.7 Hz), 4.33 (1H, q, J=8.7 Hz), 4.42 (1H, q, J=8.7 Hz),4.95 (1H, d, J=15.1 Hz), 5.03 (1H, d, J=15.1 Hz), 5.25 (1H, d, J=5.0Hz), 5.84 (1H, d, J=5.0 Hz), 8.06 (1H, s)

Preparation 11

tert-Butyl [2-(5-amino-1-methyl-1H-pyrazol-4-ylcarbamoyl)ethyl]carbamate

The title compound was obtained from 4,5-diamino-1-methylpyrazolesulfuric acid salt andN-[3-(tert-butoxycarbonylamino)propionyloxy]succinimide in the samemanner as in Preparation 10.

¹H-NMR (DMSO-d₆) δ 1.38 (9H, s), 2.35 (2H, t, J=7.1 Hz) 3.18 (2H, q,J=7.1 Hz), 3.50 (3H, s), 4.90 (2H, s), 6.83 (1H, t, J=7.1 Hz), 7.14 (1H,s), 9.06 (1H, s)

AP-MS: m/z=283

Preparation 12

tert-Butyl(2-[1-methyl-5-(tritylamino)-1H-pyrazol-4-ylcarbamoyl]ethyl}carbamate

The title compound was obtained from tert-butyl[2-(5-amino-1-methyl-1H-pyrazol-4-ylcarbamoyl)ethyl]-carbamate in thesame manner as in Preparation 6.

¹H-NMR (DMSO-d₆) δ 1.39 (9H, s), 2.08 (2H, t, J=7.1 Hz) 2.71 (3H, s),3.04 (2H, q, J=7.1 Hz), 5.57 (1H, s), 6.72 (1H, t, J=7.1 Hz), 7.1-7.4(16H, m), 8.25 (1H, s)

EXAMPLE 47β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-(3-aminopropionamido)-2-methyl-1-pyrazolio]methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem-4-carboxylateand tert-butyl{2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-ylcarbamoyl]ethyl}carbamatein the same manner as in Example 1.

¹H-NMR (D₂O) δ 1.53 (6H, s), 2.89 (2H, t, J=6.5 Hz), 3.20 and 3.47 (2H,ABq, J=18 Hz), 3.34 (2H, t, J=6.5 Hz), 3.75 (3H, s), 4.99 and 5.21 (2H,ABq, J=16 Hz), 5.25 (1H, d, J=4.8 Hz), 5.85 (1H, d, J=4.8 Hz), 8.02 (1H,s)

ESI-MS: m/z=674(M+Na)

Preparation 13

To a solution of1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine (22.3g) in dichioromethane (100 ml) were added 4,5-diamino-1-methylpyrazolesulfuric acid salt (10 g) and triethylamine (33. 2 ml) at 4° C., and themixture was stirred at room temperature overnight. The reaction mixturewas poured into a mixture of ethyl acetate and water. The aqueous layerwas separated, and the organic layer was washed with brine, dried overanhydrous magnesium sulfate and filtered. The filtrate was concentratedin vacuo. The concentrate was poured into acetonitrile, and theresulting precipitate was collected by filtration and dried in vacuo togive 5-amino-4-[2′,3′-bis(tert-butoxycarbonyl)guanidino]-1-methylpyrazole (11.62 g).

¹H-NMR (DMSO-d₆) δ 1.37 (9H, s), 1.50 (9H, s), 3.52 (3H, s), 5.14 (2H,s), 7.11 (1H, s), 9.14 (1H, s), 11.5 (1H, s)

ESI-MS: m/z=353 (M−H)

Preparation 14

4-[2′,3′-bis(tert-butoxycarbonyl)guanidino]-1-methyl-5-(tritylamino)pyrazole

The title compound was obtained from5-amino-4-[2′,3′-bis(tert-butoxycarbonyl)guanidino]-1-methylpyrazole inthe same manner -as in Preparation 6.

¹H-NMR (DMSO-d₆) δ 1.37 (9H, s), 1.50 (9H, s), 2.85 (3H, s), 5.88 (1H,s), 7.17 (1H, s), 7.21 (15H, m), 8.85 (1H, s), 11.2 (1H, s)

ESI-MS: m/z=597 (M+H)

EXAMPLE 57β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-(3-amino-4-guanidino-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate and4-[2′,3′-bis(tert-butoxycarbonyl)guanidino]-1-methyl-S-(tritylamino)pyrazolein the same manner as in Example 1.

¹H-NMR (DMSO-d₆) δ 1.53 (6H, s), 3.25 and 3.57 (2H, ABq, J=18 Hz), 3.75(3H, s), 5.00 and 5.18 (2H, ABq, J=15 Hz), 5.27 (1H, d, J=4.9 Hz), 5.85(1H, d, J=4.9 Hz), 8.05 (1H, s)

Preparation 15

To a suspension of 4,5-diamino-1-methylpyrazole sulfuric acid salt (305g) in tetrahydrofuran (3.05 L) was added tert-butyl2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethylcarbamate (415 g) underice-cooling. To the mixture was added diisopropylethylamine (556 ml)dropwise at a temperature below 10° C. The mixture was stirred at roomtemperature overnight. To the resulting solution were added brine andsaturated aqueous sodium hydrogen carbonate solution, and the mixturewas extracted with ethyl acetate (3.0 L). The aqueous layer wasextracted with tetrahydrofuran/ethyl acetate=1/1 (3.0 L) twice. Theorganic layer was dried over anhydrous magnesium sulfate, filtered andconcentrated in vacuo. The residue was triturated with diisopropyl ether(1.0 L).and dried in vacuo to give tert-butyl2-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-oxoethylcarbamate (307 g).

IR (KBr) 3440, 3349, 1670, 1631, 1525, 1276, 1163, 1074, 1014, 860, 791cm⁻¹

¹H-NMR (DMSO-d₆) δ 1.39 (9H, s), 3.44 (3H, s), 3.64 (2H, d, J=5.9 Hz),4.91 (2H, brs), 6.97 (1H, t, J=5.9 Hz), 7.15 (1H, s), 9.09 (1H, brs)

Preparation 16

To a solution of tert-butyl2-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-oxoethylcarbamate (307 g)in N,N-dimethylformamide (1.5 L) was added triphenylmethyl chloride (334g). To the mixture was added triethylamine (318 ml) dropwise. Themixture was stirred at room temperature for 1 hour. The reaction mixturewas dissolved in ethyl acetate. The solution was washed successivelywith water, 10% aqueous citric acid solution, water and brine. Theextract was dried over anhydrous magnesium sulfate, filtered andconcentrated in vacuo. The residue was triturated with acetonitrile (1.5L) and dried in vacuo to give tert-butyl2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-2-oxoethylcarbamate(468 g).

IR (KBr) 3336, 3280, 1724, 1683, 1599, 1234, 939, 704 cm⁻¹

¹H-NMR (DMSO-d₆) δ 1.38 (9H, s), 2.73 (3H, s), 3.38 (2H, d, J=5.8 Hz),5.58 (1H, s), 6.94 (1H, t, J=5.8 Hz), 7.11-7.35 (15H, m), 7.21 (1H, s),8.31 (1H, s)

ESI-MS: m/z=512.3(M+H⁺)

EXAMPLE 6

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(489 g) in N,N-dimethylformamide (1.4 L) was added sodium iodide (102g). After stirring at room temperature for 1 hour, tert-butyl2-([l-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-2-oxoethylcarbamate(383 g) was added to the mixture. Stirring was continued at 37° C. for24 hours. The resulting mixture was poured into water and extracted withethyl acetate. The organic layer was washed successively with water, 10%aqueous sodium thiosulfate solution, brine and 10% aqueous sodiumtrifluoroacetate solution, dried over magnesium sulfate, filtered andevaporated in vacuo. The residue was dissolved in ethyl acetate (3.5 L),and the solution was dropwise added to diisopropyl ether (36 L). Theprecipitate was collected by filtration. The filter cake was washed withdiisopropyl ether and dried in vacuo.

The obtained solid (700 g) was dissolved in dichloromethane (1.4 L), andto the solution were added anisole (700 ml) and trifluoroacetic acid(2.1 L) successively. After stirring at room temperature for 4 hours,the reaction mixture was poured into diisopropyl ether (30 L). Theprecipitate was collected by filtration. The obtained solid was washedwith diisopropyl ether and dried in vacuo. The crude product wasdissolved in water (3.5 L), and the pH of the solution was adjusted to-7.0 with 28% aqueous ammonia solution. The insoluble material wasfiltered off, and the pH of the filtrate was adjusted to 1 withconcentrated hydrochloric acid. The insoluble material was filtered offagain. The filtrate was chromatographed on Diaion® HP-20 eluting with20% aqueous 2-propanol. The eluate was concentrated to about 3.0 L invacuo, and 2.0M sulfuric acid (102 ml) was added to the concentrate. Themixture was lyophilized to give the crude product.

The crude product was purified by preparative HPLC (pH 7.0 phosphatebuffer and acetonitrile), and the eluate containing a desired productwas concentrated to about 6 L in vacuo. The concentrate was adjusted toabout pH 1 with concentrated hydrochloric acid and chromatographed onDiaion® HP-20 eluting with 20% aqueous 2-propanol. The eluate wasconcentrated to about 550 ml in vacuo, and 2.0M sulfuric acid (54.5 ml)was added to the concentrate. To the mixture was added dropwiseacetonitrile (880 ml), and the mixture was stirred at room temperatureovernight. To the mixture was added acetonitrile (200 ml), and themixture was stirred at room temperature for 2 hours. The resulting whitecrystals were collected by filtration, washed with 25% aqueousacetonitrile and dried under reduced pressure to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-(aminoacetyl)amino-2-methyl-1-pyrazolio]methyl-3-cephem-4-carboxylicacid hydrogen sulfate (72.5 g).

IR (KBr) 1778, 1700, 1653, 1525, 1149, 1111, 617 cm⁻¹

¹H-NMR (D₂O) δ 1.61 (6H, s), 3.22 and 3.45 (2H, ABq, J=17.8 Hz), 3.73(3H, s), 4.03 (2H, s), 5.05 and 5.27 (2H, ABq, J=15.8 Hz), 5.25 (1H, d,J=4.8 Hz), 5.87 (1H, d, J=4.8 Hz), 8.09 (1H, s)

ESI-MS: m/z=638.2(M+H⁺)

EXAMPLE 7

A solution of7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylate(36 g) in water was purified by preparative HPLC utilizing ODS column.The eluate containing a desired product was concentrated to about 1.5 Lin vacuo. The concentrate was adjusted to about pH 1 with concentratedhydrochloric acid and chromatographed on Diaion® HP-20 (6 L) elutingwith 20% aqueous 2-propanol. The eluate was concentrated to about 800 mlin vacuo, and 2M sulfuric acid (17 ml) was added. The resulting solutionwas lyophilized to give a sulfuric acid salt as an amorphous powder(23.6 g).

The powder was dissolved in water (71 ml) and ethanol (57 ml). Afteraddition of seed crystals (310 mg), which resulted in the precipitationof white solid, the mixture was stirred for 1 hour. A mixture of ethanol(47 ml) and water (37 ml) was added over 30 minutes, and ethanol (33 ml)was added over 20 minutes. Then the slurry was stirred for an additional1.5 hour. The precipitate was collected by filtration, washed withethanol/water (60 ml/20 ml) and ethanol (60 ml) and dried to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[3-(2-aminoethyl)ureido]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylicacid hydrogen sulfate as crystals (17.3 g).

IR (KBr) 3353, 3183, 1778, 1652, 1558, 1403, 1321, 1143, 1118, 997, 619.cm⁻¹

¹H-NMR (D₂O) δ 1.61 (6H, s), 3.10-3.55 (6H, m), 3.71 (3H, s), 5.02 and5.23 (2H, ABq, J=16.7 Hz), 5.25 (1H, d, J=4.9 Hz), 5.87 (1H, d, J=4.9Hz), 7.91 (1H, s)

ESI-MS: m/z=667(M+H⁺)

X-ray powder diffraction analysis (by Rigaku X-ray Diffraction systemMultiFlex) 2θ intensity 8.0 1286 12.7 586 13.8 423 16.1 618 18.9 52020.4 748 21.5 667 22.4 1058 23.3 944 24.0 618 25.5 813 26.7 472 27.9 53728.5 455 31.3 390X-ray: Cu/40 kV/30 mAPreparation 17

5-Amino-1-ethyl-4-nitrosopyrazole

The title compound was obtained from 5-amino-1-ethylpyrazole in the samemanner as in Preparation 3.

¹H-NMR (DMSO-d₆) δ 1.21 (3H, t, J=7.1 Hz), 3.93 (2H, q, J=7.1 Hz), 7.04and 8.53 (1H, s), 8.10 and 8.15 (1H, brs)

APCI-MS: m/z=141(M+H)⁺

Preparation 18

4,5-Diamino-1-ethylpyrazole sulfuric acid salt

The title compound was obtained from 5-amino-1-ethyl-4-nitrosopyrazolein the same manner as in Preparation 4.

¹H-NMR (D₂O) δ 1.36 (3H, t, J=7.3 Hz), 4.10 (2H, q, J=7.3 Hz), 7.77 (1H,s)

ESI-MS: m/z=127(M+H)⁺

Preparation 19

5-Amino-4-[3-(tert-butoxycarbonylamino)-propionylamino]-1-ethylpyrazole

The title compound was obtained from 4,5-diamino-1-ethylpyrazolesulfuric acid salt in the same manner as in Preparation 15.

¹H-NMR (DMSO-d₆) δ 1.24 (3H, t, J=7.2 Hz), 1.37 (9H, s) 2.35 (2H, t,J=7.1 Hz), 3.18 (2H, dt, J=7.1, 7.1 Hz), 3.85 (q, J=7.2 Hz), 4.88 (2H,brs), 6.75-6.90 (1H, m), 7.17 (1H, s), 9.05 (1H, brs)

APCI-MS: m/z=298(M+H)⁺

Preparation 20

4-[3-(tert-Butoxycarbonylamino)propionylamino]-1-ethyl-5-triphenylmethylaminopyrazole

The title compound was obtained from5-amino-4-[3-(tert-butoxycarbonylamino)propionylamino]-1-ethylpyrazolein the same manner as in Preparation 16.

¹H-NMR (DMSO-d₆) δ 0.88 (3H, t, J=7.2 Hz), 1.39 (9H, s) 2.02 (2H, t,J=7.1 Hz), 2.95-3.20 (4H, m), 5.59 (1H, brs), 6.60-6.75 (1H, m),7.10-7.35 (16H, m), 8.04 (1H, brs)

ESI-MS: m/z=540(M+H)⁺, 562(M+Na)⁺

EXAMPLE 87β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-(3-aminopropionylamino)-2-ethyl-1-pyrazoliolmethyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylateand4-[3-(tert-butoxycarbonylamino)propionylamino]-1-ethyl-5-triphenylmethylaminopyrazolein the same manner as in Example 1.

IR (KBr) 3415, 1763, 1658, 1598, 1529, 1402, 1361 cm⁻¹

¹H-NMR (D₂O) δ 1.33 (3H, t, J=7.2 Hz), 1.53 (6H, s), 2.89 (2H, t, J=6.5Hz), 3.17 and 3.49 (2H, ABq, J=17.7 Hz), 3.34 (2H, t, J=6.5 Hz), 4.28(2H, q, J=7.2 Hz), 5.05 and 5.16 (2H, ABq, J=15.4 Hz), 5.26 (1H, d,J=4.8 Hz), 5.85 (1H, d, J=4.8 Hz), 8.03 (1H, s)

Preparation 21

tert-Butyl2-[(5-amino-1-ethyl-1H-pyrazol-4-yl)amino]-2-oxoethylcarbamate

The title compound was obtained from 4,5-diamino-1-ethylpyrazolesulfuric acid salt in the same manner as in Preparation 15.

¹H-NMR (DMSO-d₆) δ 1.21 (3H, t, J=7.2 Hz), 1.39 (9H, s), 3.64 (2H, d,J=6.0 Hz), 3.86 (2H, d, J=7.2 Hz), 4.88 (2H, brs), 6.90-7.00 (1H, m),7.17 (1H, s), 9.06 (1H, brs)

ESI-MS: m/z=284(M+H)⁺, 306(M+Na)⁺

Preparation 22

tert-Butyl2-{[1-ethyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-2-oxoethylcarbamate

The title compound was obtained from tert-butyl2-[(5-amino-1-ethyl-1H-pyrazol-4-yl)amino]-2-oxoethylcarbamate in thesame manner as in Preparation 16.

¹H-NMR (DMSO-d₆) δ 0.88 (3H, t, J=7.2 Hz), 1.38 (9H, s) 3.16 (2H, q,J=7.2 Hz), 3.31 (2H, d), 5.59 (1H, brs), 6.80-6.95 (1H, m), 7.10-7.40(16H, m), 8.03 (1H, brs)

ESI-MS: m/z=526(M+H)⁺, 548(M+Na)⁺

EXAMPLE 97β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-(aminoacetyl)amino-2-ethyl-1-pyrazolio]methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylateand tert-butyl2-{[1-ethyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-2-oxoethylcarbamatein the same manner as in Example 1.

IR (KBr) 3444, 1761, 1635, 1626, 1446, 1406 cm⁻¹

¹H-NMR (D₂O) δ 1.33 (3H, t, J=7.2 Hz), 1.53 (6H, s), 2.89 (2H, t, J=6.5Hz), 3.17 and 3.49 (2H, ABq, J=17.7 Hz), 4.00 (2H, s), 4.28 (2H, q,J=7.2 Hz), 5.06 and 5.17 (2H, ABq, J=15.4 Hz), 5.27 (1H, d, J=4.8 Hz),5.85 (1H, d, J=4.8 Hz), 8.07 (1H, s)

Preparation 23

5-Amino-4-[2′,3′-bis(tert-butoxycarbonyl)-guanidino]-1-ethylpyrazole

The title compound was obtained from1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine and4,5-diamino-1-ethylpyrazole sulfuric acid salt in the same manner as inPreparation 13.

¹H-NMR (DMSO-d₆) δ 1.22 (3H, t, J=7.1 Hz), 1.37 (9H, s), 1.50 (9H, s),3.88 (2H, d, J=7.1 Hz), 5.12 (2H, brs), 7.14 (1H, s), 9.16 (1H, brs),11.51 (1H, brs)

ESI-MS: m/z=369(M+H)⁺

Preparation 24

4-[2′,3′-Bis(tert-butoxycarbonyl)guanidino]-1-ethyl-5-triphenylmethylaminopyrazole

The title compound was obtained from5-amino-4-[2′,3′-bis(tert-butoxycarbonyl)guanidino]-1-ethylpyrazole inthe same manner as in Preparation 16.

¹H-NMR (DMSO-d₆) δ 0.86 (3H, t, J=7.1 Hz), 1.38 (9H, s) 1.49 (9H,s),5.85 (1H, brs), 7.10-7.30 (16H, m), 8.80 (1H, brs), 11.14 (1H, brs)

ESI-MS: m/z=611(M+H)⁺, 633(M+Na)⁺

EXAMPLE 107β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-2-ethyl-4-guanidino-1-pyrazolio]methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylateand4-[2′,3′-bis(tert-butoxycarbonyl)guanidino]-1-ethyl-5-triphenylmethylaminopyrazolein the same manner as in Example 1.

IR (KBr) 3437, 1760, 1658, 1625, 1406, 1065 cm⁻¹

¹H-NMR (D₂O) δ 1.35 (3H, t, J=7.3 Hz), 1.53 (6H, s), 3.26 and 3.61 (2H,ABq, J=17.8 Hz), 4.29 (2H, q, J=7.3 Hz), 5.06 and 5.17 (2H, ABq, J=15.7Hz), 5.29 (1H, d, J=4.8 Hz), 5.85 (1H, d, J=4.8 Hz), 8.06 (1H, s)

EXAMPLE 11

To a suspension of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(500 g) in N,N-dimethylformamide (2.5 L) was added4-[2′,3′-bis(tert-butoxycarbonyl)guanidino]-1-methyl-5-triphenylmethylaminopyrazole(419 g) and the mixture was stirred at room temperature for 16 hours.The reaction mixture was added to a mixture of ethyl acetate and water.The organic layer was washed with water, brine and 10% aqueous sodiumtrifluoroacetate solution and then dried over magnesium sulfate. Themagnesium sulfate was filtered off, and the-filtrate was evaporated to3.3 kg under reduced pressure. The concentrate was poured intodiisopropyl ether (33 L), and the resulting precipitate was collected byfiltration and dried in vacuo.

To a solution of the resulting solid in methylene chloride (1500 ml)were added anisole (500 ml) and trifluoroacetic acid (1500 ml). Theresulting solution was stirred at room temperature for 4 hours andpoured into diisopropyl ether. The resulting precipitate was collectedby filtration and dried in vacuo. The crude product was dissolved inwater (3.5 L), and the pH of the solution was adjusted to 7.0 with 28%aqueous ammonia solution. The insoluble material was filtered off, andthe pH of the filtrate was adjusted to 1 with concentrated hydrochloricacid. The insoluble material was filtered off, again. The filtrate waschromatographed on Diaion® HP-20 eluting with 20% aqueous 2-propanol.The eluate was concentrated to about 3.0 L in vacuo. To the concentratewas added 2.0M sulfuric acid (150 ml), and the mixture was lyophilizedto give the crude product. The crude product was purified withpreparative HPLC utilizing ODS column (pH. 7.0 phosphate buffer andacetonitrile). The eluate containing a desired product was concentratedto about 6 L in vacuo. The concentrate was adjusted to about pH 1 withconcentrated hydrochloric acid and chromatographed on Diaion® HP-20eluting with 20% aqueous 2-propanol. The eluate was concentrated toabout 1.5 L in vacuo. To the concentrate was added 2.0M sulfuric acid(60 ml), and the mixture was lyophilized to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-(3-amino-4-guanidino-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylicacid hydrogen sulfate (48.5 g).

IR (KBr) 1776, 1714, 1677, 1651, 1402, 1112 cm⁻¹

¹H-NMR (D₂O) δ 1.61 (6H, s), 3.28 and 3.58 (2H, ABq, J=17.8 Hz), 3.74(3H, s), 5.15 and 5.23 (2H, ABq, J=15.7 Hz), 5.27 (1H, d, J=4.8 Hz),5.88 (1H, d, J=4.8 Hz), 8.07 (1H, s)

ESI-MS: m/z=623.2(M+H⁺)

Preparation 25

To a suspension of 4,5-diamino-1-(2-hydroxyethyl)pyrazole sulfuric acidsalt (2.4 g) in methylene chloride (40 ml) were addedN-ethyldiisopropylamine (2.1 ml) andN-[3-(tert-butoxycarbonylamino)propionyloxy]succinimide (2.3 g) underice-cooling, and the mixture was stirred at room temperature for 6hours. To the reaction mixture were added brine (40 ml) and saturatedaqueous sodium hydrogen carbonate solution (20 ml), and the mixture wasextracted with a mixture of ethyl acetate and 2-propanol (3:1, 60 ml).The organic layer was dried over anhydrous sodium sulfate, filtered andconcentrated in vacuo. The residue was triturated with diethyl ether togive5-amino-4-[3-(tert-butoxycarbonylamino)propionyl]-amino-1-(2-hydroxyethyl)pyrazole(1.65 g) as a solid.

¹H-NMR (DMSO-d₆) δ 1.38 (9H, s), 2.35 (2H, t, J=7.3 Hz) 3.16-3.20 (2H,m), 3.62-3.65 (2H, m), 3.90 (2H, t, J=6.0 Hz), 4.85 (2H, brs), 4.92 (1H,t, J=5.0 Hz), 6.84 (1H, t, J=5.5 Hz), 7.20 (1H, s), 9.09 (1H, brs)

EXAMPLE 127β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-(3-aminopropionamido)-2-(2-hydroxyethyl)-1-pyrazoliolmethyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem-4-carboxylateand5-amino-4-[3-(tert-butoxycarbonylamino)propionyl]amino-1-(2-hydroxyethyl)pyrazolein the same manner as in Example 1 as an amorphous solid.

¹H-NMR (D₂O) δ 1.51 (6H, s), 2.88 (2H, t, J=6.4 Hz), 3.15 (1H, d, J=17.9Hz), 3.48 (1H, d, J=17.9 Hz), 3.32 (2H, t, J=6.4 Hz), 3.88 (2H, t, J=4.8Hz), 4.39 (1H, dt, J=16.5 Hz, 4.8 Hz), 4.42 (1H, dt, J=16.5, 4.8 Hz),5.06 (1H, d, J=15.1 Hz), 5.11 (1H, d, J=15.1 Hz), 5.25 (1H, d, J=5.0Hz), 5.83 (1H, d, J=5.0 Hz), 8.05 (1H, s)

Preparation 26

To a solution of 4-formyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine(1.51 g) in sulfuric acid (7.5 ml) was added potassium nitrate (111 g)under ice-cooling. The mixture was stirred at room temperature for 17hours. The reaction mixture was added to ice (100 g). The crystallineresidue was collected by filtration and dried in vacuo to give3-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (0.63 g) as a solid.

¹H-NMR (DMSO-d₆) δ 2.00-2.05 (2H, m), 3.30-3.36 (2H, m) 3.99 (2H, t,J=6.0 Hz), 7.85 (1H, s), 7.89 (1H, s)

Preparation 27

A solution of 3-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (1.68g) in a mixture of sulfuric acid (0.6 ml), acetic acid (100 ml) andwater (10 ml) was treated with 10% palladium on carbon (0.5 g) under ahydrogen atmosphere at room temperature for 6 days. After the catalystwas filtered off, the filtrate was concentrated in vacuo. The residuewas triturated with ethanol and dried in vacuo to give3-amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine sulfuric acid salt(2.3 g) as a solid.

¹H-NMR (DMSO-d₆) δ 1.97-2.01 (2H, m), 3.22 (2H, t, J=5.0 Hz), 3.98 (2H,t, J=6.0 Hz), 7.22 (1H, s)

Preparation 28

To a solution of 3-amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidinesulfuric acid salt (2.96 g) and N-ethyldiisopropylamine (3.88 g) inmethylene chloride (70 ml) was added1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethanesulfonyl)guanidine (3.91g). The mixture was stirred at room temperature for 150 minutes. Thereaction mixture was washed with saturated aqueous sodium hydrogencarbonate solution. The organic layer was dried over anhydrous magnesiumsulfate, filtered and concentrated in vacuo. The residue was purified bycolumn chromatography on silica gel eluting with 2% methanol/chloroformto give3-[2,3-bis(tert-butoxycarbonyl)guanidino]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine(3.4 g) as a solid.

¹H-NMR (CDCl₃) δ 1.48 (9H, s), 1.52 (9H, s), 2.12-2.14 (2H, m),3.33-3.37 (2H, m), 4.08 (2H, t, J=6.0 Hz), 6.17 (1H, brs), 7.16 (1H, s),9.87 (1H, brs), 11.39 (1H, brs)

EXAMPLE 13

To a solution of benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(1.0 g) in N,N-dimethylformamide (2.0 ml) was added sodium iodide (181mg), and the mixture was stirred at room temperature for 30 minutes. Tothe reaction mixture were added3-[2,3-bis(tert-butoxycarbonyl)guanidino]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine(571 mg) and methylene chloride (2.0 ml). The whole mixture was stirredat room temperature for 7 hours. To the reaction mixture were addedethyl acetate (100 ml) and water (50 ml). The aqueous layer wasseparated, and the organic layer was washed with 10% aqueous sodiumtrifluoroacetate solution and brine, dried over sodium sulfate andfiltered. The filtrate was concentrated to about 5 ml in vacuo. Theconcentrate was poured into diisopropyl ether (150 ml), and theresulting precipitate was collected by filtration and dried in vacuo.

To a solution of the resulting solid in methylene chloride (3.0 ml) wereadded anisole (1.0 ml) and trifluoroacetic acid (2.0 ml), and themixture was stirred at room temperature for 4 hours. The reactionmixture was poured into diisopropyl ether (150 ml), and the resultingprecipitate was collected by filtration and dried in vacuo to give acrude product (570 mg), which was purified by preparative HPLC utilizingODS column. The eluate containing a desired product was concentrated toabout 30 ml in vacuo. The concentrate was adjusted to about pH 3 withconcentrated hydrochloric acid and chromatographed on Diaion® HP-20(Mitsubishi Chemical Corporation) eluting with 30% aqueous 2-propanol.The eluate was concentrated to about 30 ml in vacuo and lyophilized togive7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-guanidino-4,5,6,7-tetrahydro-1-pyrazolo[1,5-a]pyrimidinio]methyl-3-cephem-4-carboxylate(51 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (3H, s), 1.53 (3H, s), 2.05-2.25 (2H, m), 3.26 (1H,d, J=17.4 Hz), 3.56 (1H, d, J=17.4 Hz), 3.30-3.45 (2H, m), 4.15 (2H, t,J=6.0 Hz), 4.93 (1H, d, J=15.6 Hz), 5.15 (1H, d, J=15.6 Hz), 5.25 (1H,d, J=4.8 Hz), 5.84 (1H, d, J=4.8 Hz), 7.99 (1H, s)

Preparation 29

To a solution of 7-amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole sulfuricacid salt (4.4 g), 4-(dimethylamino)pyridine (244 mg) and triethylamine(8.10 g) in chloroform (45 ml) was added1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethanesulfonyl)guanidine(10.18 g). The mixture was stirred at room temperature for 2 hours. Thereaction mixture was washed successively with 10% aqueous citric acidsolution, brine and saturated aqueous sodium hydrogen carbonatesolution. The organic layer was dried over anhydrous magnesium sulfate,filtered and concentrated in vacuo. The residue was triturated withdiisopropyl ether to give7-[2,3-bis(tert-butoxycarbonyl)guanidino]-2,3-dihydro-1H-imidazo[1,2-b]pyrazole(4.6 g) as a solid.

¹H-NMR (CDCl₃) δ 1.49 (9H, s), 1.52 (9H, s), 3.97-4.01 (2H, m), 4.21(2H, t, J=7.8 Hz), 5.30 (1H, brs), 7.19 (1H, s), 9.86 (1H, brs), 11.32(1H, brs)

EXAMPLE 147β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3.-[7-guanidino-2,3-dihydro-5-(1H-imidazo[1,2-blpyrazolio)]methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem-4-carboxylateand7-[2,3-bis(tert-butoxycarbonyl)guanidino]-2,3-dihydro-1H-imidazo[1,2-b]pyrazolein the same manner as in Example 13 as an amorphous solid.

1H-NMR (D₂O) δ 1.51 (3H, s), 1.52 (3H, s), 3.35 (1H, d, J=17.9 Hz), 3.61(1H, d, J=17.9 Hz), 4.19 (2H, t, J=8.7 Hz), 4.37 (1H, q, J=8.7 Hz), 4.47(1H, q, J=8.7 Hz), 5.00 (1H, d, J=15.1 Hz), 5.04 (1H, d, J=15.1 Hz),5.26 (1H, d, J=4.8 Hz), 5.84 (1H, d, J=4.8 Hz), 8.13 (1H, s)

Preparation 30

To a solution of 5-amino-1-(2-hydroxyethyl)pyrazole (6.35 g) in a mixedsolvent of ethanol (25 ml) and concentrated hydrochloric acid (0.035 ml)was added dropwise isoamyl nitrite (7.03 g). The mixture was stirred atroom temperature for 17 hours. The crystalline residue was collected byfiltration and dried in vacuo to give5-amino-1-(2-hydroxyethyl)-4-nitrosopyrazole (4.0 g) as a solid.

¹H-NMR (DMSO-d₆) δ 3.68 (2H, t, J=5.5 Hz), 3.94 (2H, t, J=5.5 Hz), 4.89(1H, br), 8.06(2H, br), 8.53 (1H, s)

Preparation 31

A solution of 5-amino-1-(2-hydroxyethyl)-4-nitrosopyrazole (97 g) in amixed solvent of sulfuric acid (34 ml) and water (2000 ml) was treatedwith 10% palladium on carbon (10 g) under a hydrogen atmosphere at roomtemperature for 4 days. After the catalyst was filtered off, thefiltrate was concentrated in vacuo. The residue was triturated withmethanol and dried in vacuo to give4,5-diamino-1-(2-hydroxyethyl)pyrazole sulfuric acid salt (90.2 g) as asolid.

¹H-NMR (DMSO-d₆) δ 3.66 (2H, t, J=5.5 Hz), 3.95 (2H, t, J=5.5 Hz), 7.25(1H, s)

Preparation 32

To a suspension of 4,5-diamino-1-(2-hydroxyethyl)pyrazole sulfuric acidsalt (50.0 g) in chloroform (500 ml) were added4-(dimethylamino)pyridine (2.54 g), triethylamine (116 ml) and1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethanesulfonyl)guanidine (106g). The mixture was stirred under reflux for 2 hours. After cooling onan ice bath, the reaction mixture was washed successively with water, 4%aqueous citric acid solution, water and aqueous sodium hydrogencarbonate solution. The organic layer was dried over sodium sulfate,filtered and concentrated in vacuo. The residue was triturated with amixed solvent of ethyl acetate (50 ml) and diethyl ether (200 ml) togive5-amino-4-[2,3-bis(tert-butoxycarbonyl)guanidino]-1-(2-hydroxyethyl)pyrazole(50 g) as a solid.

¹H-NMR (CDCl₃) δ 1.47 (9H, s), 1.53 (9H, s), 3.28 (1H, br) 4.02-4.05(4H, m), 4.65 (2H, br), 7.22 (1H, s), 9.85 (1H, br), 11.55 (1H, br)

EXAMPLE 157β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-guanidino-2-(2-hydroxyethyl)-1-pyrazolio]methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem-4-carboxylateand5-amino-4-[2,3-bis(tert-butoxycarbonyl)guanidino]-1-(2-hydroxyethyl)pyrazolein the same manner as in Example 13 as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (3H, s), 3.21 (1H, d, J=17.9 Hz), 3.59 (1H, d,J=17.9 Hz), 3.90 (2H, t, J=4.8 Hz), 4.35-4.50 (2H, m), 5.07 (1H, d,J=14.9 Hz), 5.11 (1H, d, J=14.9 Hz), 5.28 (1H, d, J=5.0 Hz), 5.84 (1H,d, J=5.0 Hz), 8.09 (1H, s)

Preparation 33

To a solution of7-[2,3-bis(tert-butoxycarbonyl)guanidino]-2,3-dihydro-1H-imidazo[1,2-b]pyrazole(1.83 g) in pyridine (10 ml) was added triphenylmethyl chloride (1.67g). The mixture was stirred at 50° C. for 5 hours. After cooling,chloroform (50 ml) was added to the reaction mixture, and the mixturewas washed successively with 10% aqueous citric acid solution, brine andsaturated aqueous sodium hydrogen carbonate solution. The organic layerwas dried over anhydrous magnesium sulfate, filtered and concentrated invacuo. The residue was purified by column chromatography on silica geleluting with 2% methanol/chloroform to give7-[2,3-bis(tert-butoxycarbonyl)guanidino]-1-triphenylmethyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole(1.57 g) as a solid.

¹H-NMR (CDCl₃) δ 1.47* (9H, s), 1.48 (9H, s), 3.50 (2H, t, J=7.8 Hz),3.92 (2H, t, J=7.8 Hz), 7.07-7.26 (1H, m) 7.53-7.54 (6H, m), 8.34 (1H,brs), 11.12 (1H, brs)

EXAMPLE 16

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(819 mg) in N,N-dimethylformamide (2.4 ml) was addedN-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture was added7-[2,3-bis(tert-butoxycarbonyl)guanidino]-1-triphenylmethyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole(730 mg). The whole mixture was stirred at room temperature for 6 hours.To the resulting reaction mixture were added ethyl acetate (100 ml) andwater (50 ml). The aqueous layer was separated, and the organic layerwas washed with 10% aqueous sodium trifluoroacetate solution, 10%aqueous sodium thiosulfate solution and brine, dried over sodium sulfateand filtered. The filtrate was concentrated to about 5 ml in vacuo. Theconcentrate was poured into diisopropyl ether (120 ml), and theresulting precipitate was collected by filtration and dried in vacuo.

To a solution of the resulting solid in methylene chloride (2.0 ml) wereadded anisole (0.67 ml) and trifluoroacetic acid (1.34 ml), and themixture was stirred at room temperature for 4 hours. The reactionmixture was poured into diisopropyl ether (120 ml). The resultingprecipitate was collected by filtration and dried in vacuo to give acrude product (430 mg), which was purified by preparative HPLC utilizingODS column. The eluate containing a desired product was concentrated toabout 30 ml in vacuo. The concentrate was adjusted to about pH 3 withconcentrated hydrochloric acid and chromatographed on Diaion® HP-20(Mitsubishi Chemical Corporation) eluting with 30% aqueous 2-propanol.The eluate was concentrated to about 30 ml in vacuo and lyophilized togive7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[7-guanidino-2,3-dihydro-5-(1H-imidazo[1,2-b]pyrazolio)]methyl-3-cephem-4-carboxylate(20.4 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.51 (3H, s), 1.52 (3H, s), 3.35 (1H, d, J=17.9 Hz), 3.61(1H, d, J=17.9 Hz), 4.19 (2H, t, J=8.7 Hz), 4.37 (1H, q, J=8.7 Hz), 4.47(1H, q, J=8.7 Hz), 5.00 (1H, d, J=15.1 Hz), 5.04 (1H, d, J=15.1 Hz),5.26 (1H, d, J=4.8 Hz), 5.84 (1H, d, J=4.8 Hz), 8.13 (1H, s)

Preparation 34

To a suspension of1,1′-carbonyldiimidazole (1.94 g) in methylenechloride (20 ml) was added tert-butyl N-(3-aminopropyl)carbamate (2.30g), and the mixture was stirred at room temperature for 1 hour. To thereaction mixture were added N-ethyldiisopropylamine (2.56 g) and4,5-diamino-1-methylpyrazole sulfuric acid salt (2.10 g), and themixture was stirred at 30° C. for 3 days. The reaction mixture wasconcentrated in vacuo. The residue was purified by column chromatographyon silica gel eluting with 6% methanol/chloroform to give5-amino-4-(3-(3-[(tert-butoxycarbonyl)amino]propyl)ureido)-1-methylpyrazole(1.75 g) as a solid.

¹H-NMR (DMSO-d₆) δ 1.37 (9H, s), 1.43-1.49 (2H, m), 2.89-2.93 (2H, m),2.98-3.01 (2H, m), 3.50 (3H, s), 4.79 (2H, br), 5.85 (1H, br), 6.77 (1H,br), 6.96 (1H, s), 7.12 (1H, br)

EXAMPLE 17

To a solution of benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(1.0 g) in N,N-dimethylformamide (2.0 ml) was added sodium iodide (199mg), and the mixture was stirred at room temperature for 30 minutes. Tothe reaction mixture was added5-amino-4-(3-(3-[(tert-butoxycarbonyl)amino]propyl)ureido)-1-methylpyrazole(415 mg) and the whole mixture was stirred at 32° C. for 24 hours. Tothe resulting reaction mixture were added ethyl acetate (50 ml) andwater (50 ml). The aqueous layer was separated, and the organic layerwas washed with 10% aqueous sodium trifluoroacetate solution and brine,dried over anhydrous sodium sulfate and filtered. The filtrate wasconcentrated to about 5 ml in vacuo. The concentrate was poured intodiisopropyl ether (100 ml), and the resulting precipitate was collectedby filtration and dried in vacuo. To a solution of the resulting solidin methylene chloride (3.6 ml) were added anisole (1.2 ml) andtrifluoroacetic acid (2.4 ml). The resulting solution was stirred atroom temperature for 4 hours and poured into diisopropyl ether (100 ml).The resulting precipitate was collected by filtration and dried in vacuoto give a crude product (939 mg), which was purified by preparative HPLCutilizing ODS column. The eluate containing a desired product wasconcentrated to about 30 ml in vacuo. The concentrate was adjusted toabout pH 3 with concentrated hydrochloric acid and chromatographed onDiaion® HP-20 (Mitsubishi Chemical Corporation) eluting with 30% aqueous2-propanol. The eluate-was concentrated to about 30 ml in vacuo andlyophilized to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-(3-amino-4-[3-(3-aminopropyl)ureido]-2-methyl-1-pyrazoliomethyl-3-cephem-4-carboxylate(53 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (3H, s), 1.53 (3H, s), 1.85-1.88 (2H, m), 3.03 (2H,t, J=8 Hz), 3.22(2H, t, J=l8 Hz), 3.26 (2H, t, J=7 Hz), 3.49 (1H, d,J=18 Hz), 3.72 (3H, s), 4.96 (1H, d, J=15 Hz), 5.16 (1H, d, J=15 Hz),5.25 (1H, d, J=5 Hz), 5.84 (1H, d, J=5 Hz), 7.88 (1H, s)

Preparation 35

To a suspension of 1,11-carbonyldiimidazole (973 mg) in methylenechloride (10 ml) was added tert-butyl N-(2-aminoethyl)carbamate (1.11 g)under ice-cooling, and the mixture was stirred at room temperature for 2hours. To the reaction mixture were added N-ethyldiisopropylamine (1.28g) and 3-amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine sulfuric acidsalt (1.18 g), and the mixture was stirred at 50° C. for 6 hours. Thereaction mixture was washed with brine. The organic layer was dried overanhydrous magnesium sulfate, filtered and concentrated in vacuo. Theresidue was purified by column chromatography on silica gel eluting with5% methanol/chloroform to give3-(3-{2-[(tert-butoxycarbonyl)amino]ethyl)ureido)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine(150 mg) as a solid.

¹H-NMR (CDCl₃) δ 1.43 (9H, s), 2.-11-2.16 (2H, m), 3.22-3.35 (6H, m),4.09 (2H, t, J=7 Hz), 4.69 (1H, br), 5.14 (2H, br), 5.69 (1H, br), 7.17(1H, s)

EXAMPLE 187β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-(3-[3-(2-aminoethyl)ureido]-4,5,6,7-tetrahydro-1-pyrazolo[1,5-a]pyrimidinio)methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem-4-carboxylateand3-(3-(2-[(tert-butoxycarbonyl)amino]ethyl}ureido)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidinein the same manner as in Example 17 as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (3H, s), 1.53 (3H, s), 2.09-2.21 (2H, m), 3.13 (2H,t, J=6 Hz), 3.24 (1H, d, J=18 Hz), 3.35-3.52 (5H, m), 4.12-4.15 (2H, m),4.88 (1H, d, J=16 Hz), 5.13 (1H, d, J=16 Hz), 5.25 (1H, d, J=5 Hz), 5.85(1H, d, J=5 Hz), 7.83 (1H, s)

Preparation 36

To a suspension of 1,1′-carbonyldiimidazole (973 mg) in methylenechloride (10 ml) was addedO-[2-(tert-butoxycarbonylamino)ethyl]hydroxylamine (1.11 g) underice-cooling, and the mixture was stirred at room temperature for 2hours. To the reaction mixture were added N-ethyldiisopropylamine (1.28g) and 4,5-diamino-1-methylpyrazole sulfuric acid salt (1.05 g), and themixture was stirred under reflux for 4 hours. The reaction mixture waswashed with brine. The organic layer was dried over anhydrous magnesiumsulfate, filtered and concentrated in vacuo. The residue was purified bycolumn chromatography on silica gel eluting with 10% methanol/chloroformto give5-amino-4-(3-{2-[(tert-butoxycarbonyl)amino]ethoxy}ureido)-1-methylpyrazole(255 mg) as a solid.

¹H-NMR (DMSO-d₆) δ 1.38 (9H, s), 3.19-3.20 (2H, m), 3.51 (3H, s), 3.72(2H, t, J=6 Hz), 4.86 (2H, br), 6.95 (1H, br), 7.06 (1H, s), 8.02 (1H,brs), 9.15 (1H, brs)

EXAMPLE 197β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-(3-amino-4-[3-(2-aminoethoxy)ureido]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem-4-carboxylateand5-amino-4-(3-{2-[(tert-butoxycarbonyl)amino]ethoxy)-ureido)-1-methylpyrazolein the same manner as in Example 17 as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (3H, s), 1.53 (3H, s), 3.21 (1H, d, J=18 Hz), 3.33(2H, t, J=5 Hz), 3.47 (1H, d, J=18 Hz), 3.74 (3H, s), 4.17 (2H, t, J=5Hz), 4.99 (1H, d, J=l5 Hz), 5.17 (1H, d, J=15 Hz), 5.26 (1H, d, J=5 Hz),5.86 (1H, d, J=5 Hz), 7.93 (1H, s)

Preparation 37

To a suspension of 1,1′-carbonyldiimidazole (1.95 g) in methylenechloride (20 ml) was added tert-butyl N-(2-aminoethyl)carbamate (1.92 g)under ice-cooling, and the mixture was stirred at room temperature for 2hours. To the reaction mixture were added N-ethyldiisopropylamine (2.59g) and 7-amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole sulfuric acid salt(2.22 g), and the mixture was stirred at room temperature for 16 hours.To the reaction mixture were added trityl chloride (9.0 g) andtriethylamine (3.0 g). The mixture was stirred at room temperature for24 hours. The reaction mixture was washed with 10% aqueous citric acidsolution, brine and saturated aqueous sodium hydrogen carbonatesolution. The organic layer was dried over anhydrous magnesium sulfate,filtered and concentrated in vacuo. The residue was purified by columnchromatography on silica gel eluting with 3% methanol/chloroform to give7-(3-{2-[(tert-butoxycarbonyl)amino]ethyl)ureido)-2,3-dihydro-1-tritylimidazo[1,2-b]pyrazole(800 mg) as a solid.

¹H-NMR (CDCl₃) δ 1.43 (9H, s), 3.19 (4H, br), 3.69 (1H, brs), 3.78-3.85(4H, m), 4.51 (1H, br),. 5.07 (1H, br), 7.20 (1H, s), 7.26-7.34 (9H, m),7.46-7.47 (6H, m)

EXAMPLE 20

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(820 mg) in N,N-dimethylformamide (2.4 ml) was addedN-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture was added7-(3-{2-[(tert-butoxycarbonyl)amino]ethyl)ureido)-2,3-dihydro-1-tritylimidazo[1,2-b]pyrazole(700 mg), and the whole mixture was stirred at room temperature for 6hours. To the resulting reaction mixture were added ethyl acetate (50ml) and water (50 ml). The aqueous layer was separated, and the organiclayer was washed with 10% aqueous sodium trifluoroacetate solution andbrine, dried over anhydrous sodium sulfate and filtered. The filtratewas concentrated to about 5 ml in vacuo. The concentrate was poured intodiisopropyl ether (120 ml)., and the resulting precipitate was collectedby filtration and dried in vacuo. To a solution of the resulting solidin methylene chloride (3.0 ml) were added anisole (1.0 ml) andtrifluoroacetic acid (2.0 ml). The resulting solution was stirred atroom temperature for 4 hours and poured into diisopropyl ether (120 ml).The resulting precipitate was collected by filtration and dried in vacuoto give a crude product (830 mg), which was purified by preparative HPLCutilizing ODS column. The eluate containing a desired product wasconcentrated to about 30 ml in vacuo. The concentrate was adjusted toabout pH 3 with concentrated hydrochloric acid and chromatographed onDiaion® HP-20 (Mitsubishi Chemical Corporation) eluting with 30% aqueous2-propanol. The eluate was concentrated to about 30 ml in vacuo andlyophilized to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{7-[3-(2-aminoethyl)ureido]-2,3-dihydro-5-(1H-imidazo[1,2-b]pyrazolio))methyl-3-cephem-4-carboxylate(28.5 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.53 (3H, s), 1.54 (3H, s), 3.14 (2H, t, J=6 Hz), 3.29(1H, d, J=18 Hz), 3.49 (2H, t, J=6 Hz), 3.57 (1H, d, J=18 Hz), 4.16 (2H,t, J=9 Hz), 4.31-4.45 (2H, m), 4.94 (1H, d, J=15 Hz), 5.02 (1H, d, J=15Hz), 5.27 (1H, d, J=5 Hz), 5.85 (1H, d, J=5 Hz), 7.95 (1H, s)

Preparation 38

To a suspension of 1,1′-carbonyldiimidazole (2.0 g) in dehydratedchloroform (30 ml) was added a solution of tert-butylN-(2-hydroxyethyl)carbamate (1.92 g) in dehydrated chloroform (10 ml)under ice-cooling, and the mixture was stirred at room temperature for 1hour. To the reaction mixture were added N-ethyldiisopropylamine (2.2ml) and 4,5-diamino-1-methylpyrazole sulfuric acid salt (2.58 g), andthe mixture was stirred at room temperature for 17.5 hours. To thereaction mixture were added trityl chloride (3.42 g) and triethylamine(1.25 g). The mixture was stirred at room temperature for 2 hours. Thereaction mixture was washed with 10% aqueous citric acid solution, brineand saturated aqueous sodium hydrogen carbonate solution. The organiclayer was dried over anhydrous magnesium sulfate, filtered andconcentrated in vacuo. The residue was purified by column chromatographyon silica gel eluting with 5% methanol/chloroform to give4-{[2-(tert-butoxycarbonylamino)ethoxycarbonyl]amino}-5-(tritylamino)-1-methylpyrazole(1.91 g) as a solid.

¹H-NMR (CDCl₃) δ 1.46 (9H, s), 2.89 (3H, s), 3.30-3.36 (2H, m),4.03-4.07 (2H, m), 4.37 (1H, brs), 4.75 (1H, br), 5.42 (1H, br),7.17-7.30 (16H, m)

EXAMPLE 217β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[(2-aminoethoxycarbonyl)amino]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylateand4-{[2-(tert-butoxycarbonylamino)ethoxycarbonyl]amino}-5-(tritylamino)-1-methylpyrazolein the same manner as in Example 20 as an amorphous solid.

¹H-NMR (D₂O) δ 1.53 (3H, s), 1.54 (3H, s), 3.18 (1H, d, J=18 Hz),3.30-3.38 (2H, m), 3.43 (1H, d, J=18 Hz), 3.71 (3H, s), 4.37-4.40 (2H,m), 4.97 (1H, d, J=15 Hz), 5.18 (1H, d, J=15 Hz), 5.24 (1H, d, J=5 Hz),5.83 (1H, d, J=5 Hz), 7.95 (1H, s)

Preparation 39

To a solution of 7-amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole sulfuricacid salt (1.42 g) and N-ethyldiisopropylamine (2.73 g) in methylenechloride (50 ml) was addedN-[2-(tert-butoxycarbonylamino)-acetoxy]succinimide (1.90 g). Themixture was stirred at room temperature for 22 hours. The reactionmixture was washed with saturated aqueous sodium hydrogen carbonatesolution, and the organic layer was dried over anhydrous magnesiumsulfate, filtered and concentrated in vacuo. The oily residue waspurified by column chromatography on silica gel eluting with 5%methanol/chloroform to give7-[2-(tert-butoxycarbonylamino)acetyl]amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole(1.07 g) as a solid.

¹H-NMR (CDCl₃) δ 1.47 (9H, s), 3.89 (2H, d, J=5.5 Hz), 3.97 (2H, dt,J=2.7, 7.3 Hz), 4.18 (2H, t, J=7.3 Hz), 4.55 (1H, br), 5.22 (1H, br),7.16 (1H, s), 7.95 (1H, br)

EXAMPLE 22

To a solution of benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido)-3-chloromethyl-3-cephem-4-carboxylate(1.0 g) in N,N-dimethylformamide (2.0 ml) was added sodium iodide (181mg), and the mixture was stirred at room temperature for 30 minutes. Tothe reaction mixture was added7-[2-(tert-butoxycarbonylamino)acetyl]amino-2,3-dihydro-1H-imidazo[1,2-b]pyrazole(421 mg). The whole mixture was stirred at 30° C. for 3 hours. To theresulting reaction mixture were added ethyl acetate (100 ml) and water(50 ml). The aqueous layer was separated, and the organic layer waswashed with 10% aqueous sodium trifluoroacetate solution and brine,dried over anhydrous sodium sulfate and filtered. The filtrate wasconcentrated to about 5 ml in vacuo. The concentrate was poured intodiisopropyl ether (150 ml), and the resulting precipitate was collectedby filtration and dried in vacuo. To a solution of the resulting solidin methylene chloride (3.0 ml) were added anisole (1.0 ml) andtrifluoroacetic acid (2.0 ml). The resulting solution was stirred atroom temperature for 4 hours and poured into diisopropyl ether (150 ml).The resulting precipitate was collected by filtration and dried in vacuoto give a crude product (830 mg), which was purified by preparative HPLCutilizing ODS column. The eluate containing a desired product wasconcentrated to about 30 ml in vacuo. The concentrate was adjusted toabout pH 3 with concentrated hydrochloric acid and chromatographed onDiaion® HP-20 (Mitsubishi Chemical Corporation) eluting with 30% aqueous2-propanol. The eluate was concentrated to about 30 ml in vacuo andlyophilized to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[7-(2-aminoacetamido)-2,3-dihydro-5-(1H-imidazo[1,2-b]pyrazolio)]methyl-3-cephem-4-carboxylate(20.8 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.51 (3H, s), 1.52 (3H, s), 3.26 (2H, d, J=18 Hz), 3.54(2H, d, J=18 Hz), 3.97 (2H, s), 4.16 (2H, t, J=9 Hz), 4.35 (1H, q, J=9Hz), 4.44 (1H, q, J=9 Hz), 4.97 (2H, d, J=15 Hz), 5.04 (2H, d, J=15 Hz),5.25 (1H, d, J=4 Hz), 5.84 (1H, d, J=4 Hz), 8.10 (1H, s)

Preparation 40

To a suspension of 4,5-diamino-1-(2-hydroxyethyl)pyrazole sulfuric acidsalt (1.20 g) and N-[2-(tert-butoxycarbonylamino)acetoxy]succinimide(1.35 g) in methylene chloride (20 ml) was added N-ethyldiisopropylamine(2.1 ml) under ice-cooling, and the mixture was stirred at roomtemperature for 17 hours. The reaction mixture was washed with water (40ml), saturated aqueous sodium hydrogen carbonate solution (40 ml) andbrine (40 ml). The organic layer was dried over anhydrous sodiumsulfate, filtered and concentrated in vacuo. The oily residue waspurified by column chromatography on silica gel eluting with 10%methanol/chloroform to give5-amino-4-[2-(tert-butoxycarbonylamino)acetyl]amino-1-(2-hydroxyethyl)pyrazole(1.20 g) as a solid.

¹H-NMR (CDCl₃) δ 1.46 (9H, s), 3.89-3.90 (4H, m), 4.00-4.04 (2H, m),4.26 (2H, br), 5.51 (1H, br), 7.17 1(H, s), 8.06 (1H, br)

EXAMPLE 237β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-(2-aminoacetamido)-2-(2-hydroxyethyl)-1-pyrazoliolmethyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem-4-carboxylateand5-amino-4-[2-(tert-butoxycarbonylamino)acetyl]amino-1-(2-hydroxyethyl)pyrazolein the same manner as in Example 22 as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (6H, s), 3.15 (2H, d, J=l8 Hz), 3.48 (2H, d, J=18Hz), 3.88 (1H, dt, J=16 Hz), 4.02 (2H, s), 4.42 (1H, dt, J=16.5 Hz),5.07 (2H, d, J=15 Hz), 5.13 (2H, d, J=15 Hz), 5.27 (1H, d, J=5 Hz), 5.84(1H, d, J=5 Hz), 8.09 (1H, s)

Preparation 41

To a solution of 3-amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidinesulfuric acid salt (2.96 g) and N-ethyldiisopropylamine (2.59 g) inmethylene chloride (70 ml) was addedN-[2-(tert-butoxycarbonylamino)acetoxy]succinimide (2.72 g). The mixturewas stirred at room temperature for 14 hours. The reaction mixture waswashed with saturated aqueous sodium hydrogen carbonate solution. Theorganic layer was dried over anhydrous magnesium sulfate, filtered andconcentrated in vacuo. The residue was purified by column chromatographyon silica gel eluting with 6% methanol/chloroform to give3-[2-(tert-butoxycarbonylamino)acetyl]amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine(2.4 g) as a solid.

¹H-NMR (CDCl₃) δ 1.46 (9H, s), 2.08-2.12 (2H, m), 3.29-3.32 (2H, m),3.90 (2H, br), 4.07 (2H, t, J=6.0 Hz), 5.00 (1H, br), 5.38 (1H, br),7.12 (1H, s), 8.11 (1H, br)

EXAMPLE 247β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido)-3-[3-(2-aminoacetamido)-4,5,6,7-tetrahydro-1-pyrazolo[1,5-a]pyrimidinio]methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem-4-carboxylateand3-[2-(tert-butoxycarbonylamino)acetyl]amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidinein the same manner as in Example 22 as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (3H, s), 1.53 (3H, s), 2.05-2.25 (2H, m), 3.21 (2H,d, J=18 Hz), 3.45 (2H, d, J=18 Hz), 3.30-3.45 (2H, m), 4.00 (2H, s),4.10-4.25 (2H, m), 4.92 (2H, d, J=15 Hz), 5.17 (2H, d, J=15 Hz), 5.24(1H, d, J=5 Hz), 5.84 (1H, d, J=5 Hz), 7.97 (1H, s)

Preparation 42

To a solution of 3-amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidinesulfuric acid salt (4.44 g) and N-ethyldiisopropylamine (3.88 g) inmethylene chloride (100 ml) was addedN-[3-(tert-butoxycarbonylamino)propionyloxy]succinimide (4.29 g). Themixture was stirred at room temperature for 6 hours. The reactionmixture was washed with saturated aqueous sodium hydrogen carbonatesolution. The organic layer was dried over anhydrous magnesium sulfate,filtered and concentrated in vacuo. The residue was purified by columnchromatography on silica gel eluting with 5% methanol/chloroform to give3-[3-(tert-butoxycarbonylamino)propionyl]amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine(3.67 g) as an oil.

¹H-NMR (CDCl₃) δ 1.43 (9H, s), 2.08-2.13 (2H, m), 2.52 (2H, t, J=6.0Hz), 3.32 (2H, t, J=5.0 Hz), 3.43-3.46 (2H, m), 4.07 (2H, t, J=6.0 Hz),5.12 (1H, br), 5.23 (1H, br), 7.13 (1H, s), 7.97 (1H, br)

EXAMPLE 257β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino.)acetamido]-3-[3-(3-aminopropionamido)-4,5,6,7-tetrahydro-1-pyrazolo[1,5-a]pyrimidinio]methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-tert-butoxycarbonylamino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)-acetamido]-3-chloromethyl-3-cephem-4-carboxylateand3-[3-(tert-butoxycarbonylamino)propionyl]amino-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidinein the same manner as in Example 22 as an amorphous solid.

¹H-NMR (D₂O) δ 1.51 (3H, s), 1.52 (3H, s), 2.05-2.25 (2H, m), 2.85 (2H,t, J=7 Hz), 3.20 (2H, d, J=18 Hz), 3.44 (2H, d, J=18 Hz), 3.30-3.45 (2H,m), 3.31 (2H, t, J=7 Hz), 4.05-4.20 (2H, m), 4.91 (2H, d, J=16 Hz), 5.16(2H, d, J=16 Hz), 5.23 (1H, d, J=5 Hz), 5.84 (1H, d, J=5 Hz), 7.92 (1H,s)

Preparation 43

To a solution of 5-amino-1-methylpyrazole (100 g) in water (700 ml) wereadded concentrated hydrochloric acid (86 ml) and sodium nitrite (63.9 g)in water (200 ml) at a temperature below 10° C. The reaction mixture wasstirred at 5° C. for 30 minutes. The precipitated solid was collected byfiltration and dried to give 5-amino-1-methyl-4-nitrosopyrazole (117 g).

¹H-NMR (DMSO-d₆) δ 3.52 and 3.59 (3H, s), 7.22 and 8.51 (1H, s), 8.17and 8.51 (1H, brs)

Preparation 44

To a suspension of 5-amino-1-methyl-4-nitrosopyrazole (117 g) were addedsulfuric acid (91 g) and 10% palladium on carbon (58 g). The mixture washydrogenated under balloon pressure for 10 hours. The reaction mixturewas filtered, and the filtrate was concentrated in vacuo. To theconcentrate was added isopropyl alcohol (2.3 L), and the mixture wasstirred for 1 hour. The precipitated solid was collected by filtrationand dried to give 4,5-diamino-1-methylpyrazole sulfuric acid salt (158g).

¹H-NMR (D₂O) δ 3.74 (3H, s), 7.80 (1H, s)

Preparation 45

A solution of 4,5-diamino-1-methylpyrazole sulfuric acid salt (158 g) inwater (1.1 L) was neutralized to pH 6.9 with 4N aqueous sodium hydroxidesolution, and dioxane (474 ml) was added to this solution. To theresulting mixture was added dropwise phenyl chloroformate (124 g)maintaining pH of the mixture at 6.9 with 4N aqueous sodium hydroxidesolution at a temperature below 10° C. The reaction mixture was stirredfor 1 hour. The precipitated solid was collected by filtration and driedto give 5-amino-1-methyl-4-phenoxycarbonylaminopyrazole (155 g).

¹H-NMR (DMSO-d₆) δ 3.52 (3H, s), 5.00 (2H, brs), 7.10-7.50 (6H, m), 8.93(1H, brs)

Preparation 46

To a suspension of 5-amino-1-methyl-4-phenoxycarbonylaminopyrazole(153.8 g) in tetrahydrofuran (1 L) were added triethylamine (67 g) andtriphenylmethyl chloride (185 g) at room temperature. The mixture wasstirred for 6.5 hours. To the reaction mixture was added heptane (2.6L), and the mixture was stirred for 1 hour. The precipitated solid wascollected by filtration and washed with heptane-diisopropyl ether (1:1).The crude solid was suspended in water (3 L), and the suspension wasstirred for 1 hour. The solid was collected by filtration and dried togive 1-methyl-4-phenoxycarbonylamino-5-triphenylmethylaminopyrazole(253.6 g).

¹H-NMR (DMSO-d₆) δ 2.74 (3H, s), 5.57 (1H, brs), 7.00-7.50 (21H, m),8.12 (1H, brs)

Preparation 47

To a suspension of1-methyl-4-phenoxycarbonylamino-5-triphenylmethylaminopyrazole (253.6 g)in N,N-dimethylformamide (1.5 L) were added triethylamine (59.5 g) andtert-butyl N-(2-aminoethyl)carbamate (94.2 g) in N,N-dimethylformamide(254 ml). The mixture was stirred for 5 hours and poured into water(10.6 L). The slurry was stirred for 1 hour. The precipitated solid wascollected by filtration and dried to give a crude product. The crudeproduct was suspended in N,N-dimethylformamide, and the suspension washeated under reflux for 20 minutes. The suspension was cooled to ambienttemperature over 4 hours. The solid was collected by filtration, washedwith acetonitrile and dried to give4-[N-(2-tert-butoxycarbonylaminoethyl)carbamoylamino]-1-methyl-5-triphenylmethylaminopyrazole(261.2 g).

¹H-NMR (DMSO-d₆) δ 2.69 (3H, s), 2.90-3.05 (4H, m), 5.69 (1H, brs),5.91-6.01 (1H, m), 6.74-6.81 (1H, m), 6.87 (1H, brs), 7.00 (1H, s),7.10-7.30 (15H, m)

Preparation 48

To a solution of(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)aceticacid (319 g) in N,N-dimethylacetamide (1.5 L) were added potassiumcarbonate (113 g) and methanesulfonyl chloride (126 ml) underice-cooling. The mixture was stirred at 10° C. for 2 hours. The reactionmixture was added to a mixture of ethyl acetate and water. The organiclayer was washed with water and brine to give an activated acidsolution. On the other hand, a suspension of 4-methoxybenzyl71-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride (300 g) ina mixture of water (1 L) and ethyl acetate (1 L) was adjusted to pH 6with triethylamine under ice-cooling. To the resulting mixture wasdropwise added the above obtained activated acid solution at 10° C.under stirring. Stirring was continued at 5-10° C. for 1.5 hours keepingpH of the reaction mixture at 6 with triethylamine. The organic layerwas separated, washed with water and brine, and evaporated in vacuo. Theconcentrate was poured into diisopropyl ether (15 L), and the resultingprecipitate was collected by filtration and dried to give4-methoxybenzyl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(495.7 g).

¹H-NMR (DMSO-d₆) δ 1.39 (9H, s), 1.44 (6H, s), 3.45-3.70 (2H, m), 3.76(3H, s), 4.46 and 4.54 (1H, ABq, J=16 Hz) 5.10-5.28 (2H+1H, m), 5.90(1H, dd, J=4.9, 8.5 Hz), 6.94 (2H, d, J=8.7 Hz), 7.36 (2H, d, J=8.7 Hz),8.18 (2H, brs), 9.52 (1H, d, J=8.5 Hz)

EXAMPLE 26

To a solution of 4-methoxybenzyl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(150 g) in N,N-dimethylformamide (400 ml) was added1,3-bis(trimethylsilyl)urea (225 g) and the mixture was stirred for 30minutes. Potassium iodide (51.2 g) was added to this solution, and themixture was stirred for 30 minutes.

4-[N-(2-tert-Butoxycarbonylaminoethyl)-carbamoylamino]-1-methyl-5-triphenylmethylaminopyrazole(147 g) was dissolved in N,N-dimethylformamide (650 ml) at 78° C. andthe solution was cooled to 45° C. The solution was added to the solutionof7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylateobtained above. The reaction mixture was stirred at 35° C. for 18.5hours and poured into a mixture of ethyl acetate (2 L), water (1.8 L).and 20% aqueous sodium chloride solution (150 ml). The organic layer waswashed with a mixture of 10% aqueous sodium thiosulfate solution (375ml) and 20% aqueous sodium chloride solution (375 ml). The organic layerwas washed successively with 10% aqueous sodium trifluoroacetatesolution three times (750 ml×3) and 20% aqueous sodium chloride solution(750 ml). The organic layer was concentrated in vacuo, and theprecipitated4-[N-(2-tert-butoxycarbonylaminoethyl)-carbamoylamino]-1-methyl-5-triphenylmethylaminopyrazolewas filtered off. The filtrate was further concentrated in vacuo to avolume of approximately 600 ml. This solution was added to diisopropylether and the suspension was stirred for 1 hour. The resulting solid wascollected by filtration and dried. The solid was dissolved indichloromethane (669 ml) To the solution were added anisole (223 ml) andtrifluoroacetic acid (669 ml). The reaction mixture was stirred for 4hours and poured into diisopropyl ether. The resulting solid wascollected by filtration and dried. This solid was suspended in water,and pH of the suspension was adjusted to 7 with aqueous ammonia solutionat a temperature below 10° C. The resulting precipitate was filteredoff. The filtrate was acidified to pH 1 with concentrated hydrochloricacid at a temperature below 10° C., and the resulting precipitate wasfiltered off. The filtrate was chromatographed on Diaion® HP-20 (11 L)eluting with 20% aqueous 2-propanol. The eluate was concentrated toabout 3.5 L in vacuo, and 2M sulfuric acid (51 ml) was added. Themixture was lyophilized to give a crude product (72.2 g).

The crude product (3 g) was purified by preparative HPLC utilizing ODScolumn. The eluate containing a desired product was concentrated invacuo. The concentrate was adjusted to about pH 1 with concentratedhydrochloric acid and chromatographed on Diaion® HP-20 (400 ml) elutingwith 20% aqueous 2-propanol. The eluate was concentrated to about 73 mlin vacuo, and 2M sulfuric acid (1.5 ml) was added. The mixture wasfurther evaporated to a volume of approximately 12.5 ml, and water (6ml) was added. After addition of seed crystals (10 mg), which resultedin the precipitation of a white solid, the mixture was stirred at roomtemperature for 1 hour. The mixture was further stirred at 5° C. for 13hours. 2-Propanol (20 ml) was added at 5° C. over 20 minutes, and theslurry was stirred at room temperature for 4 hours. 2-Propanol (20 ml)was added over 30 minutes, and the slurry was stirred at roomtemperature for 3 hours. The precipitated crystals were collected byfiltration and dried to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[N-(2-aminoethyl)carbamoylamino]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylicacid hydrogen sulfate (1.51 g) as crystals.

¹H-NMR (D₂O) δ 1.61 (6H, s), 3.10-3.55 (6H, m), 3.71 (3H, s), 5.02 and5.23 (2H, ABq, J=16.7 Hz), 5.25 (1H, d, J=4.9 Hz), 5.87 (1H, d, J=4.9Hz), 7.91 (1H, s)

Preparation 49

A suspension of 4,5-diamino-1-methylpyrazole sulfuric acid salt (20 g)in triethylamine (29.2 ml) was stirred at 0° C. for 10 minutes. Amixture of acetic anhydride (9.87 ml) and formic acid (7.96 ml) wasstirred at 40° C. for 30 minutes, cooled to 0° C., and added dropwise tothe above solution at 0° C. The whole mixture was stirred at 0° C. for 2hours. To the mixture was added brine, and the whole mixture wasextracted with tetrahydrofuran. The organic layer was dried overmagnesium sulfate and evaporated under reduced pressure to give crudeN-(5-amino-1-methyl-1H-pyrazol-4-yl)formamide, which was used in thenext step without further purification.

Preparation 50

The crude product of N-(5-amino-1-methyl-1H-pyrazol-4-yl)formamide(13.33 g) was dissolved in N,N-dimethylformamide (130 ml). To thesolution were added trityl chloride (29.2 g), triethylamine (66.3 ml)and 4-dimethylaminopyridine (465 mg), and the mixture was stirred at 60°C. for 5 hours. To the reaction mixture was added water, and the wholemixture was extracted with ethyl acetate. The organic layer was washedwith water and brine, and dried over magnesium sulfate. The solvent wasevaporated under reduced pressure to give a white solid. The solid wastriturated with ethyl acetate/diisopropyl ether (1:1) to giveN-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]formamide (19.18 g). The NMRspectrum of this compound indicates the existence of its rotamer.

¹H-NMR (DMSO-d₆) δ 2.76 and 2.92 (3H, s), 5.56 and 5.84 (1H, s), 7.0-7.4(16H, m), 7.66 (1H, d, J=1.7 Hz), 8.3-8.4 (1H, m)

ESI-MS: m/z=405.2(M+Na)⁺

Preparation 51

To a solution of N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]formamide(3.825 g) in N,N-dimethylformamide (66 ml) was added sodium hydride (264mg, 60% oil suspension) under a nitrogen atmosphere at 0° C. understirring. The mixture was stirred at 0° C. for 15 minutes. To themixture were added tert-butyl N-(3-bromopropyl)carbamate (2.62 g) inN,N-dimethylformamide (10 ml) and sodium iodide (1.65 g). The mixturewas warmed to room temperature and stirred for 2 hours. 10% Aqueouspotassium hydrogen sulfate solution (5 ml) was added, and the mixturewas extracted with ethyl acetate. The organic layer was washed withwater and brine, and dried over magnesium sulfate. The solvent wasevaporated under reduced pressure, and the residue was chromatographedon silica gel eluting with methylene chloride/ethyl acetate (4:1) togive tert-butyl3-{N-formyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)propylcarbamate(2.714 g). The NMR spectrum of this compound indicates the existence ofits rotamer.

¹H-NMR (DMSO-d₆) δ 1.37 and 1.39 (9H, s), 2.6-2.9 (6H, m), 2.89 (3H, s),5.34 and 6.01 (1H, s), 6.6-6.9 (1H, m), 7.0-7.4 (15H, m), 7.5-7.6 (1H,m), 7.95 (1H, s)

ESI-MS: m/z=562.3(M+Na)⁺

EXAMPLE 277β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-13-amino-4-[N-(3-aminopropyl)-N-formylamino]-2-methyl-1-pyrazoliolmethyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylateand tert-butyl3-{N-formyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)propylcarbamatein the same manner as in Example 1. The NMR spectrum of this compoundindicates the existence of its rotamer.

¹H-NMR (D₂O) δ 1.53 (6H, s), 1.7-2.1 (2H, m), 2.9-3.9 (9H, m), 4.97 and5.20 (2H, ABq, J=15.2 Hz), 5.26 (1H, d, J=4.8 Hz), 5.84 (1H, d, J=4.8Hz), 8.0-8.3 (2H, m)

EXAMPLE 28

To a suspension of7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)-acetamido]-3-{3-amino-4-[N-(3-aminopropyl)-N-formylamino]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylate(140 mg) in methanol (2.6 ml) was added concentrated hydrochloric acid(0.176 ml) at room temperature, and the mixture was stirred for 6.5hours. To the reaction mixture was added sodium hydrogen carbonate (177mg), and the mixture was purified by preparative HPLC (ODS column,acetonitrile/phosphate buffer (pH 7)=5:95). The eluate containing adesired product was evaporated to remove acetonitrile, acidified withdiluted hydrochloric acid and. chromatographed on Diaion® HP-20 elutingwith 20t aqueous 2-propanol. The eluate was concentrated under reducedpressure and lyophilized to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[(3-aminopropyl)amino]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylate439 mg).

¹H-NMR (D₂O) δ 1.52-1.54 (6H, m), 1.95 (2H, tt, J=7.3 Hz, 7.3 Hz),3.0-3.2 (4H, m), 3.16 and 3.38 (2H, ABq, J=17.7 Hz), 3.68 (3H, s), 4.89and 5.11 (2H, ABq, J=15.6 Hz), 5.22 (1H, d, J=4.8 Hz), 5.83 (1H, d,J=4.8 Hz), 7.59 (1H, s)

ESI-MS: m/z=636.3(M−H)⁻

Preparation 52

tert-Butyl2-{N-formyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)ethylcarbamate

The title compound was obtained fromN-[l-methyl-5-(tritylamino)-1H-pyrazol-4-yl]formamide and tert-butylN-(2-bromoethyl)carbamate in the same manner as in Preparation 51.

IR (KBr) 1709, 1670, 1170, 704 cm⁻¹

¹H-NMR (DMSO-d₆) δ 1.35 and 1.36 (9H, s), 2.65 and 2.75 (3H, s),2.73-2.90 (4H, m), 5.45 and 6.02 (1H, s), 6.78 and 6.88 (1H, t-like),7.05-7.30 (15H, m), 7.31 and 7.57 (1H, s)

ESI-MS: m/z=426.3(M+H⁺), 548.3(M+Na⁺)

EXAMPLE 297β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[N-(2-aminoethyl)-N-formylamino]-2-methyl-1-pyrazolio}methyl-3-cephem-4-carboxylate

The title compound was obtained from benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylateand tert-butyl2-{N-formyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)ethylcarbamatein the same manner as in Example 1.

IR (KBr) 1770, 1675, 1653, 1597 cm⁻¹

¹H-NMR (DMSO-d₆) δ 1.53 (6H, s), 3.12-3.78 (4H, m), 3.77 and 3.78 (3H,s), 3.86-3.96 (2H, m), 5.00 and 5.19 (2H, ABq, J=15.2 Hz), 5.28 (1H, d,J=4.8 Hz), 5.86 (1H, d, J=4.8 Hz), 8.15 and 8.18 (1H, s), 8.19 and 8.33(1H, s)

ESI-MS: m/z=652.2(M+H⁺)

EXAMPLE 307β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[(2-aminoethyl)amino]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylate

The title compound was obtained from7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-{3-amino-4-[N-(2-aminoethyl)-N-formylamino]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylatein the same manner as in Example 28.

IR (KBr) 1770, 1651, 1593 cm⁻¹

¹H-NMR (DMSO-d₆) δ 1.53 (3H, s), 1.59 (3H, s), 3.13-3.26 (4H, m), 3.26and 3.39 (2H, ABq, J=17.8 Hz), 3.68 (3H, s), 4.87 and 5.11 (2H, ABq,J=15.7 Hz), 5.25 (1H, d, J=4.8 Hz), 5.84 (1H, d, J=4.8 Hz), 7.63 (1H, s)

ESI-MS: m/z=622.2(M−H⁻)

Preparation 53

To a suspension of 1-methyl-1H-pyrazole-4,5-diamine sulfate (86 g) intetrahydrofuran (1.3 L) was added triethylamine (117 ml), and then(2S)-4-[(tert-butoxycarbonyl)amino]-2-hydroxybutanoic acid (82.5 g) wasadded to the mixture. To the mixture were added 1-hydroxybenzotriazole(58.3 g) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (82.7 g) under ice-cooling. The reaction mixture wasstirred at room temperature for 8 hours. To the reaction mixture wereadded ethyl acetate (1.3 L), saturated aqueous sodium hydrogen carbonatesolution and sodium chloride, and the mixture was stirred for 30minutes. The organic layer was separated, and the aqueous layer wasextracted with ethyl acetate (1.0 L) six times. The extract was driedover anhydrous magnesium sulfate, filtered and concentrated in vacuo.The residue was purified by silica gel column chromatography elutingwith ethyl acetate/tetrahydrofuran (1/1) to give tert-butyl{(3S)-4-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-hydroxy-4-oxobutyl)carbamate(69.5g).

¹H-NMR (CDCl₃) δ 1.43 (9H, s), 1.6-1.9 (1H, m), 1.9-2.2 (1H, m), 3.1-3.3(1H, m), 3.3-3.5 (1H, m), 3.65 (3H, s), 4.20 (1H, dd, J=3.6, 6.6 Hz),4.7-5.3 (4H, m), 7.24 (1H, s), 8.58 (1H, s)

[α]²⁰ _(D)(c=1.05, CHCl₃)=−27.06°

Preparation 54

To a solution of tert-butyl{(3S)-4-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-hydroxy-4-oxobutyl}carbamate(68.51 g) in N,N-dimethylformamide (350 ml) was addedchlorotriphenylmethane (67 g). To the mixture was dropwise addedtriethylamine (67 ml). The mixture was stirred at room temperature for12 hours. The reaction mixture was dissolved in dichloromethane (2 L).The solution was washed successively with water and brine. The extractwas dried over anhydrous magnesium sulfate, filtered and concentrated invacuo. The residue was triturated with acetonitrile and dried in vacuoto give tert-butyl((3S)-3-hydroxy-4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-4-oxobutyl)carbamate(64 g).

¹H-NMR (CDCl₃) δ 1.46 (9H, s), 1.3-1.6 (1H, m), 1.8-2.1 (1H, m), 2.95(3H, s), 2.9-3.2 (1H, m), 3.3-3.6 (1H, m), 3.95 (1H, m), 4.53 (1H, d,J=4.5 Hz), 4.74 (1H, s), 4.92 (1H, brs), 7.1-7.3 (15H, m), 7.39 (1H, s),7.73 (1H, s)

ESI-MS: m/z=638.2(M+H+Na⁺)

[α]²⁰ _(D)(C=1.025, CHCl₃)=−36.5°

EXAMPLE 31

To a solution of 4-methoxybenzyl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(130 g) in N,N-dimethylformamide (400 ml) was added1,3-bis(trimethylsilyl)urea (195 g), and the mixture was stirred at roomtemperature for 30 minutes. To the solution was added potassium iodide(44.4 g), and the mixture was stirred at room temperature for 30minutes. To the reaction mixture was added tert-butyl((3S)-3-hydroxy-4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-4-oxobutyl)carbamate(106 g), and the whole mixture was stirred at 35° C. for 22 hours. Tothe reaction mixture was added ethyl acetate (1.7 L), and the mixturewas washed successively with water (1.6 L), 10% aqueous sodiumtrifluoroacetate solution (650 ml×3) and brine (650 ml), dried overmagnesium sulfate and filtered. The filtrate was concentrated to about 1L in vacuo. The concentrate was poured into diisopropyl ether (3 L), andthe resulting precipitate was collected by filtration and dried invacuo. To a solution of the solid in methylene chloride (660 ml) wereadded anisole (220 ml) and trifluoroacetic acid (660 ml).

The resulting solution was stirred at room temperature for 4 hours andpoured into diisopropyl ether (7 L). The resulting precipitate wascollected by filtration and dried in vacuo to give a crude product(156.2 g). The crude product was dissolved in water (3.5 L). Thesolution was adjusted to about pH 3 with concentrated hydrochloric acidand chromatographed on Diaion® HP-20 (Mitsubishi Chemical Corporation)eluting with 20% aqueous 2-propanol. The eluate was concentrated toabout 1.5 L in vacuo, and 2M aqueous sulfuric acid solution (33.18 ml)was added. The mixture was lyophilized. The lyophilized product (40 g)was dissolved in phosphate buffer (pH 7) and purified by preparativeHPLC utilizing ODS column. The eluate containing a desired product wasconcentrated to about 30 ml in vacuo. The concentrate was adjusted toabout pH 3 with concentrated hydrochloric acid and chromatographed onDiaion® HP-20 (Mitsubishi Chemical Corporation) eluting with 10% aqueous2-propanbl. The eluate was concentrated to about 1 L in vacuo, and 2Maqueous sulfuric acid solution was added (13.59 ml). The resultingsolution was lyophilized to give7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-(3-amino-4-[((2S)-4-amino-2-hydroxybutanoyl)amino]-2-methyl-1-pyrazolio)methyl-3-cephem-4-carboxylicacid hydrogen sulfate (20.82 g) as an amorphous solid.

¹H-NMR (D₂O) δ 1.61 (6H, s), 1.9-2.4 (2H, m), 3.20 (1H, d, J=17.6 Hz),3.0-3.3 (2H, m), 3.45 (1H, d, J=17.6 Hz), 3.74 (3H, s), 4.47 (1H, dd,J=4, 6.3 Hz), 5.06 (1H, d, J=15.7 Hz), 5.25 (1H, d, J=4.8 Hz), 5.28 (1H,d, J=15.7 Hz), 5.87 (1H, d, J=4.8 Hz), 8.07 (1H, s)

Preparation 55

To a suspension of 1-methyl-N⁵-trityl-1H-pyrazole-4,5-diamine (1.60 g)in ethanol (50 ml) were added triethylamine (0.627 ml) and diethylsquarate (0.858 ml), and the mixture was stirred at room temperature for22 hours. To the reaction mixture were added ethyl acetate (200 ml) andhexane (100 ml), and the solution was washed successively with water, 5%aqueous citric acid solution and brine. The organic layer was dried overanhydrous sodium sulfate, filtered and concentrated in vacuo. Thecrystalline residue was washed with diethyl ether and dried in vacuo togive3-ethoxy-.4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-cyclobutene-1,2-dione(1.45 g) as a solid.

¹H-NMR (CDCl₃) δ 1.42 (3H, br), 2.99 (3H, s), 4.41 (1H, brs), 4.69 (2H,q, J=7.2 Hz), 6.40 (1H, br), 7.13-7.35 (16H, m)

Preparation 56

To a suspension of tert-butyl 2-aminoethylcarbamate (288 mg) and3-ethoxy-4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-cyclobutene-1,2-dione(718 mg) in ethanol (20 ml) was added triethylamine (0.209 ml), and themixture was stirred under reflux for 4 hours. To the reaction mixturewere added diethyl ether and hexane. The crystalline precipitate wascollected by filtration and dried in vacuo to give tert-butyl2-[(2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3,4-dioxocyclobut-1-en-1-yl)aminolethylcarbamate(830 mg) as a solid.

¹H-NMR (CDCl₃) δ 1.40 (9H, s), 3.07-3.28 (5H, m), 3.38-3.67 (2H, m),4.53-4.84 (1H, br), 4.84 (1H, br), 7.15-7.22 (6H, m), 7.23 (1H_(,) s),7.22-7.34 (9H, m)

EXAMPLE 32

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(901 mg) in N,N-dimethylformamide (1.8 ml) was addedN-(trimethylsilyl)acetamide (720 mg), and the mixture was stirred atroom temperature for 1 hour. To the reaction mixture was added asolution of tert-butyl2-[(2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3,4-dioxocyclobut-1-en-1-yl)amino]ethylcarbamate(682 mg) in N,N-dimethylformamide (6.3 ml), and the whole mixture wasstirred at 35-40° C. for 7 hours. To the resulting reaction mixture wasadded ethyl acetate, and the precipitate was filtered off. The filtratewas washed successively with water and brine, dried over anhydroussodium sulfate and filtered. The filtrate was concentrated to about 5 mlin vacuo. The concentrate was poured into diisopropyl ether (80 ml), andthe resulting precipitate was collected by filtration and dried invacuo. To a solution of the resulting solid in methylene chloride (2.6ml) were added anisole (0.88 ml) and trifluoroacetic acid (2.6 ml). Theresulting solution was stirred at room temperature for 3 hours andpoured into diisopropyl ether (80 ml). The resulting precipitate wascollected by filtration and dried in vacuo to give a crude product (580mg), which was purified by preparative HPLC utilizing ODS column. Theeluate containing a desired product was concentrated to about 30 ml invacuo. The concentrate was adjusted to about pH 3 with concentratedhydrochloric acid and chromatographed on Diaion® HP-20 (MitsubishiChemical Corporation) eluting with 30% aqueous 2-propanol. The eluatewas concentrated to about 10 ml in vacuo and lyophilized to give3-{[3-amino-4-((2-[(2-aminoethyl)amino]-3,4-dioxo-1-cyclobuten-1-yl}amino)-2-methyl-1-pyrazolio]methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(22 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.53 (3H, s), 1.54 (3H, s), 3.26-3.36 (1H, m), 3.27 (2H,t, J=5.7 Hz), 3.58-3.69 (1H, m), 3.74 (3H, s), 3.86-4.03 (2H, m), 4.93(1H, d, J=14.5 Hz), 5.10 (1H, d, J=14.5 Hz), 5.29 (1H, d, J=4.3 Hz),5.83 (1H, d, J=4.3 Hz), 7.99 (1H, s)

Preparation 57

To a suspension-of tert-butyl 3-aminopropylcarbamate (366 mg) and3-ethoxy-4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl)amino}-3-cyclobutene-1,2-dione(670 mg) in ethanol (30 ml) was added triethylamine (0.195 ml), and themixture was stirred under reflux for 3 hours. To the reaction mixturewere added diethyl ether (40 ml) and hexane (10 ml). The crystallineprecipitate was collected by filtration and dried in vacuo to givetert-butyl{3-[(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3,4-dioxo-1-cyclobuten-1-yl)amino]propyl)carbamate(788 mg) as a solid.

¹H-NMR (CDCl₃) δ 1.43 (9H, s), 1.67 (2H, quintet, J=5.5 Hz) 3.15 (2H, q,J=5.5 Hz), 3.17 (3H, s), 3.60 (2H, q, J=5.5 Hz), 4.82 (1H, brs), 4.86(1H, t, J=5.5 Hz), 5.44 (1H, br), 5.86 (1H, br), 7.13-7.33 (15H, m),7.17 (1H, s)

EXAMPLE 33

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(819 mg) in N,N-dimethylformamide (1.6 ml) was addedN-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred atroom temperature for 40 minutes. To the reaction mixture was-added asolution of tert-butyl(3-[(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3,4-dioxo-1-cyclobuten-1-yl)amino]propyl}carbamate(637 mg) in N,N-dimethylformamide (3.2 ml), and the whole mixture wasstirred at 35-400° C. for 3.5 hours. To the resulting reaction mixturewas added ethyl acetate (60 ml) and the precipitate was filtered off.The filtrate was washed successively with water (50 ml×2) and brine (50ml), dried over anhydrous sodium sulfate and filtered. The filtrate wasconcentrated to about 8 ml in vacuo. The concentrate was poured intodiisopropyl ether (80 ml), and the resulting precipitate was-collectedby filtration and dried in vacuo. To a solution of the resulting solidin methylene chloride (2.4,ml) were added anisole (0.80 ml) andtrifluoroacetic acid (1.6 ml). The resulting solution was stirred atroom temperature for 3 hours and poured into diisopropyl ether (80 ml).The resulting precipitate was collected by filtration and dried in vacuoto give a crude product (565 mg), which was purified by preparative HPLCutilizing ODS column eluting with a mixture of acetonitrile andphosphate buffer (pH 5.5). The eluate containing a desired product wasconcentrated to about 20 ml in vacuo. The concentrate was desalted bypreparative HPLC utilizing ODS column, and the fraction eluted with 8%acetonitrile/0.01 M hydrochloric acid was concentrated to about 10 ml invacuo and lyophilized to give3-{[3-amino-4-({2-[(3-aminopropyl)amino]-3,4-dioxo-1-cyclobuten-1-yl}amino)-2-methyl-1-pyrazolio]methyl}-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylatetrihydrochloride (34 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.62 (6H, s), 2.02 (2H, quintet, J=7.3 Hz), 3.09 (2H, t,J=7.3 Hz), 3.32 (1H, d, J=17.5 Hz), 3.54-3.65 (1H, m), 3.67-3.78 (2H,m), 3.75 (3H, s), 4.93-5.23 (2H, m), 5.30 (1H, d, J=4.5 Hz), 5.86 (1H,d, J=4.5 Hz), 7.99 (1H, s)

Preparation 58

To a solution of 1,1′-(1,2-dioxo-1,2-ethanediyl)bis-1H-imidazole (761mg) in N,N-dimethylformamide (8 ml) was added1-methyl-N⁵-trityl-1H-pyrazole-4,5-diamine (709 mg) under ice-cooling,and the mixture was stirred at room temperature for 30 minutes. To thereaction mixture was added a solution of tert-butyl2-aminoethylcarbamate (1.28 g) in N,N-dimethylformamide (2 ml), and themixture was stirred at room temperature for 27 hours. To the reactionmixture was added ethyl acetate (50 ml). After the precipitate wasfiltered off, the filtrate was washed successively with water, 5%.aqueous citric acid solution and brine. The organic layer was dried overanhydrous sodium sulfate, filtered and concentrated in vacuo. Thecrystalline residue was washed with a mixed solvent of diethyl ether andethyl acetate and dried in vacuo to give tert-butyl{2-[(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-2-oxoacetyl)amino]ethyl}carbamate(823 mg) as a solid.

¹H-NMR (CDCl₃) δ 1.43 (9H, s), 2.97 (3H, s), 3.31 (2H, q, J=5.5 Hz),3.43 (2H, q, J=5.5 Hz), 4.53 (1H, s), 4.84 (1H, brs), 7.10-7.30 (15H,m), 7.47 (1H, s), 7.67 (1H, brs), 8.20 (1H, brs)

EXAMPLE 34

To a solution of 4-methoxybenzyl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(618 mg) in N,N-dimethylformamide (1.5 ml) was addedN-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred atroom temperature for 40 minutes. To the solution was added potassiumiodide (232 mg), and the mixture was stirred at room temperature for 35minutes. To the reaction mixture was added a solution of tert-butyl{2-[(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-2-oxoacetyl)amino]ethyl}carbamate(626 mg) in N,N-dimethylformamide (3 ml), and the whole mixture wasstirred at 35-40° C. for 24 hours. To the resulting reaction mixture wasadded ethyl acetate (50 ml), and the solution was washed successivelywith water (50 ml×2), 10% aqueous sodium trifluoroacetate solution (50ml×2) and brine (50 ml), dried over anhydrous sodium sulfate andfiltered. The filtrate was concentrated to about 10 ml in vacuo. Theconcentrate was poured into diisopropyl ether (60 ml), and the resultingprecipitate was collected by filtration and dried in vacuo. To asolution of the solid in methylene chloride (2.9 ml) were added anisole(0.95 ml) and trifluoroacetic acid (2.9 ml). The resulting solution wasstirred at room temperature for 4 hours and poured into diisopropylether (60 ml). The resulting precipitate was collected by filtration anddried in vacuo to give a crude product (770 mg), which was purified bypreparative HPLC utilizing ODS column. The eluate containing a desiredproduct was concentrated to about 30 ml in vacuo. The concentrate wasadjusted to about pH 3 with concentrated hydrochloric acid andchromatographed on Diaion® HP-20 (Mitsubishi Chemical Corporation)eluting with 30% aqueous 2-propanol. The eluate was concentrated toabout 10 ml in vatcuo and lyophilized to give3-([3-amino-4-({2-[(2-aminoethyl)amino]-2-oxoacetyl)amino)-²-methyl-1-pyrazolio]methyl}-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(31 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.52. (3H, s), 1.53 (3H, s), 3.20 (1H, d, J=18.0 Hz),3.24 (2H, t, J=6.0 Hz), 3.45 (1H, d, J=18.0 Hz), 3.66 (2H, t, J=6.0 Hz),3.75 (3H, s), 5.02 (1H, d, J=15.5 Hz), 5.21 (1H, d, J=15.5 Hz), 5.25(1H, d, J=5.0 Hz), 5.85 (1H, d, J=5.0 Hz), 8.14 (1H, s)

Preparation 59

To a suspension of phenyl[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (711 mg) andtert-butyl 3-azetidinylcarbamate acetic acid salt (418 mg) in methylenechloride (8 ml) was added N-ethyldiisopropylamine (0.62 ml), and themixture was stirred under reflux for 16 hours. To the reaction mixturewas added methylene chloride, and the solution was washed successivelywith 10% aqueous citric acid solution, 10% aqueous sodium hydroxidesolution and brine. The organic layer was dried over anhydrous magnesiumsulfate, filtered and concentrated in vacuo. The residue was trituratedwith a mixed solvent of ethyl acetate and hexane to give tert-butyl[1-(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino]carbonyl)-3-azetidinyl]carbamate(735 mg) as a solid.

¹H-NMR (CDCl₃) δ 1.47 (9H, s), 2.92 (3H, s), 3.56 (2H, dd, J=7.5, 5.0Hz), 4.02 (2H, dd, J=7.5, 7.5 Hz), 4.42 (1H, brs), 4.71 (1H, s), 4.74(1H, s), 4.94 (1H, brs), 7.18-7.21 (7H, m), 7.25-7.32 (9H, m)

EXAMPLE 35

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(819 mg) in N,N-dimethylformamide (2.4 ml) was addedN-(trimethylsilyl)acetamide (655 mg), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture was added asolution of tert-butyl[1-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-3-azetidinyl]carbamate(553 mg) in N,N-dimethylformamide (3 ml), and the whole mixture wasstirred at room temperature for 3 hours, and then stirred at 50° C. for1 hour. To the resulting reaction mixture were added ethyl acetate (50ml) and water (50 ml). The aqueous layer was separated, and the organiclayer was washed with water and brine, dried over anhydrous magnesiumsulfate and filtered. The filtrate was concentrated to about 5 ml invacuo. The concentrate was poured into diisopropyl ether (80 ml), andthe resulting precipitate was collected by filtration and dried invacuo. To a solution of the resulting solid in methylene chloride (2.1ml) were added anisole (0.7 ml) and trifluoroacetic acid (2.1 ml). Theresulting solution was stirred at room temperature for 4.5 hours andpoured into diisopropyl ether (80 ml). The resulting precipitate wascollected by filtration and dried in vacuo to give a crude product (521mg), which was purified by preparative HPLC utilizing ODS column elutingwith a mixture of acetonitrile and phosphate buffer (pH 5.5). The eluatecontaining a desired product was concentrated to about 20 ml in vacuo.The concentrate was desalted by preparative HPLC utilizing ODS column,and the fraction eluted with 7% acetonitrile/0.01 M hydrochloric acidwas concentrated to about 10 ml in vacuo and lyophilized to give3-[(3-amino-4-([(3-amino-1-azetidinyl)carbonyl]amino]-2-methyl-1-pyrazolio)methyl]-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylatetrihydrochloride (22 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.62 (3H, s), 1.63 (3H, s), 3.25 (1H, d, J=17.9 Hz), 3.50(1H, d, J=17.9 Hz), 3.72 (3H, s), 4.14 (2H, dd, J=9.6, 4.4 Hz), 4.25(1H, tt, J=7.8, 4.6 Hz), 4.46 (2H, dd, J=9.6, 7.8 Hz), 5.08 (1H, d,J=15.6 Hz), 5.24 (1H, d, J=15.6 Hz), 5.27 (1H, d, J=4.6 Hz), 5.88 (1H,d, J=4.6 Hz), 7.91 (1H, s)

Preparation 60

To a suspension of phenyl[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (2.18 g) andtert-butyl 3-amino-1-azetidinecarboxylate (793 mg) in methylene chloride(20 ml) was added N-ethyldiisopropylamine (1.07 ml), and the mixture wasstirred under reflux for 40 hours. To the reaction mixture was addedmethylene chloride, and the solution was washed successively with 10%aqueous citric acid solution, 10% aqueous sodium hydroxide solution andbrine. The organic layer was dried over anhydrous magnesium sulfate,filtered and concentrated in vacuo. The residue was purified by columnchromatography on silica gel eluting with 10% methanol/methylenechloride to give tert-butyl3-[(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-1-azetidinecarboxylate(1.52 g) as a solid.

¹H-NMR (CDCl₃) δ 1.44 (9H, s), 3.03 (3H, s), 3.59 (2H, dd, J=9.2, 5.0Hz), 4.17 (2H, dd, J=9.2, 7.8 Hz), 4.39-4.43 (3H, m), 4.64 (1H, brs),7.18-7.21 (6H, m), 7.27 (1H, s) 7.29-7.32 (9H, m)

EXAMPLE 36

To a solution of 4-methoxybenzyl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(1.48 g) in N,N-dimethylformamide (3.0 ml) was addedN-(trimethylsilyl)acetamide (1.42 g), and the mixture was stirred atroom temperature for 30 minutes. To the solution was added potassiumiodide (504 mg) and the mixture was stirred at room temperature for 30minutes. To the reaction mixture was added a solution of tert-butyl3-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-1-azetidinecarboxylate(1.20 g) in N,N-dimethylformamide (2.2 ml), and the whole mixture wasstirred at 50° C. for 16 hours. To the 35 -resulting reaction mixturewas added ethyl-acetate (200 ml), and the solution was washedsuccessively with water (50 ml), 10% aqueous sodium trifluoroacetatesolution (50 ml×2) and brine (50 ml), dried over anhydrous sodiumsulfate and filtered. The filtrate was concentrated to about 10 ml invacuo. The concentrate was poured into diisopropyl ether (160 ml), andthe resulting precipitate was collected by filtration and dried invacuo. To a solution of the solid in methylene chloride (8.64 ml) wereadded anisole (2.88 ml) and trifluoroacetic acid (8.64 ml). Theresulting solution was stirred at room temperature for 3 hours andpoured into diisopropyl ether (160 ml). The resulting precipitate wascollected by filtration and dried in vacuo to give a crude product (2.22g), which was purified by preparative HPLC utilizing ODS column elutingwith a mixture of acetonitrile and phosphate buffer (pH 5.5). The eluatecontaining a desired product was concentrated to about 20 ml in vacuo.The concentrate was desalted by preparative HPLC utilizing ODS column,and the fraction eluted with 8% aqueous acetonitrile was concentrated toabout 10 ml in vacuo and lyophilized to give3-[(3-amino-4-{[(3-azetidinylamino)carbonyl]amino}-2-methyl-1-pyrazolio)methyl]-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(220 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.50 (3H, s), 1.51 (3H, s), 3.20 (1H, d, J=17.6 Hz), 3.47(1H, d, J=17.6 Hz), 3.70 (3H, s), 4.18 (2H, dd, J=11.2, 7.6 Hz), 4.31(2H, dd, J=11.2, 8.3 Hz), 4.68 (1H, tt, J=8.3, 7.6 Hz), 4.94 (1H, d,J=15.6 Hz), 5.15 (1H, d, J=15.6 Hz), 5.23 (1H, d, J=4.8 Hz), 5.83 (1H,d, J=4.8 Hz), 7.87 (1H, s)

Preparation 61

To a suspension of phenyl[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (786 mg) andtert-butyl 3-pyrrolidinylcarbamate (373 mg) in methylene chloride (6 ml)was added N-ethyldiisopropylamine (0.43 ml), and the mixture was stirredunder reflux for 10 hours. The reaction mixture was washed successivelywith 10% aqueous citric acid solution, brine and saturated aqueoussodium hydrogen carbonate solution. The organic layer was dried overanhydrous magnesium sulfate, filtered and concentrated in vacuo to givetert-butyl[1-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-3-pyrrolidinyl]carbamate(730 mg) as a solid.

¹H-NMR (CDCl₃) δ 1.48 (9H, s), 1.82-1.88 (1H, m), 2.12-2.18 (1H, m),2.89 (3H, s), 2.89-3.03 (1H, m), 3.20-3.30 (2H, m), 3.38-3.43 (1H, m),4.22 (1H, br), 4.69 (1H, br) 4.88 (1H, brs),. 4.96 (1H, brs), 7.18-7.27(16H, m)

EXAMPLE 37

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(819 mg) in N,N-dimethylformamide (2.4 ml) was addedN-(trimethylsilyl)acetamide (655 mg), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture was added asolution of tert-butyl[1-(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-3-pyrrolidinyl]carbamate(567 mg) in N,N-dimethylformamide (3.0 ml). The whole mixture wasstirred at room temperature for 3 hours. To the resulting reactionmixture were added ethyl acetate (100 ml) and water (50 ml). The aqueouslayer was separated, and the organic layer was washed successively with10% aqueous sodium trifluoroacetate solution, 10% aqueous sodiumthiosulfate solution and brine, dried over sodium sulfate and filtered.The filtrate was concentrated to about 2.5 ml in vacuo. The concentratewas poured into diisopropyl ether (80 ml), and the resulting precipitatewas collected by filtration and dried in vacuo. To a solution of theresulting solid in methylene chloride (2.55 ml) were added anisole (0.85ml) and trifluoroacetic acid (2.55 ml), and the mixture was stirred atroom temperature for 3 hours. The reaction mixture was poured intodiisopropyl ether (80 ml), and the resulting precipitate was collectedby filtration and dried in vacuo to give a crude product (608 mg), whichwas purified by preparative HPLC utilizing ODS column eluting with amixture of acetonitrile and phosphate buffer (pH 5.5). The eluatecontaining a desired product was concentrated to about 20 ml in vacuo.The concentrate was desalted by preparative HPLC utilizing ODS column,and the fraction eluted with 7% acetonitrile/0.01 M hydrochloric acidwas concentrated to about 10 ml in vacuo and lyophilized to give3-[(3-amino-4-{[(3-amino-1-pyrrolidinyl)carbonyl]amino)-2-methyl-1-pyrazolio)methyl}-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylatetrihydrochloride (31 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.61 (3H, s), 1.61 (3H, s), 2.13-2.27 (1H, m), 2.39-2.54(1H, m), 3.29 (1H, d, J=18.1 Hz), 3.51 (1H, d, J=18.1 Hz), 3.55-3.68(3H, m), 3.73 (3H, s), 3.80 (1H, dd, J=11.5, 6.0 Hz), 4.01-4.11 (1H, m),5.20 (1H, d, J=16.0 Hz), 5.24 (1H, d, J=16.0 Hz), 5.28 (1H, d, J=4.8Hz), 5.89 (1H, d, J=4.8 Hz), 7.91 (1H, s)

Preparation 62

To a suspension of phenyl[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (711 mg) andtert-butyl 3-amino-1-pyrrolidinecarboxylate (372 mg) in methylenechloride (15 ml) was added N-ethyldiisopropylamine (0.51 ml), and themixture was stirred under reflux for 17 hours. The reaction mixture waswashed successively with 10% aqueous citric acid solution, brine andsaturated aqueous sodium hydrogen carbonate solution. The organic layerwas dried over anhydrous magnesium sulfate, filtered and concentrated invacuo. The residue was purified by column chromatography on silica geleluting with 10% methanol/methylene chloride to give tert-butyl3-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-1-pyrrolidinecarboxylate(511 mg) as a solid.

¹H-NMR (CDCl₃) δ 1.46 (9H, s), 1.66-1.74 (1H, m), 2.04-2.11 (1H, m),2.9-7 (3H, s), 3.05-3.11 (1H, m), 3.30-3.43 (2H, m), 3.53-3.58 (1H, m),4.16-4.23 (2H, m), 4.45 (1H, brs), 4.74 (1H, br), 7.18-7.20 (6H, m),7.28-7.30 (10H, m)

EXAMPLE 38

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(707 mg) in N,N-dimethylformamide (2.1 ml) was addedN-(trimethylsilyl)acetamide (566 mg), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture-was added asolution of tert-butyl3-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)amino]-1-pyrrolidinecarboxylate(490 mg) in N,N-dimethylformamide (2.0 ml). The whole mixture wasstirred at room temperature for 3 hours. To the resulting reactionmixture were added ethyl acetate (100 ml) and water (50 ml). The aqueouslayer was separated, and the organic layer was washed successively with10% aqueous sodium trifluoroacetate solution, 10% aqueous sodiumthiosulfate solution and brine, dried over sodium sulfate and filtered.The filtrate was concentrated to about 3 ml in vacuo. The concentratewas poured into diisopropyl ether (80 ml), and the resulting precipitatewas collected by filtration and dried in vacuo. To a solution of theresulting solid in methylene chloride (1.83 ml) were added anisole (0.61ml) and trifluoroacetic acid (1.83 ml), and the mixture was stirred atroom temperature for 5 hours. The reaction mixture was poured intodiisopropyl ether (8-0 ml), and the resulting precipitate was collectedby filtration and dried in vacuo to give a crude product (440 mg), whichwas purified by preparative HPLC utilizing ODS column. The eluatecontaining desired products was concentrated to about 30 ml in vacuo.The concentrate was adjusted to about pH 3 with concentratedhydrochloric acid and chromatographed on Diaion® HP-20 (MitsubishiChemical Corporation) eluting with 30% aqueous 2-propanol. The eluatewas concentrated to about 30 ml in vacuo and lyophilized to give3-[(3-amino-2-methyl-4-{[(3-pyrrolidinylamino)carbonyl]amino)-1-pyrazolio)methyl]-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(18 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.54 (3H, s), 1.55 (3H, s), 2.00-2.10 (1H, m), 2.30-2.40(1H, m), 3.23 (0.5H, d, J=17.9 Hz), 3.24 (0.5H, d, J=17.9 Hz), 3.27-3.34(1H, m), 3.34-3.43 (1H, m), 3.45-3.57 (3H, m), 3.72 (3H, s), 4.36-4.46(1H, m), 4.95 (0.5H, d, J=15.1 Hz), 4.96 (0.5H, d, J=15.6 Hz), 5.17 (1H,d, J=15.6 Hz), 5.26 (1H, d, J=5.0 Hz), 5.85 (1H, d, J=5.0 Hz), 7.88 (1H,s)

Preparation 63

To a suspension of tert-butyl{2-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-ethyl}carbamate(10.8 g) in methanol (50 ml) was added 4M hydrogen chloride solution indioxane (50 ml). The mixture was stirred at room temperature for 3hours. The solvent was concentrated in vacuo, and the residue wastriturated with ethyl acetate and dried in vacuo to giveN-(2-aminoethyl)-N′-(5-amino-1-methyl-1H-pyrazol-4-yl)ureatrihydrochloride (5.6 g) as a solid.

¹H-NMR (DMSO-d₆) δ 2.84-2.87 (2H, m), 3.30 (2H, brs), 3.71 (3H, s), 6.57(1H, br), 7.91 (1H, s), 8.05 (4H, br), 8.55 (1H, br)

Preparation 64

To a solution ofN-(2-aminoethyl)-N′-(5-amino-1-methyl-1H-pyrazol-4-yl)ureatrihydrochloride (3.1 g) and triethylamine (4.6 g) in chloroform (100ml) was added di-tert-butyl({[(trifluoromethyl)sulfonyl]imino)-methylene)biscarbamate (5.9 g). Themixture was stirred at room temperature for 90 minutes. The reactionmixture was washed successively with 10% aqueous citric acid solution,brine and saturated aqueous sodium hydrogen carbonate solution. Theorganic layer was dried over anhydrous magnesium sulfate, filtered andconcentrated in vacuo. The residue was triturated with ethyl acetate togive di-tert-butyl((Z)-{[2-(([(5-amino-1-methyl-1H-pyrazol-4-yl)amino]carbonyl)amino)-ethyl]amino}methylidene)biscarbamate(4.3 g) as a'solid.

¹H-NMR (DMSO-d₆) δ 1.39 (9H, s), 1.48 (9H, s), 3.18 (2H, q, J=6.0 Hz),3.35 (2H, br), 3.49 (3H, s), 4.77 (1H, brs), 6.05 (1H, br), 6.97 (1H,s), 7.19 (1H, brs), 8.36 (1H, t, J=5.5 Hz), 11.49 (1H, brs)

Preparation 65

To a solution of di-tert-butyl((Z)-{[2-({[(5-amino-1-methyl-1H-pyrazol-4-yl)amino)carbonyl)amino)-ethyl]amino}methylidene)biscarbamate(2.2 g) and triethylamine (0.6 g) in chloroform (30 ml) was added tritylchloride (1.7 g), and the mixture was stirred at room temperature for 14hours. The reaction mixture was washed successively with 10% aqueouscitric acid solution, brine and saturated aqueous sodium hydrogencarbonate solution. The organic layer was dried over anhydrous magnesiumsulfate, filtered and concentrated in vacuo. The residue was trituratedwith ethyl acetate to give di-tert-butyl[(Z)-((2-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-ethyl}amino)methylidene]biscarbamate(1.9 g) as a solid.

¹H-NMR (DMSO-d₆) δ 1.39 (9H, s), 1.47 (9H, s), 2.72 (3H, s), 3.09-3.10(2H, m), 3.31-3.34 (2H, m), 5.69 (1H, s), 6.10 (1H, br), 6.77 (1H, brs),7.02 (1H, s), 7.14-7.16 (6H, m), 7.22-7.27 (9H, m), 8.36 (1H, t, J=5.5Hz), 11.51 (1H, brs)

EXAMPLE 39

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(820 mg) in N,N-dimethylformamide (1.4 ml) was addedN-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture were addeddi-tert-butyl[(Z)-({2-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]ethyl}amino)methylidene]-biscarbamate(820 mg) and N,N-dimethylformamide (2.0 ml). The whole mixture wasstirred at room temperature for 3 hours. To the resulting reactionmixture were added ethyl acetate (100 ml) and water (50 ml). The aqueouslayer was separated, and the organic layer was washed successively with10% aqueous sodium trifluoroacetate solution, 10% aqueous sodiumthiosulfate solution and brine, dried over sodium sulfate and filtered.The filtrate was concentrated to about 5 ml in vacuo. The concentratewas poured into diisopropyl ether (120 ml), and the resultingprecipitate was collected by filtration and dried in vacuo. To asolution of the resulting solid in methylene chloride (3.0 ml) wereadded anisole (1.0 ml) and trifluoroacetic acid (2.0 ml), and themixture was stirred at room temperature for 4 hours. The reactionmixture was poured into diisopropyl ether (100 ml), and the resultingprecipitate was collected by filtration and dried in vacuo to give acrude product (740 mg), which was purified by preparative HPLC utilizingODS column. The eluate containing a desired product was concentrated toabout 30 ml in vacuo. The concentrate was adjusted to about pH 3 withconcentrated hydrochloric acid and chromatographed on Diaion® HP-20(Mitsubishi Chemical Corporation) eluting with 30% aqueous 2-propanol.The eluate was concentrated to about 30 ml in vacuo and lyophilized togive3-([3-amino-4-({[(2-guanidinoethyl)amino]carbonyl}amino)-2-methyl-1-pyrazolio]methyl}-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(70 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.55 (3H, s), 1.56 (3H, s), 3.24 (1H, d, J=17.6 Hz),3.28-3.40 (4H, m), 3.52 (1H, d, J=17.6 Hz), 3.73 (3H, s), 4.97 (1H, d,J=15.4 Hz), 5.16 (1H, d, J=15.4 Hz), 5.27 (1H, d, J=4.8 Hz), 5.84 (1H,d, J=4.8 Hz), 7.87 (1H, s)

Preparation 66

To a suspension of phenyl[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (950 mg) andtert-butyl (3S)-3-pyrrolidinylcarbamate (560 mg) in methylene chloride(20 ml) was added N-ethyldiisopropylamine (390 mg), and the mixture wasstirred under reflux for 23 hours. The reaction mixture was washedsuccessively with 10% aqueous citric acid solution, brine and saturatedaqueous sodium hydrogen carbonate solution. The organic layer was driedover anhydrous magnesium sulfate, filtered and concentrated in vacuo.The residue was purified by column chromatography on silica gel elutingwith 4% methanol/chloroform to give tert-butyl[(3S)-1-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-3-pyrrolidinyl]carbamate(680 mg) as a solid.

¹H-NMR (CDCl₃) δ 1.48 (9H, s), 1.82-1.88 (1H, m), 2.12-2.18 (1H, m),2.89 (3H, s), 2.89-3.03 (1H, m), 3.20-3.30 (2H, m), 3.38-3.43 (1H, m),4.22 (1H, br), 4.69 (1H, br), 4.88 (1H, brs), 4.96 (1H, brs), 7.18-7.27(16H, m)

EXAMPLE 40

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(820 mg) in N,N-dimethylformamide (2.4 ml) was addedN-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture was addedtert-butyl[(3S)-1-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-3-pyrrolidinyl]carbamate(680 mg). The whole mixture was stirred at room temperature for 3 hours.To the resulting reaction mixture were added ethyl acetate (80 ml) andwater (50 ml). The aqueous layer was separated, and the organic layerwas washed successively with 10% aqueous sodium trifluoroacetatesolution, 10% aqueous sodium thiosulfate Evolution and brine, dried oversodium sulfate and filtered. The filtrate was concentrated to about 5 mlin vacuo. The concentrate was poured into diisopropyl ether (120 ml),and the resulting precipitate was collected by filtration and dried invacuo. To a solution of the resulting solid in methylene chloride (3.0ml) were added anisole (1.0 ml) and trifluoroacetic acid (2.0 ml), andthe mixture was stirred at room temperature for 4 hours. The reactionmixture was poured-into diisopropyl ether (100 ml), and the resultingprecipitate was collected by filtration and dried in vacuo to give acrude product (690 mg), which was purified by preparative HPLC utilizingODS column. The eluate containing a desired product was concentrated toabout 30 ml in vacuo. The concentrate was adjusted to about pH 3 withconcentrated hydrochloric acid and chromatographed on Diaion® HP-20(Mitsubishi Chemical Corporation) eluting with 30% aqueous 2-propanol.The eluate was concentrated to about 30 ml in vacuo and lyophilized togive3-{[3-amino-4-({[(3S)-3-amino-1-pyrrolidinyl]carbonyl}amino)-2-methyl-1-pyrazolio]methyl}-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(60 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (6H, s), 2.13-2.27 (1H, m), 2.38-2.53 (1H, m), 3.20(1H, d, J=17.4 Hz), 3.46 (1H, d, J=17.4 Hz), 3.54-3.67 (3H, m), 3.73(3H, s), 3.79 (1H, dd, J=11.5, 6.0 Hz), 4.00-4.10 (1H, m), 4.97 (1H, d,J=15.4 Hz), 5.16 (1H, d, J=15.4 Hz), 5.25 (1H, d, J=4.8 Hz), 5.83 (1H,d, J=4.8 Hz), 7.85 (1H, s)

Preparation 67

To a suspension of phenyl[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (950 mg) andtert-butyl (3R)-3-pyrrolidinylcarbamate (560 mg) in methylene chloride(20 ml) was added N-ethyldiisopropylamine (390 mg), and the mixture wasstirred under reflux for 23 hours. The reaction mixture was washedsuccessively with 10% aqueous citric acid solution, brine and saturatedaqueous sodium hydrogen carbonate solution. The organic layer was driedover anhydrous magnesium sulfate, filtered and concentrated in vacuo.The residue was purified by column chromatography on silica gel elutingwith 4% methanol/chloroform to give tert-butyl[(3R)-1-(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-3-pyrrolidinyl]carbamate(700 mg) as a solid.

¹H-NMR (CDCl₃) δ 1.48 (9H, s), 1.82-1.88 (1H, m), 2.12-2.18 (1H, m),2.89 (3H, s), 2.89-3.03 (1H, m), 3.20-3.30 (2H, m), 3.38-3.43 (1H, m),4.22 (1H, br), 4.69 (1H, br), 4.88 (1H, brs), 4.96 (1H, brs), 7.18-7.27.(16H, m)

EXAMPLE 41

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(820 mg) in N,N-dimethylformamide (2.4 ml) was addedN-(trimethylsilyl)acetamide. (656 mg), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture was addedtert-butyl[(3R)-1-(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-3-pyrrolidinyl]carbamate(680 mg). The whole mixture was stirred at room temperature for 3 hours.To the resulting reaction mixture were added ethyl acetate (80 ml) andwater (50 ml). The aqueous layer was separated, and the organic layerwas washed successively with 10% aqueous sodium trifluoroacetatesolution, 10% aqueous sodium thiosulfate solution and brine, dried oversodium sulfate and filtered. The filtrate was concentrated to about 5 mlin vacuo. The concentrate was poured into diisopropyl ether (120 ml),and the resulting precipitate was collected by filtration and dried invacuo. To a solution of the resulting solid in methylene chloride (3.0ml) were added anisole (1.0 ml) and trifluoroacetic acid (2.0 ml), andthe mixture was stirred at room temperature for 4 hours. The reactionmixture was poured into diisopropyl ether (100 ml), and the resultingprecipitate was collected by filtration and dried in vacuo to give acrude product (760 mg), which was purified by preparative HPLC utilizingODS column. The eluate containing a desired product was concentrated toabout 30 ml in vacuo. The concentrate was adjusted to about pH 3 withconcentrated hydrochloric acid and chromatographed on Diaion® HP-20(Mitsubishi Chemical Corporation) eluting with 30% aqueous-2-propanol.The eluate was concentrated to about 30 ml in vacuo and lyophilized togive3-{[3-amino-4-({[(3R)-3-amino-1-pyrrolidinyl]carbonyl)amino}-2-methyl-1-pyrazolio]methyl}-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(68 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (6H, s), 2.13-2.27 (1H, m), 2.38-2.53 (1H, m), 3.20(1H, d, J=17.6 Hz), 3.47 (1H, d, J=17.6 Hz), 3.56-3.66 (3H, m), 3.73(3H, s), 3.79 (1H, dd, J=11.0, 6.0 Hz), 4.00-4.10 (1H, m), 4.96 (1H, d,J=15.1 Hz), 5.15 (1H, d, J=15.1 Hz), 5.26 (1H, d, J=4.8 Hz), 5.83 (1H,d, J=4.8 Hz), 7.84 (1H, s)

Preparation 68

To a suspension of phenyl (5-amino-1-methyl-1H-pyrazol-4-yl)carbamate(1.86 g) and (3S)-1-benzyl-3-pyrrolidinamine (2.0 g) in chloroform (50ml) was added N-ethyldiisopropylamine (3.1 g), and the mixture wasstirred under reflux for 19 hours. The reaction mixture was concentratedin vacuo to give crude(S)-5-amino-4-[3-(1-benzyl-3-pyrrolidinyl)ureido]-1-methyl-1H-pyrazoleas a solid. A solution of the crude product in acetic acid was treatedwith palladium black (3 ml) under a hydrogen atomosphere at roomtemperature for 24 hours. After the catalyst was filtered off, thefiltrate was concentrated in vacuo, and the residue was dissolved insaturated aqueous sodium hydrogen carbonate solution (100 ml). To thesolution was added a solution of di-tert-butyl dicarbonate (5.0 g) intetrahydrofuran (40 ml), and the mixture was stirred at room temperaturefor hours. The reaction mixture was extracted with chloroform. Theorganic layer was dried over anhydrous magnesium sulfate, filtered andconcentrated in vacuo. The residue was triturated with diethyl ether togive tert-butyl(3S)-3-({[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]carbonyl}amino)-1-pyrrolidinecarboxylate(1.9 g) as a solid.

¹H-NMR (DMSO-d₆) δ 1.40 (9H, s), 1.70-1.76 (1H, m), 1.95-2.02 (1H, m),3.01-3.05 (1H, m), 3.24-3.34 (2H, m), 3.38-3.45 (1H, m) 3.50 (3H, s),4.06-4.11 (1H, m), 4.78 (2H, brs), 6.19 (1H, brs), 6.97 (1H, s), 7.09(1H, brs)

Preparation 69

To a solution of tert-butyl(3S)-3-({[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]carbonyl}amino)-1-pyrrolidinecarboxylate(1.8 g) and N-ethyldiisopropylamine (720 mg) in chloroform (50 ml) wasadded trityl chloride (1.6 g), and the mixture was stirred at roomtemperature for 28 hours. The reaction mixture was washed successivelywith 10% aqueous citric acid solution, brine and saturated aqueoussodium hydrogen carbonate solution. The organic layer was dried overanhydrous magnesium sulfate, filtered and concentrated in vacuo. Theresidue was purified by column chromatography on silica gel eluting with3% methanol/chloroform to give tert-butyl(3S)-3-[(([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-1-pyrrolidinecarboxylate(1.7 g) as a solid.

¹H-NMR (CDCl₃) δ 1.46 (9H, s), 1.66-1.74 (1H, m), 2.04-2.11 (1H, m),2.97 (3H, s), 3.05-3.11 (1H, m), 3.30-3.43 (2H, m), 3.53-3.58 (1H, m),4.16-4.23 (2H, m), 4.45 (1H, brs), 4.74 (1H, br), 7.18-7.20 (6H, m),7.28-7.30 (1H, m)

EXAMPLE 42

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(820 mg) in N,N-dimethylformamide (2.4 ml) was addedN-(trimethylsilyl)acetamide (656 mg), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture was addedtert-butyl(3S)-3-[({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)amino]-1-pyrrolidinecarboxylate(680 mg). The whole mixture was stirred at room temperature for 3 hours.To the resulting reaction mixture were added ethyl acetate (80 ml) andwater (50 ml). The aqueous layer was separated, and the organic layerwas washed successively with 10% aqueous sodium trifluoroacetatesolution, 10% aqueous sodium thiosulfate solution and brine, dried oversodium sulfate and filtered. The filtrate was concentrated to about 5 mlin vacuo. The concentrate was poured into diisopropyl ether (120 ml),and the resulting precipitate was collected by filtration and dried invacuo. To a solution of the resulting solid in methylene chloride (3.0ml) were added anisole (1.0 ml) and trifluoroacetic acid (2.0 ml), andthe mixture was stirred at room temperature for 5 hours. The reactionmixture was poured into diisopropyl ether (100 ml), and the resultingprecipitate was collected by filtration and dried in vacuo to give acrude product (870 mg), which was purified by preparative HPLC utilizingODS column. The eluate containing a desired product was concentrated toabout 30 ml in vacuo. The concentrate was adjusted to about pH 3 withconcentrated hydrochloric acid and chromatographed on Diaion® HP-20(Mitsubishi Chemical Corporation) eluting with 30% aqueous 2-propanol.The eluate was concentrated to about 30 ml in vacuo and lyophilized togive 3-{[3-amino-2-methyl-4-({[(3S)-3-pyrrolidinylamino]carbonyl)-amino)-1-pyrazolio]methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)-acetamido]-3-cephem-4-carboxylate(68 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.52 (3H, s), 1.53 (3H, s), 2.00-2.09 (1H, m), 2.28-2.38(1H, m), 3.22 (1H, d, J=17.4 Hz), 3.29 (1H, dd, J=12.4, 4.6 Hz),3.34-3.42 (1H, m), 3.44-3.54 (3H, m), 3.71 (3H, s), 4.36-4.43 (1H, m),4.95 (1H, d, J=15.6 Hz), 5.15 (1H, d, J=15.6 Hz), 5.25 (1H, d, J=4.6Hz), 5.84 (1H, d, J=4.6 Hz), 7.87 (1H, s)

Preparation 70

To a suspension of 4-[(tert-butoxycarbonyl)amino]butanoic acid (2.13 g)in dichloromethane (40 ml) was added 1-hydroxybenzotriazole (HOBT) (1.41g) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride(WSCD HCl) (3.65 g), and the mixture was stirred for 1 hour. To thesolution were added 1-methyl-1H-pyrazole-4,5-diamine sulfate (2 g) andN,N-diisopropylethylamine (3.32 ml). The reaction mixture was stirredfor 18 hours. To the resulting solution were added brine and saturatedaqueous sodium hydrogen carbonate solution, and the mixture wasextracted with ethyl acetate. The aqueous layer was extracted withtetrahydrofuran/ethyl acetate=1/1 twice. The extract was dried overanhydrous magnesium sulfate, filtered and concentrated in vacuo. To theresidue was added pyridiny (40 ml), and then addedchlorotriphenylmethane (5.3 g). The mixture was stirred at 65° C. for 6hours. The mixture was dissolved in ethyl acetate. The solution waswashed successively with water, 10% aqueous citric acid solution, waterand brine. The extract was dried over anhydrous magnesium sulfate,filtered and concentrated in vacuo. The residue was purified by columnchromatography on silica gel eluting with 60% ethylacetate/dichloromethane to give tert-butyl(4-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-4-oxobutyl)carbamate(2.01 g).

¹H-NMR (CDCl₃) δ 1.44 (9H, s), 1.67 (2H, tt, J=6.7, 6.7 Hz), 1.92 (2H,t, J=6.7 Hz), 2.90 (3H, s), 3.09 (2H, dt, J=6.7, 6.7 Hz), 4.50 (1H, s),4.71 (1H, t, J=6.7 Hz), 6.53 (1H, s), 7.0-7.35 (16H, m), 7.56 (1H, s)

EXAMPLE 43

To a solution of benzhydryl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-iodomethyl-3-cephem-4-carboxylate(2 g) in N,N-dimethylformamide (6 ml) was addedN-(trimethylsilyl)acetamide (1.77 g), and the mixture was stirred atroom temperature for 30 minutes. To the reaction mixture was addedtert-butyl(4-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-4-oxobutyl)carbamate(1.98 g), and the whole mixture was stirred at 35° C. for 30 hours. Tothe resulting reaction mixture was added ethyl acetate, and the solutionwas washed successively with water, 10% aqueous sodium trifluoroacetatesolution and brine, dried over magnesium sulfate and filtered. Thefiltrate was concentrated to about 25 ml in vacuo. The concentrate waspoured into diisopropyl ether (150 ml), and the resulting precipitatewas collected by filtration and dried in vacuo. To a solution of thesolid in methylene chloride (5 ml) were added anisole (1.5 ml) andtrifluoroacetic acid (5 ml). The resulting solution was stirred at roomtemperature for 4 hours and poured into diisopropyl ether. The resultingprecipitate was collected by filtration and dried in vacuo to give acrude product (1.2 g). The crude product was dissolved in a mixture ofphosphate buffer (pH 6.86, 10 ml) and saturated aqueous sodium hydrogencarbonate solution and purified by preparative HPLC utilizing ODScolumn. The eluate containing a desired product was concentrated toabout 20 ml in vacuo. The concentrate was adjusted to about pH 3 withconcentrated hydrochloric acid and chromatographed on Diaion® HP-20(Mitsubishi Chemical Corporation) eluting with 20% aqueous 2-propanol.The eluate was concentrated to about 30 ml in vacuo, and 2M aqueoussulfuric acid solution (72 ml) was added. The mixture was lyophilized togive3-({3-amino-4-[(4-aminobutanoyl)amino]-2-methyl-1-pyrazolio}methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylicacid hydrogen sulfate (113 mg) as an amorphous solid.

¹H-NMR (D₂O) δ 1.61 (6H, s), 2.01 (2H, tt, J=7.6, 7.6 Hz) 2.58 (2H, t,J=7.6 Hz), 3.07 (2H, t, J=7.6 Hz), 3.23 (1H, d, J=18 Hz), 3.45 (1H, d,J=18 Hz), 3.72 (3H, s), 5.06 (1H, d, J=15.7 Hz), 5.25 (1H, d, J=4.8 Hz),5.28 (1H, d, J=15.7 Hz), 5.87 (1H, d, J=4.8 Hz), 8.03 (1H, s)

Preparation 71

tert-Butyl(5-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-5-oxopentyl)carbamate

The title compound was obtained from5-[(tert-butoxycarbonyl)amino]pentanoic acid in the same manner as inPreparation 70.

¹H-NMR (CDCl₃) δ 1.43 (9H, s), 1.2-1.6 (4H, m), 1.90 (2H, t, J=7.0 Hz),2.90 (3H, s), 3.09 (2H, dt, J=7.0, 7.0 Hz), 4.52 (1H, s), 4.61 (1H, t,J=7.0 Hz), 6.28 (1H, s), 7.0-7.35 (16H, m), 7.59 (1H, s)

EXAMPLE 443-({3-Amino-4-[(5-aminopentanoyl)amino]-2-methyl-1-pyrazolio)methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylicacid hydrogen sulfate

The title compound was obtained from tert-butyl(5-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-5-oxopentyl)carbamatein the same manner as in Example 43.

¹H-NMR (D₂O) δ 1.61 (6H, s), 1.65-1.8 (4H, m), 2.50 (2H, m)o, 3.02 (2H,m), 3.23 (1H, d, J=18 Hz) 3.45 (1H, d, J=18 Hz), 3.72 (3H, s), 5.06 (1H,d, J=15.7 Hz), 5.25 (1H, d, J=4.8 Hz), 5.28 (1H, d, J=15.7 Hz), 5.87(1H, d, J=4.8 Hz), 8.02 (1H, s)

Preparation 72

To a solution of 1-methyl-N⁵-trityl-1H-pyrazole-4,5-diamine (4 g) indichloromethane (100 ml) was added tert-butyl4-{[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl}-1-piperidinecarboxylate(4.05 g), and the mixture was refluxed for 72 hours. The reactionmixture was washed successively with water, 10% aqueous citric acidsolution, water and brine. The extract was dried over anhydrousmagnesium sulfate, filtered and concentrated in vacuo to give tert-butyl4-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-1-piperidinecarboxylate(1.806 g).

¹H-NMR (CDCl₃) δ 1.3-1.9 (14H, m), 1.5-1.8 (2H, m), 2.95 (3H, s), 4.10(2H, m), 4.36 (1H, s), 6.53 (1H, s), 7.0-7.35 (16H, m), 7.68 (1H, s)

EXAMPLE 453-({3-Amino-2-methyl-4-[(4-piperidinylcarbonyl)amino]-1-pyrazolio)methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from tert-butyl4-({([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-1-piperidinecarboxylatein the same manner as in Example 36.

¹H-NMR (D₂O) δ 1.57 (6H, s), 1.8-2.3 (4H, m), 2.7-3.6 (7H, m), 3.72 (3H,s), 5.06 (1H, d, J=15.7 Hz), 5.25 (1H, d, J=4.8 Hz), 5.28 (1H, d, J=15.7Hz), 5.87 (1H, d, J=4.8 Hz), 8.01 (AH, s)

Preparation 73

To a suspension of 3-[N-(tert-butoxycarbonyl)-N-methylaminolpropanoicacid (3.33 g) in dichloromethane (33 ml) and tetrahydrofuran (33 ml)were added HOBT (3.33 g) and WSC HCl (6.29 g), and the mixture wasstirred for 1 hour. To the solution were added1-methyl-1H-pyrazole-4,5-diamine sulfate (3.45 g) andN,N-diisopropylethylamine (11.4 ml). The reaction mixture was stirred atroom temperature overnight. To the resulting solution was added brineand extracted with tetrahydrofuran/ethyl acetate=1/1. The extract wasdried over anhydrous magnesium sulfate, filtered and concentrated invacuo to give tert-butylN-{3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-oxopropyl}-N-methylcarbamateas an oil (2.4 g). This product was used in the next step withoutfurther purification.

Preparation 74

To a solution of tert-butylN-{3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-oxopropyl)-N-methylcarbamate(4.88 g) in N,N-dimethylformamide (50 ml) were added trityl chloride(6.86 g), triethylamine (6.86 ml) and 4-dimethylaminopyridine (80 mg)succesively. The mixture was stirred at room temperature overnight. Tothe resulting mixture was added ethyl acetate and washed with water(three times) and brine. The organic layer was dried over anhydrousmagnesium sulfate, filtered and concentrated in vacuo. The residue waspurified by column chromatography on silica gel to give tert-butylN-methyl-N-(3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3-oxopropyl)carbamate(4.20 g) as an amorphous solid.

IR (KBr) 1659, 1587, 1491, 1446, 1173, 1151, 762, 739, 708 cm⁻¹

¹H-NMR (DMSO-d₆) δ 1.40 (9H, s), 2.12 (2H, t, J=7.4 Hz) 2.74 (3H, s),2.74 (3H, s), 3.24 (2H, t, J=7.4 Hz), 5.58 (1H, s), 7.13-7.40 (16H, m),8.30 (1H, s)

EXAMPLE 463-[(3-Amino-2-methyl-4-{[3-(methylamino)propanoyl]amino}-1-pyrazolio)methyl]-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from tert-butylN-methyl-N-(3-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3-oxopropyl)carbamatein the same manner as in Example 32 as an amorphous solid.

IR (KBr) 1770, 1664, 1599, 1531, 1400, 1360 cm⁻¹

¹H-NMR (D₂O) δ 1.53 (6H, s), 2.77 (3H, s), 2.92 (2H, t, J=6.5 Hz), 3.19and 3.45 (2H, ABq, J=17.7 Hz), 3.74 (3H, s), 5.00 and 5.21. (2H, ABq,J=15.4 Hz), 5.25 (1H, d, J=4.8 Hz), 5.85 (1H, d, J=4.8 Hz), 8.02 (1H, s)

ESI-MS 666.3 (M+H⁺)

Preparation 75

tert-Butyl3-{[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]carbonyl}-1-azetidinecarboxylate

The title compound was obtained from1-(tert-butoxycarbonyl)-3-azetidinecarboxylic acid in the same manner asin Preparation 73 as an oil. This product was used in the next stepwithout further purification.

Preparation 76

tert-Butyl3-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-1-azetidinecarboxylate

The title compound was obtained from tert-butyl3-{[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]carbonyl}-1-azetidinecarboxylatein the same manner as in Preparation 74 as an amorphous solid.

IR (KBr) 3367, 3321, 1701, 1662, 1489, 1414, 1144, 766, 704 cm⁻¹

¹H-NMR (DMSO-d₆) δ 1.39 (9H, s), 2.75 (3H, s), 2.97-3.05 (1H, m),3.63-3.70 (2H, m)0, 3.82-3.90 (2H, m), 5.57 (1H, s), 7.10-7.33 (16H, m),8.41 (1H, s)

ESI-MS 560.3 (M+Na⁺)

EXAMPLE 473-({3-Amino-4-[(3-azetidinylcarbonyl)amino]-2-methyl-1-pyrazolio}methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from tert-butyl3-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}carbonyl)-1-azetidinecarboxylatein the same manner as in Example 32 as an amorphous solid.

IR (KBr) 1768, 1663, 1624, 1605, 1406, 1362 cm⁻¹

¹H-NMR (D₂O) δ 1.53 *(3H, s), 1.53 (3H, s), 3.19 and 3.50 (2H, ABq,J=17.7 Hz), 3.82-3.98 (1H, m), 4.31-4.35 (4H, m), 4.49 and 5.20 (2H,ABq, J=15.3 Hz), 5.25 (1H, d, J=4.8 Hz), 5.85 (1H, d, J=4.8 Hz), 8.04(1H, s)

ESI-MS 664.2 (M+H⁺)

Preparation 77

tert-ButylN-{2-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-oxoethyl}-N-methylcarbamate

The title compound was obtained from[N-(tert-butoxycarbonyl)-N-(methyl)amino]acetic acid in the same manneras in Preparation 73 as an oil. This product was used in the next stepwithout further purification.

Preparation 78

tert-ButylN-methyl-N-(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-2-oxoethyl)carbamate

The title compound was obtained from tert-butylN-(2-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-oxoethyl)-N-methylcarbamatein the same manner as in Preparation 74 as a white solid. The NMRspectrum of this compound indicates the existence of its rotamer.

¹H-NMR (DMSO-d₆) δ 1.32 and 1.39 (9H, s), 2.72 and 2.77 (3H, s), 3.52and 3.61 (2H, brs), 5.61 (1H, s), 7.13-7.33 (16H, m), 8.20 and 8.30 (1H,brs)

ESI-MS 548;3 (M+Na⁺)

EXAMPLE 483-[(3-Amino-2-methyl-4-{[(methylamino)acetyl]amino}-1-pyrazolio)methyl]-71-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from tert-butylN-methyl-N-(2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-2-oxoethyl)carbamatein the same manner as in Example 32 as an amorphous-solid.

IR (KBr) 1770, 1657, 1601, 1400, 1362 cm⁻¹

¹H-NMR (D₂O) δ 1.53 (6H, s), 2.82 (3H, s), 3.18 and 3.45 (2H, ABq,J=17.7 Hz), 3.74 (3H, s), 4.08 (2H, s), 5.00 and 5.20 (2H, ABq, J=15.3Hz), 5.25 (1H, d, J=4.8 Hz), 5.84 (1H, d, J=4.8 Hz), 8.05 (1H, s)

ESI-MS 652.2 (M+H⁺)

Preparation 79

N-(5-Amino-1-methyl-1H-pyrazol-4-yl)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetamide

The title compound was obtained from(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetic acid in the same manneras in Preparation 73 as a solid.

¹H-NMR (DMSO-d₆) δ 3.55. (3H, s), 4.36 (2H, s), 4.91 (2H, brs), 7.14(1H, s), 7.85-8.02 (4H, m), 9.48 (1H, s)

ESI-MS 322.2 (M+Na⁺)

Preparation 80

2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]acetamide

The title compound was obtained fromN-(5-amino-1-methyl-1H-pyrazol-4-yl)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetamidein the same manner as in Preparation 74 as a solid.

¹H-NMR (DMSO-d₆) δ 2.70 (3H, s), 4.12 (2H, s), 5.41 (1H, s), 7.12-7.33(16H, m), 7.85-7.95 (4H, m), 8.93 (1H, s)

ESI-MS 564.3 (M+Na⁺)

Preparation 81

Hydrazine monohydrate (1.46 ml) was added to a solution of2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]acetamide(5.42 g) in ethanol (108 ml) and tetrahydrofuran (54 ml) at roomtemperature, and the mixture was stirred at 70° C. for 2 hours. Thereaction mixture was cooled to 0° C., and the insoluble materials wereremoved-by filtration. The filtrate was concentrated in vacuo. Theresidue was triturated with diisopropyl ether, collected by filtrationand dried in vacuo to give2-amino-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]acetamide (3.37 g)as a solid. This product was used in the next step without furtherpurification.

Preparation 82

To a solution of2-amino-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]acetamide (2.47 g)in tetrahydrofuran (50 ml) were added di-tert-butyl({[(trifluoromethyl)sulfonyl]imino}methylene)-biscarbamate (2.35 g) andtriethylamine (2.5 ml), and the mixture was stirred at room temperaturefor 30 minutes. The reaction mixture was poured into a mixture of ethylacetate and water. The aqueous layer was separated, and the organiclayer was washed with brine, dried over anhydrous magnesium sulfate andfiltered. The filtrate was concentrated in vacuo. The concentrate waspurified by silica gel column chromatography to give di-tert-butyl{(E)-[(2-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-2-oxoethyl)amino]methylidene}-biscarbamate(3.25 g) as an amorphous solid.

¹H-NMR (DMSO-d₆) δ 1.38 (9H, s), 1.49 (9H, s), 2.75 (3H, s), 3.79 (2H,d, J=4.7 Hz), 5.47 (1H, s), 7.12-7.33 (16H, m), 8.55 (1H, t, J=4.7 Hz),8.61 (1H, s), 11.43 (1H, s)

ESI-MS 676.3 (M+Na⁺)

EXAMPLE 493-({3-Amino-4-[(guanidinoacetyl)amino]-2-methyl-1-pyrazolio}methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from di-tert-butyl{(E)-[(2-{[1-methyl-5-(tritylamino)-1H-pyrazol-⁴-yl]amino}-2-oxoethyl)amino]methylidene)biscarbamatein the same manner as in Example 32 as an amorphous solid.

IR (KBr) 1770, 1668, 1655, 1620, 1601, 1402, 1363 cm⁻¹

¹H-NMR (D₂O) δ 1.53 (6H, s), 3.20 and 3.48 (2H, ABq, J=17.6 Hz), 3.75(3H, s), 4.21 (2H, s), 5.00 and 5.20 (2H, ABq, J=15.3 Hz), 5.26 (1H, d,J=4.8 Hz), 5.85 (1H, d, J=4.8 Hz), 8.02 (1H, s)

ESI-MS 678.2 (M−H⁺) (negative)

EXAMPLE 50

To a solution of3-({3-amino-4-[(3-aminopropanoyl)amino]-2-methyl-1-pyrazolio)methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(652 mg) in water (30 ml) and acetonitrile (3 ml) were added ethylformimidate hydrochloride (658 mg) and potassium carbonate (1.106 g)under ice cooling. After stirring at 5° C. for 3 hours, 1N HCl was addedto neutralize the reaction mixture. The resulting solution was purifiedby preparative HPLC eluting with a mixture of phosphate buffer (pH 5.5)and acetonitrile, and the eluate was subjected to column chromatographyon Diaion® HP20 (Mitsubishi Chemical Corporation) and lyophilized togive3-({3-amino-4-[(3-guanidinopropanoyl)amino]-2-methyl-1-pyrazolio}methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(23 mg) as an amorphous. The NMR spectrum of this compound indicates theexistence of its rotamer. Only major isomer was described.

IR (KBr) 1770, 1714, 1668, 1653, 1456, 1400, 1360 cm⁻¹

¹H-NMR (D₂O) δ 1.53 (6H, s), 2.85 (2H, t, J=6.4 Hz), 3.19 and 3.46 (2H,ABq, J=17.7 Hz), 3.65 (2H, t, J=6.4 Hz), 5.00 and 5.21 (2H, ABq, J=15.2Hz), 5.26 (1H, d, J=4.8 Hz), 5.85 (1H, d, J=4.8 Hz), 7.80 (1H, s), 8.01(1H, s)

ESI-MS 677.2 (M−H⁺) (negative)

Preparation 83

To a stirred solution of 1-methyl-1H-pyrazole-4,5-diamine sulfate (2.1g) and 3-ethoxy-3-oxopropanoic acid (1.32 g) in dichloromethane (10 ml)and-tetrahydrofuran (10 ml) was added WSCD HCl (3.83 g) andN,N-diisopropylethylamine (6.96 ml), and the mixture was stirredovernight. The solvent was removed under reduced pressure, and the cruderesidue which includes ethyl3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-oxopropanoate was used forthe next reaction without further purification.

Preparation 84

The crude residue containing ethyl3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-3-oxopropanoate wasdissolved in N,N-dimethylformamide (20 ml), and trityl chloride (5.52 g)and triethylamine (4.14 ml) were added with stirring. The mixture wasstirred overnight and quenched with water (10 ml). The whole mixture wasextracted with ethyl acetate, and the extract was washed with water andbrine, dried over magnesium sulfate and concentrated under reducedpressure to give a residual oil, which was chromatographed on silica geleluting with dichloromethane-ethyl acetate (2:3) to give ethyl3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropanoate(1.23 g).

ESI-MS 491.2 [M+Na]⁺(positive), 467.3 [M−HV⁻ (negative)

¹H-NMR (DMSO-d₆) δ 1.18 (3H, t, J=7.1 Hz), 2.75 (3H, s) 3.04 (2H, s),4.07 (2H, q, J=7.1 Hz), 5.55 (1H, s), 7.1-7.4 (16H, m), 8.54 (1H, s)

Preparation 85

To a stirred solution of ethyl3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3-oxopropanoate (1.3g) in tetrahydrofuran (30 ml) was added 1N aqueous sodium hydroxidesolution (3.1 ml), and the mixture was stirred at room temperature for 3hours. Tetrahydrofuran was removed in vacuo and the residue was madeacidic with diluted citric acid. The resulting precipitate was collectedby filtration and dried under reduced pressure to give3-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropanoic acid(1.22 g).

ESI-MS 463.2 [M+Na]⁺ (positive)

¹H-NMR (DMSO-d₆) δ 2.74 (3H, s), 2.95 (2H, s), 5.56 (1H, s), 7.0-7.4(16H, m), 8.54 (1H, s), 12.0-13.0 (1H, brs)

Preparation 86

To a suspension of3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropanoic acid(600 mg) and tert-butyl (2-aminoethyl)carbamate (240 mg) intetrahydrofuran (12 ml) and dichloromethane (6 ml) was added WSCD HCl(522 mg), and the whole mixture was stirred at room temperatureovernight. To the reaction mixture was added water (3 ml), and the wholemixture was extracted with ethyl acetate. The extract was washed withwater and brine and dried over magnesium sulfate. The evaporation of thesolvent gave a crude residue, which was triturated with diisopropylether-ethyl acetate (2:1) to give tert-butyl{2-[(3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropanoyl)amino]ethyl}carbamate(537 mg).

ESI-MS 604.9 [M+Na]⁺ (positive)

¹H-NMR (DMSO-d₆) δ 1.38 (9H, s), 2.74 (3H, s), 2.85 (2H, s), 2.9-3.2(4H, m), 5.61 (1H, s), 6.7-6.9 (1H, m), 7.0-7.4 (16H, m), 8.0-8.1 (1H,m), 8.63 (1H, s)

EXAMPLE 513-{[3-Amino-4-({3-[(2-aminoethyl)amino]-3-oxopropanoyl}amino)-2-methyl-1-pyrazolio]methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from tert-butyl(2-[(3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropanoyl)amino]ethyl}carbamatein the same manner as in Example 34.

ESI-MS 731.2 [M+Na]⁺ (positive)

¹H-NMR (D₂O) δ 1.53 (6H, s), 3.1-3.3 (2H, m), 3.19 and 3.44 (2H, ABq,J=17.7 Hz), 3.54 (2H, s), 3.5-3.7 (2H, m), 3.74 (3H, s), 5.00 and 5.22(2H, ABq, J=15.5 Hz), 5.25 (1H, d, J=4.7 Hz), 5.86 (1H, d, J=4.8 Hz),8.05 (1H, s)

Preparation 87

To a stirred solution of 3-amino-2-hydroxypropanoic acid (2.1 g) intetrahydrofuran (30 ml) and water (30 ml) was added 1N aqueous sodiumhydroxide solution to make the solution basic (pH=9). To the mixture wasadded di-tert-butyl dicarbonate (4.36 g), and the mixture was stirred atroom temperature for 4 hours keeping pH of the mixture between 8.5 and9.0. The whole mixture was washed with diethyl ether. The aquous layerwas made acidic (pH=2) with 10% aqueous potassium hydrogen sulfate,saturated with sodium chloride and extracted with ethyl acetate. Theextract was dried over magnesium sulfate. The solvent was evaporatedunder reduced pressure to give3-[(tert-butoxycarbonyl)amino]-2-hydroxypropanoic acid (3.96 g).

ESI-MS 228.2 [M+Na]⁺ (positive)

¹H-NMR (DMSO-d₆) δ 1.37 (9H, s), 3.0-3.8 (3H, m), 3.9-4.1 (1H, m),6.5-6.8 (1H, m)

Preparation 88

To a solution of 3-[(tert-butoxycarbonyl)amino]-2-hydroxypropanoic acid(1.61 g) in dichloromethane (8 ml) and tetrahydrofuran (8 ml) were addedHOBT (1.59 g) and WSCD HCl (3.01 g), and the mixture was stirred at roomtemperature for 1 hour. The solution was cooled to 0° C., and1-methyl-1H-pyrazole-4,5-diamine sulfate and N,N-diisopropylethylamine(4.1 ml) were added. The mixture was stirred at room temperature for 8hours. The solvent was removed under reduced pressure to give crudetert-butyl(3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-hydroxy-3-oxopropyl)carbamate,which was used in the next reaction without further purification.

Preparation 89

tert-Butyl(2-hydroxy-3-{[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropyl)carbamate

The title compound was obtained from tert-butyl{3-[(5-amino-1-methyl-1H-pyrazol-4-yl)amino]-2-hydroxy-3-oxopropyl]carbamatein the same manner as in Preparation 84.

ESI-MS 564.3 [M+Na]⁺ (positive)

¹H-NMR (DMSO-d₆) δ 1.39 (9H, s), 2.7-2.9 (1H, m), 2.83 (3H, s), 3.1-3.4(1H, m), 3.7-3.9 (1H, m), 5.79 (1H, d, J=5.3 Hz), 5.98 (1H, s), 6.5-6.7(1H, m), 7.1-7.4 (16H, m), 8.36 (1H, s)

EXAMPLE 523-((3-Amino-4-[(3-amino-2-hydroxypropanoyl)amino]-2-methyl-1-pyrazoliomethyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from tert-butyl(2-hydroxy-3-([1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropyl)carbamatein the same manner as in Example 32.

¹H-NMR (D₂O) δ 1.49 (6H, s), 3.1-3.6 (4H, m), 3.76 (3H, s) 4.6-4.7 (1H,m), 5.02-and 5.21 (2H, ABq, J=15.4 Hz), 5.26 (1H, d, J=4.8 Hz), 5.86(1H, d, J=4.8 Hz), 8.05 (1H_(,) s)

Preparation 90

To a suspension of 2-(4,5-diamino-1H-pyrazol-1-yl)ethanol sulfate (5 g)in dichloromethane (50 ml) was added triethylamine (6.38 ml) at 0° C.,and the mixture was stirred at 0° C. for 10 minutes. A mixture of aceticanhydride (2.16 ml) and formic acid (1.74 ml) was stirred at 40° C. for30 minutes, cooled to 0° C. and added dropwise to the above solution at0° C. The whole mixture was stirred at 0° C. for 2 hours. To the mixturewas added brine, and the whole mixture was extracted withtetrahydrofuran. The extract was dried over magnesium sulfate andevaporated under reduced pressure to give crude[5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]formamide, which was used inthe next reaction without further purification.

Preparation 91

[1-(2-Hydroxyethyl)-5-(tritylamino)-1H-pyrazol-4-yl]formamide

The title compound was obtained from[5-amino-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]formamide in the same manneras in Preparation 84. The NMR spectrum of this compound indicates theexistence of its rotamer.

¹H-NMR (DMSO-d₆) δ 3.10 (2H, t, J=6.2 Hz), 3.3-3.5 and 3.4-3.6 (2H, m),4.89 and 5.06 (1H, t, J=5.1 Hz), 5.77 and 6.07 (1H, s), 7.1-7.4 (16H,m), 7.58 and 8.07 (1H, s), 7.58 (1H, s)

Preparation 92

To a stirred solution of[1-(2-hydroxyethyl)-5-(tritylamino)-1H-pyrazol-4-yl]formamide (2 g) inN,N-dimethylformamide (30 ml) was added sodium hydride (213 mg, 60% oilsuspension) under a nitrogen stream at 0° C., and the whole mixture wasstirred at 0° C. for 20 minutes. A solution of tert-butyl(3-bromopropyl)carbamate (1.27 g) in N,N-dimethylformamide (10 ml) andsodium iodide (799 mg) were added to the above solution, and the mixturewas stirred overnight. 10% Aqueous potassium hydrogen sulfate solution(5 ml) was added, and the whole mixture was extracted with ethylacetate. The extract was washed with water and brine and dried overmagnesium sulfate. Evaporation of the solvent under reduced pressuregave an oil, which was chromatographed on silica gel eluting withdichloromethane-ethyl acetate (2:1) to give tert-butyl(3-{N-formyl-N-[1-(2-hydroxyethyl)-5-(tritylamino)-1H-pyrazol-4-yl]amino}propyl)carbamate(1 g). The NMR spectrum of this compound indicates the existence of itsrotamer.

ESI-MS 592.3 [M+Na]⁺ (positive)

¹H-NMR (DMSO-d₆) δ 1.37 and 1.38 (9H, s), 2.7-3.5 (10H, m) 4.80 and 4.88(1H, t, J=5.0 Hz), 5.52 & 6.06 (1H, s), 6.5-6.9 (1H, m), 7.0-7.4 (16H,m), 7.52 (1H, s)

EXAMPLE 533-({3-Amino-4-[N-(3-aminopropyl)-N-formylamino]-2-(2-hydroxyethyl)-1-pyrazolio)methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from tert-butyl(3-{N-formyl-N-[1-(2-hydroxyethyl)-5-(tritylamino)-1H-pyrazol-4-yl]amino}propyl)carbamatein the same manner as in Example 32.

ESI-MS 694.2 [M−H]⁻ (negative)

¹H-NMR (D₂O) δ 1.53 (6H, s), 1.7-2.1 (2H, m), 2.9-3.1 (2H, m), 3.1-3.8(4H, m), 3.8-4.0 (2H, m), 4.3-4.6 (2H, m), 4.8-5.2 (2H, m), 5.29 (1H, d,J=4.8 Hz), 5.85 (1H, d, J=4.7 Hz), 8.0-8.3 (2H, m)

EXAMPLE 54

To a stirred suspension of3-({3-amino-4-[N-(3-aminopropyl)-N-formylamino]-2-(2-hydroxyethyl)-1-pyrazolio}methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(100 mg) in methanol (1.4 ml) was added concentrated hydrochloric acid(0.125 ml) at room temperature, and the mixture was stirred for 6.5hours. To the above solution was added sodium hydrogen carbonate (109mg), and the mixture was purified by preparative HPLC (ODS column;acetonitrile:phosphate buffer (pH 7)=5:95). The eluate containing adesired product was evaporated to remove acetonitrile, made acidic withdiluted hydrochloric acid and chromatographed on Diaion® HP20(Mitsubishi Chemical Corporation) eluting with 20% aqueous 2-propanol.The eluate was concentrated under reduced pressure and lyophilized togive3-({3-amino-4-[(3-aminopropyl)amino]-2-(2-hydroxyethyl)-1-pyrazolio}methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate(18 mg).

ESI-MS 666.2 [M−H]⁻ (negative)

¹H-NMR (DMSO-d₆) δ 1.53 (6H, s), 1.96 (2H, tt, J=7.5 Hz), 3.0-3.2 (4H,m), 3.13 and 3.43 (2H, ABq, J=17.6 Hz), 3.87 (2H, t, J=4.8 Hz), 4.2-4.4(2H, m), 4.87 and 5.03 (2H, ABq, J=15.2 Hz), 5.24 (1H, d, J=4.8 Hz),5.83 (1H, d, J=4.8 Hz), 7.64 (1H, s)

Preparation 93

To a stirred solution ofN-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]-2-(tritylamino)acetamide (2g) in N,N-dimethylformamide (20 ml) was added sodium hydride (245 mg,60% oil suspension) at 0° C., and the mixture was stirred for 30 minuteswith warming to room temperature. The mixture was cooled to 0° C., andmethyl iodide (1.3 g) was added. The whole mixture was stirred at roomtemperature overnight. Water (5 ml) was added, and the whole mixture wasextracted with ethyl acetate. The organic layer was washed with waterand brine and dried over magnesium sulfate. Evaporation of the solventunder reduced pressure gaveN-methyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]-2-(tritylamino)acetamide(2.05 g).

ESI-MS 690.3 [M+Na]⁺ (positive)

¹H-NMR (DMSO-d₆) δ 1.99 (3H, s), 2.3-2.8 (3H, m), 2.52 (3H, s), 5.44(1H, s), 6.85 (1H, s), 6.9-7.5 (30H, m)

Preparation 94

Lithium aluminum-hydride (455 mg) was added slowly to tetrahydrofuran(40 ml) at 0° C. and the mixture was stirred for 20 minutes.N-Methyl-N-[1-methyl-5-(tritylamino)-1H-pyrazol-⁴-yl]-2-(tritylamino)acetamide(2 g) was added to the mixture at 0° C., and the whole mixture wasstirred for 2 hours with warming to room temperature and refluxed for 2hours. Sodium fluoride (2.51 g) and water (862 mg) were added to themixture, and the whole mixture was stirred at room temperature for 30minutes. The precipitate was filtered off, and the filtrate wasconcentrated under reduced pressure to give crude residue, which waschromatographed (silica gel; ethyl acetate:dichloromethane=1:10) to giveN4,1-dimethyl-N⁵-trityl-N⁴-[2-(tritylamino)ethyl]-1H-pyrazole-4,5-diamine(740 mg).

ESI-MS 676.2 [M+Na]⁺ (positive)

¹H-NMR (DMSO-d₆) δ 1.7-2.0 (2H, m), 1.98 (3H, s), 2.2-2.4 (1H, m),2.6-2.8 (2H, m), 2.81 (3H, s), 5.24 (1H, s), 7.00 (1H, s), 7.0-7.5 (30H,m)

EXAMPLE 553-({3-Amino-4-[N-(2-aminoethyl)-N-methylamino]-2-methyl-1-pyrazolio)methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from N⁴,1-dimethyl-N⁵-trityl-N⁴-[2-(tritylamino)ethyl]-1H-pyrazole-4,5-diaminein the same manner as in Example 32.

ESI-MS 636.2 [M−H]⁻ (negative)

¹H-NMR (D₂O) δ 1.60 (6H, s), 2.60 (3H, s), 3.0-3.2 (4H, m) 3.19 and 3.39(2H, ABq, J=17.7 Hz), 3.67 (3H, s), 4.87 and 5.20 (2H, ABq, J=15.8 Hz),5.22 (1H, d, J=4.9 Hz), 5.85 (1H, d, J=4.7 Hz), 7.90 (1H, s)

Preparation 95

To a solution of [1-(2-fluoroethyl)-1H-pyrazol-5-yl]formamide (15.7 g)in methanol (78 ml) was added concentrated hydrochloric acid (21 ml) atroom temperature. The reaction mixture was stirred for 3.5 hours andevaporated in vacuo. The residue was dissolved in ethyl acetate andwashed with aqueous sodium hydrogen carbonate solution. The organiclayer was dried over magnesium sulfate and concentrated in vacuo to give1-(2-fluoroethyl)-1H-pyrazol-5-amine (12 g).

¹H-NMR (DMSO-d₆) δ 4.15 (2H, dt, J=25.2, 5.1 Hz), 4.66 (2H, dt, J=47.2,5.1 Hz), 5.1 (2H, brs), -5.27 (1H, d, J=1.7 Hz), 7.06 (1H, d, J=1.7 Hz)

Preparation 96

To a solution of 1-(2-fluoroethyl)-1H-pyrazol-5-amine (12 g) in ethanol(30 ml) were added concentrated hydrochloric acid (70 mg) and isoamylnitrite (10.9 g). The reaction mixture was stirred at 25-38° C. for 2hours. Diisopropyl ether and hexane were added to the reaction mixture,and the resulting oil was purified by column chromatography on silicagel (ethyl acetate:hexane=1:2→1:1→2:1→1:0) to give1-(2-fluoroethyl)-4-nitroso-1H-pyrazol-5-amine (4.8 g).

¹H-NMR (DMSO-d₆) δ 4.10-4.90 (4H, m), 7.09 and 8.59 (1H, s), 8.20 and8.26 (1H, brs)

Preparation 97

To a solution of 1-(2-fluoroethyl)-4-nitroso-1H-pyrazol-5-amine (4.8 g)in water (30 ml) and methanol (30 ml) were added sulfuric acid (2.98 g)and 10% palladium on carbon (2.5 g), and the mixture was hydrogenatedunder balloon pressure for 7.5 hours. The reaction mixture was filteredthrough a bed of Celite, and the filtrate was concentrated in vacuo.2-Propanol was added to the residue, and the precipitate was collectedby filtration to give 1-(2-fluoroethyl)-1H-pyrazole-4,5-diamine sulfate(7 g).

¹H-NMR (D₂O) δ 4.25-4.95 (4H, m), 7.66 (1H, s)

Preparation 98

To a suspension of 1-(2-fluoroethyl)-1H-pyrazole-4,5-diamine sulfate (3g) in tetrahydrofuran (30 ml) were added tert-butyl(3-[(2,5-dioxo-1-pyrrolidinyl)oxy]-3-oxopropyl)carbamate (3.9 g) andN,N-diisoporpylethylamine (3.5 g) under ice-cooling. The reactionmixture was stirred at room temperature for 2 hours. An aqueous sodiumhydrogen carbonate solution and sodium chloride were added, and themixture was extracted with ethyl acetate-tetrahydrofuran (three times).The organic layer was dried over magnesium sulfate and concentrated invacuo. The residue was purified by column chromatography on silica gel(ethyl acetate→ethyl acetate:ethanol=8:1) to give tert-butyl(3-{[5-amino-1-(2-fluoroethyl)-1H-pyrazol-4-yl]amino}-3-oxopropyl)carbamate(2.3 g).

¹H-NMR (DMSO-d₆) δ 1.38 (9H, s), 2.36 (2H, t, J=7.1 Hz) 3.10-3.27 (2H,m), 4.16 (2H, dt, J=25.5, 5.0 Hz),4.67 (2H, dt, J=47.2, 5.0 Hz), 5.27(2H, brs), 6.75-6.90 (1H, m), 7.23 (1H_(,) s), 9.08 (1H, brs)

Preparation 99

To a solution of tert-butyl(3-{[5-amino-1-(2-fluoroethyl)-1H-pyrazol-4-yl]amino}-3-oxopropyl)carbamate(2.3 g) in N,N-dimethylformamide (12 ml) were added triethylamine (1.48g), 4-dimethylaminopyridine (35.6 mg) and trityl chloride (2.2 g) atroom temperature. The reaction mixture was stirred for 2 hours, andwater was added. The mixture was extracted with ethyl acetate, and theorganic layer was washed with water and aqueous sodium chloridesolution. The organic layer was dried over magnesium sulfate andconcentrated in vacuo. Acetonitrile was added, and the precipitate wascollected by filtration to give tert-butyl(3-([1-(2-fluoroethy1)-5-(tritylamino)-1H-pyrazol-4-yl]amino)-3-oxopropyl)carbamate(2 g).

¹H-NMR (DMSO-d₆) δ 1.39 (9H, s), 2.05 (2H, t, J=7.2 Hz) 3.00-3.08 (2H,m), 3.23 (2H, dt, J=25.3, 5.1 Hz), 4.41 (2H, dt, J=47.1, 5.1 Hz)

EXAMPLE 563-({3-Amino-4-[(3-aminopropionyl)amino]-2-(2-fluoroethyl)-1-pyrazolio}methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from tert-butyl(3-{[1-(2-fluoroethyl)-5-(tritylamino)-1H-pyrazol-4-yl]amino}-3-oxopropyl)carbamatein the same manner as in Example 38.

¹H-NMR (D₂O) δ 2.89 (2H, t, J=6.5 Hz), 3.22 (1H, d, J=9.2 Hz), 3.34 (1H,t, J=6.5 Hz), 3.50 (1H, d, J=9.2 Hz), 4.55-4.95 (4H, m), 5.08 (2H, brs),5.26 (1H, d, J=4.9 Hz), 5.84 (1H, d, J=4.9 Hz), 8.-09(1H, s)

Preparation 100

1-Methyl-7-nitroso-1H-imidazo[1,2-b]pyrazole

The title compound was obtained from 1-methyl-1H-imidazo[1,2-b]pyrazolein the same manner as in Preparation 96.

¹H-NMR (DMSO-d₆) δ 3.93 (1H, s), 7.48 (1H, m), 7.92 (1H, m), 9.03 (1H,s)

Preparation 101

1-Methyl-1H-imidazo[1,2-b]pyrazol-7-amine sulfate

The title compound was obtained from1-methyl-7-nitroso-1H-imidazo[1,2-b]pyrazole in the same manner as inPreparation 97.

¹H-NMR (DMSO-d₆) δ 3.73 (3H, s), 7.24 (1H, m), 7.62 (2H, m)

Preparation 102

Di-tert-butyl((Z)-[(1-methyl-1H-imidazo[1,2-b]pyrazol-7-yl)amino]methylidene)biscarbamate

The title compound was obtained from1-methyl-1H-imidazo[1,2-b]pyrazol-⁷-amine sulfate in the same manner asin Preparation 64.

¹H-NMR (DMSO-d₆) δ 1.34 (9H, s), 1.52 (9H, s), 3.61 (3H, s), 7.14 (1H,m), 7.42 (1H, m), 7.52 (1H, m)

EXAMPLE 577β-[(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-([7-guanidino-1-methyl-5-(1H-imidazo[1,2-b]pyrazolio)]methyl)-3-cephem-4-carboxylate

The title compound was obtained from di-tert-butyl{(Z)-[(1-methyl-1H-imidazo[1,2-b]pyrazol-7-yl)amino]methylidene)biscarbamatein the same manner as in Example 43.

¹H-NMR (D₂O) δ 1.51 (6H, s), 3.40 (2H, m), 3.85 (3H, s), 5.15-5.30 (3H,m), 5.83 (1H, d, J=4.8 Hz) 7.49 (1H, d, J=2.2 Hz), 8.02 (1H, d, J=2.2Hz), 8.27 (1H, d, J=1.0 Hz)

IR (KBr) 3400, 3392, 1770, 1672, 1606, 1531 cm⁻¹

Preparation 103

tert-Butyl{3-[(1-methyl-1H-imidazo[1,2-b]pyrazol-7-yl)amino]-3-oxopropyl)carbamate

The title compound was obtained from1-methyl-1H-imidazo[1,2-b]pyrazol-7-amine sulfate and3-[(tert-butoxycarbonyl)amino]propanoic acid in the same manner as inPreparation 70.

¹H-NMR (DMSO-d₆) δ 1.43 (9H, s), 2.61 (2H, m), 3.49 (2H, m), 3.65 (3H,s), 7.22 (1H, m), 7.26 (1H, m), 7.44 (1H, m)

EXAMPLE 583-({7-[(3-Aminopropanoyl)amino]-1-methyl-5-(1H-imidazo[1,2-b]pyrazolio))methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylate

The title compound was obtained from tert-butyl{3-[(1-methyl-1H-imidazo[1,2-b]pyrazol-7-yl)amino]-3-oxopropyl)carbamatein the same manner as in Example 43.

¹H-NMR (D₂O) δ 1.50 (6H, s), 2.97 (2H, d, J=6.5 Hz), 3.36 (2H, d, J=6.5Hz), 3.4 (2H, m), 3.81 (3H, s), 5.15-5.30 (3H, m), 5.82 (1H, d, J=4.8Hz), 7.44 (1H, d, J=2.2 Hz), 7.98 (1H, d, J=2.2 Hz), 8.11 (1H, d, J=1.0Hz)

IR (KBr) 3401, 1770, 1666, 1606, 1525 cm⁻¹

Preparation 104

To a suspension of phenyl[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]carbamate (4.6 g) inN,N-dimethylformamide (32 ml) were added triethylamine (1.08 g) andtert-butyl 1-piperazinecarboxylate (1.99 g). The reaction mixture wasstirred for 3 hours and poured into water. The mixture was extractedwith ethyl acetate, and the organic layer was concentrated in vacuo. Theresidue was purified by column chromatography on silica gel (ethylacetate→ethyl acetate:ethanol=20:1) to give tert-butyl4-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-1-piperazinecarboxylate(4.7 g).

¹H-NMR (CDCl₃) δ 1.46 (9H, s), 2.90 (3H, s), 3.05-3.25 (4H, m),3.30-3.45 (4H, m), 4.76 (1H, brs), 5.34 (1H, brs), 7.10-7.30 (16H, m)

EXAMPLE 59

To a solution of 4-methoxybenzyl7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetamido]-3-chloromethyl-3-cephem-4-carboxylate(2 g) in N,N-dimethylformamide (6 ml) was added1,3-bis(trimethylsilyl)urea (3 g), and the reaction mixture was stirredfor 30 minutes. Potassium iodide (680 mg) was added to this solution,and the mixture was stirred for 30 minutes tert-Butyl4-({[1-methyl-5-(tritylamino)-1H-pyrazol-4-yl]amino)carbonyl)-1-piperazinecarboxylate(2 g) was added to this solution. The reaction mixture was stirred at25° C. for 23 hours and poured into a mixture of ethyl acetate-water-20%aqueous sodium chloride solution. The organic layer was washed with amixture of 10% aqueous sodium thiosulfate solution and 20% aqueoussodium chloride solution. The organic layer was washed successively with10% aqueous sodium trifluoroacetate solution twice and 20% aqueoussodium chloride solution. The organic layer was concentrated in vacuo toa volume of approximately 10 ml. The concentrate was added todiisopropyl ether, and the suspension was stirred for 1 hour. Theresulting solid was collected by filtration and dried.

The solid was dissolved in dichloromethane (6 ml). To this solution wasadded anisole (2 ml) and trifluoroacetic acid (6 ml). The reactionmixture was stirred for 4 hours and poured into diisopropyl ether. Theresulting solid was collected by filtration and dried. This solid waspurified by preparative HPLC utilizing ODS column. The eluate containinga desired product was concentrated in vacuo. The concentrate wasadjusted to about pH 1 with concentrated hydrochloric acid andchromatographed on Diaion® HP-20 (Mitsubishi Chemical Corporation)eluting with 20% aqueous 2-propanol. The eluate was concentrated invacuo, and 2M sulfuric acid was added. The mixture was lyophilized togive3-({3-amino-2-methyl-4-[(1-piperazinylcarbonyl)amino]-1-pyrazolio)methyl)-7β-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-cephem-4-carboxylicacid hydrogen sulfate (679 mg).

¹H-NMR (D₂O) δ 1.60 (6H, s), 3.20 (2H, d, J=17.7 Hz), 3.25-3.45 (4H, m),3.45 (1H, d, J=17.7 Hz) 3.72 (3H, m), 3.75-3.85 (4H, m), 5.00 (1H, d,J=15.7 Hz), 5.24 (1H, d, J=15.7 Hz), 5.25 (1H, d, J=4.8 Hz), 5.86(1H, d,J=4.8 Hz), 7.89 (1H, s)

This application is based on application No. 2002952355 filed inAustralia on Oct. 30, 2002, and application No. 2003904813 filed inAustralia on Sep. 4, 2003, the content of which is incorporated hereintoby reference.

1. A compound of the formula [I]:

wherein R¹ is lower alkyl, hydroxy (lower) alkyl or halo (lower) alkyl,and R² is hydrogen or amino protecting group, or R¹ and R² are bondedtogether and form lower alkylene or lower alkenylene; R³ is hydrogen orlower alkyl; R⁴ is

wherein A is

wherein X is O or NH, R⁷ is hydrogen, lower alkyl or amino protectinggroup, R⁸ is hydrogen or hydroxy, R⁹ is amino, mono or di (lower)alkylamino, protected amino, guanidino, protected guanidino or saturated3- to 8-membered heterocyclic group containing 1 to 4 nitrogen atomsoptionally substituted by amino or protected amino, k, m, n and q areindependently 0 or 1, and p is 0, 1, 2 or 3; R⁵ is carboxy or protectedcarboxy; and R⁶ is amino or protected amino, or a pharmaceuticallyacceptable salt thereof.
 2. The compound of claim 1 wherein R¹ is loweralkyl or hydroxy(lower)alkyl, and R² is hydrogen or amino protectinggroup, or R¹ and R² are bonded together and form lower alkylene; R³ ishydrogen; A is

wherein X is O or NH; R⁷ is hydrogen or amino protecting group; R⁹ isamino or protected amino; and p is 0, 1 or 2, or a pharmaceuticallyacceptable salt thereof.
 3. The compound of claim 2 wherein R⁸ ishydrogen, or a pharmaceutically acceptable salt thereof.
 4. The compoundof claim 1 wherein R¹ is lower alkyl, hydroxy(lower)alkyl orhalo(lower)alkyl, and R² is hydrogen, aryl(lower)alkyl or acyl, or R¹and R² are bonded together and form lower alkylene or lower alkenylene;R⁵ is carboxy or esterified carboxy; R⁶ is amino or acylamino; R⁷ ishydrogen, lower alkyl or acyl; and R⁹ is amino, mono ordi(lower)alkylamino, acylamino, guanidino, acylguanidino or saturated 3-to 8-membered heterocyclic group containing 1 to 4 nitrogen atomsoptionally substituted by amino or acylamino, or a pharmaceuticallyacceptable salt thereof.
 5. The compound of claim 4 wherein R¹ is loweralkyl or hydroxy(lower)alkyl, and R² is hydrogen, aryl(lower)alkyl oracyl, or R¹ and R² are bonded together and form lower alkylene; R⁵ iscarboxy or esterified carboxy; R⁶ is amino or acylamino; R⁷ is hydrogenor acyl; and R⁹ is amino or acylamino, or a pharmaceutically acceptablesalt thereof.
 6. The compound of claim 5 wherein R¹ is lower alkyl orhydroxy(lower)alkyl, and R² is hydrogen, aryl(lower)alkyl, loweralkanoyl or lower alkoxycarbonyl, or R¹ and R² are bonded together andform lower alkylene; R⁵ is carboxy or lower alkoxycarbonyl; R⁶ is amino,lower alkanoylamino or lower alkoxycarbonylamino; R⁷ is hydrogen, loweralkanoyl or lower alkoxycarbonyl; and R⁹ is amino, lower alkanoylaminoor lower alkoxycarbonylamino, or a pharmaceutically acceptable saltthereof.
 7. The compound of claim 6 wherein R¹ is lower alkyl orhydroxy(lower)alkyl, and R² is hydrogen, or R¹ and R² are bondedtogether and form lower alkylene; R⁵ is carboxy; R⁶ is amino; R⁷ ishydrogen or lower alkanoyl; and R⁹ is amino, or a pharmaceuticallyacceptable salt thereof.
 8. The compound of claim 1 wherein R⁴ isselected from the group consisting of

wherein R⁷, A, m, p and q are each as defined in claim 1, R¹⁴ is amino,mono or di(lower)alkylamino or protected amino, R¹⁵ is guanidino orprotected guanidino, and R¹⁶ is saturated 3- to 8-membered heterocyclicgroup containing 1 to 4 nitrogen atoms optionally substituted by aminoor protected amino, or a pharmaceutically acceptable salt thereof. 9.The compound of claim 1 wherein R⁴ is selected from the group consistingof

wherein p is 0, 1 or 2, q is 0 or 1, R⁷ is hydrogen or amino protectinggroup, and R⁹ is amino or protected amino, or a pharmaceuticallyacceptable salt thereof.
 10. The compound of claim 9 wherein R⁷ ishydrogen, lower alkanoyl or lower alkoxycarbonyl; and R⁹ is amino, loweralkanoylamino or lower alkoxycarbonylamino, or a pharmaceuticallyacceptable salt thereof.
 11. The compound of claim 10 wherein R⁷ ishydrogen or lower alkanoyl; and R⁹ is amino, or a pharmaceuticallyacceptable salt thereof.
 12. A process for preparing a compound of theformula [I]:

wherein R¹ is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, andR² is hydrogen or amino protecting group, or R¹ and R² are bondedtogether and form lower alkylene or lower alkenylene; R³ is hydrogen orlower alkyl; R⁴ is

wherein A is

wherein X is O or NH, R⁷ is hydrogen, lower alkyl or amino protectinggroup, R⁸ is hydrogen or hydroxy, R⁹ is amino, mono ordi(lower)alkylamino, protected amino, guanidino, protected guanidino orsaturated 3- to 8-membered heterocyclic group containing 1 to 4 nitrogenatoms optionally substituted by amino or protected amino, k, m, n and qare independently 0 or 1, and p is 0, 1, 2 or 3; R⁵ is carboxy orprotected carboxy; and R⁶ is amino or protected amino, or a saltthereof, which comprises (1), reacting a compound of the formula [II]:

wherein R¹, R², R³ and R⁴ are each as defined above, or its reactivederivative at the amino group, or a salt thereof with a compound of theformula [III]:

wherein R⁵ and R⁶ are each as defined above, or its reactive derivativeat the carboxy group, or a salt thereof to give a compound of theformula [I]:

wherein R¹ , R², R³, R⁴, R⁵ and R⁶ are each as defined above, or a saltthereof, or (2) subjecting a compound of the formula [Ia]:

wherein R¹ , R², R³, R⁵, R⁶, R⁷, R⁸, A, k, m, n, p and q are each asdefined above, and R⁹a is protected amino, protected guanidino orsaturated 3- to 8-membered heterocyclic group containing 1 to 4 nitrogenatoms substituted by protected amino, or a salt thereof to eliminationreaction of the amino protecting group to give a compound of the formula[Ib]:

wherein R¹, R², R³, R⁵, R⁶, R⁷, R⁸, A, k, m, n, p and q are each asdefined above, and R⁹b is amino, guanidino or saturated 3- to 8-memberedheterocyclic group containing 1 to 4 nitrogen atoms substituted byamino, or a salt thereof, or (3) reacting a compound of the formula[VI]:

wherein R⁵ and R⁶ are each as defined above, R¹⁰, is protected carboxy,and Y is a leaving group, or a salt thereof with a compound of theformula [VII]:

wherein R¹ , R², R³ and R⁴ are each as defined above, or a salt thereofto give a compound of the formula [VIII]:

wherein R¹, R², R³, R⁴, R⁵, R⁶ and R¹⁰ are each as defined above, andZ^({circle around (−)}) is an anion, or a salt thereof, and subjectingthe compound of the formula [VIII] or a salt thereof to eliminationreaction of the carboxy protecting group, to give a compound of theformula [I]:

wherein R¹, R², R³, R⁴, R⁵ and R⁶ are each as defined above, or a saltthereof.
 13. A pharmaceutical composition comprising a compound of claim1 or a pharmaceutically acceptable salt thereof in admixture with apharmaceutically acceptable carrier.
 14. A compound of claim 1 or apharmaceutically acceptable salt thereof for use as a medicament.
 15. Acompound of claim 1 or a pharmaceutically acceptable salt thereof foruse as an antimicrobial agent.
 16. Use of a compound of claim 1 or apharmaceutically acceptable salt thereof for manufacture of a medicamentfor treating infectious diseases.
 17. A method for the treatment ofinfectious diseases which comprising administering a compound of claim 1or a pharmaceutically acceptable salt thereof to human or animals.